0001602078
true
2023
FY
Amendment No 1
0001602078
2022-04-01
2023-03-31
0001602078
2023-03-31
0001602078
2023-07-13
0001602078
2021-04-01
2022-03-31
0001602078
2022-03-31
0001602078
us-gaap:CommonStockMember
2021-03-31
0001602078
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001602078
us-gaap:RetainedEarningsMember
2021-03-31
0001602078
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-03-31
0001602078
2021-03-31
0001602078
us-gaap:CommonStockMember
2022-03-31
0001602078
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001602078
us-gaap:RetainedEarningsMember
2022-03-31
0001602078
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-03-31
0001602078
us-gaap:CommonStockMember
2021-04-01
2022-03-31
0001602078
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2022-03-31
0001602078
us-gaap:RetainedEarningsMember
2021-04-01
2022-03-31
0001602078
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-04-01
2022-03-31
0001602078
us-gaap:CommonStockMember
2022-04-01
2023-03-31
0001602078
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2023-03-31
0001602078
us-gaap:RetainedEarningsMember
2022-04-01
2023-03-31
0001602078
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-04-01
2023-03-31
0001602078
us-gaap:CommonStockMember
2023-03-31
0001602078
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001602078
us-gaap:RetainedEarningsMember
2023-03-31
0001602078
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31
0001602078
currency:USD
2023-03-31
0001602078
currency:USD
2022-03-31
0001602078
currency:GBP
2023-03-31
0001602078
currency:GBP
2022-03-31
0001602078
currency:EUR
2023-03-31
0001602078
currency:EUR
2022-03-31
0001602078
nmrd:WarrantsMember
2023-03-31
0001602078
nmrd:WarrantsMember
2022-03-31
0001602078
nmrd:StockOptionsMember
2023-03-31
0001602078
nmrd:StockOptionsMember
2022-03-31
0001602078
us-gaap:FairValueInputsLevel1Member
2023-03-31
0001602078
us-gaap:FairValueInputsLevel2Member
2023-03-31
0001602078
us-gaap:FairValueInputsLevel3Member
2023-03-31
0001602078
us-gaap:FairValueInputsLevel12And3Member
2023-03-31
0001602078
us-gaap:FairValueInputsLevel1Member
2022-03-31
0001602078
us-gaap:FairValueInputsLevel2Member
2022-03-31
0001602078
us-gaap:FairValueInputsLevel3Member
2022-03-31
0001602078
us-gaap:FairValueInputsLevel12And3Member
2022-03-31
0001602078
us-gaap:FairValueInputsLevel3Member
2022-04-01
2023-03-31
0001602078
us-gaap:PatentsMember
2023-03-31
0001602078
us-gaap:PatentsMember
2022-03-31
0001602078
us-gaap:PatentsMember
2022-04-01
2023-03-31
0001602078
us-gaap:PatentsMember
2021-04-01
2022-03-31
0001602078
us-gaap:ComputerSoftwareIntangibleAssetMember
2023-03-31
0001602078
us-gaap:ComputerSoftwareIntangibleAssetMember
2022-03-31
0001602078
us-gaap:ComputerSoftwareIntangibleAssetMember
2022-04-01
2023-03-31
0001602078
us-gaap:ComputerSoftwareIntangibleAssetMember
2021-04-01
2022-03-31
0001602078
2023-01-01
2023-01-31
0001602078
us-gaap:WarrantMember
2022-04-01
2023-03-31
0001602078
us-gaap:WarrantMember
2023-01-30
2023-01-31
0001602078
nmrd:NotePurchaseAgreement1Member
2023-03-31
0001602078
nmrd:NotePurchaseAgreement1Member
2022-03-31
0001602078
nmrd:NotePurchaseAgreement2Member
2023-03-31
0001602078
nmrd:NotePurchaseAgreement2Member
2022-03-31
0001602078
nmrd:NotePurchaseAgreement3Member
2023-03-31
0001602078
nmrd:NotePurchaseAgreement3Member
2022-03-31
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement1Member
2020-04-15
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement1Member
2020-04-14
2020-04-15
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2021-02-08
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2021-02-07
2021-02-08
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2022-02-01
2022-02-28
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2022-04-30
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2022-05-31
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2022-10-01
2022-10-31
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2022-10-31
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2023-03-31
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement2Member
2022-04-01
2023-03-31
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement3Member
2022-05-20
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement3Member
2022-05-19
2022-05-20
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement3Member
2021-02-08
0001602078
nmrd:SecuredNoteMember
us-gaap:InvestorMember
nmrd:NotePurchaseAgreement3Member
2023-03-31
0001602078
country:US
2022-04-01
2023-03-31
0001602078
country:US
2021-04-01
2022-03-31
0001602078
country:GB
2022-04-01
2023-03-31
0001602078
country:US
2023-03-31
0001602078
country:GB
2023-03-31
0001602078
2022-03-24
0001602078
us-gaap:CommonStockMember
nmrd:ArmisticeCapitalLLCAndAlyeskaMasterFundLLCMember
2023-01-01
2023-01-31
0001602078
us-gaap:CommonStockMember
nmrd:ArmisticeCapitalLLCAndAlyeskaMasterFundLLCMember
2023-01-31
0001602078
us-gaap:WarrantMember
nmrd:ArmisticeCapitalLLCAndAlyeskaMasterFundLLCMember
2023-01-01
2023-01-31
0001602078
nmrd:ArmisticeCapitalLLCAndAlyeskaMasterFundLLCMember
us-gaap:WarrantMember
2023-01-31
0001602078
nmrd:ArmisticeCapitalLLCAndAlyeskaMasterFundLLCMember
2023-01-01
2023-01-31
0001602078
nmrd:MarketOfferingAgreementMember
nmrd:HCWainwrightAndCoLLCMember
2021-04-02
0001602078
nmrd:AtTheMarketofferingAgreementMember
2021-04-01
2022-03-31
0001602078
nmrd:TigerTradingPartnersLLCMember
2021-04-01
2022-03-31
0001602078
nmrd:AtTheMarketofferingAgreementMember
2022-03-31
0001602078
nmrd:TigerManagementLLCMember
2021-04-01
2022-03-31
0001602078
nmrd:TigerManagementLLCMember
2022-03-31
0001602078
nmrd:ATMFacility2021Member
2021-04-01
2022-03-31
0001602078
nmrd:ATMFacility2021Member
2022-02-09
2022-02-10
0001602078
nmrd:BoardOfDirectorsMember
us-gaap:CommonStockMember
2022-01-27
2022-01-28
0001602078
nmrd:BoardOfDirectorsMember
us-gaap:CommonStockMember
2022-01-28
0001602078
us-gaap:StockOptionMember
2021-03-31
0001602078
us-gaap:StockOptionMember
2021-04-01
2022-03-31
0001602078
us-gaap:StockOptionMember
2022-03-31
0001602078
us-gaap:StockOptionMember
2022-04-01
2023-03-31
0001602078
us-gaap:StockOptionMember
2023-03-31
0001602078
us-gaap:WarrantMember
2021-03-31
0001602078
us-gaap:WarrantMember
2020-04-01
2021-03-31
0001602078
us-gaap:WarrantMember
2021-04-01
2022-03-31
0001602078
us-gaap:WarrantMember
2022-03-31
0001602078
us-gaap:WarrantMember
2023-03-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
iso4217:GBP
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————
FORM 10-K/A
——————
x |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended March
31, 2023
OR
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _________
to _________
Commission File Number 001-38355
NEMAURA MEDICAL INC.
(Exact
name of registrant as specified in its charter)
Nevada |
46-5027260 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
57 West 57th Street
New York, NY 10019
Address of principal executive offices) (Zip Code)
Registrant's telephone number, including
area code: + 1 646-416-8000
Securities registered pursuant to Section 12(b)
of the Act:
|
Title of Each Class |
|
Name of each exchange on which registered |
|
Trading Symbol |
Common Stock |
|
The Nasdaq Stock Market LLC |
|
NMRD |
Securities registered pursuant to Section
12(g) of the Act: None
Indicate by check mark if the registrant is
a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐
No ý
Indicate by check mark if the registrant is
not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐
No ý
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes ý No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ý No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging
growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
Accelerated filer ☐ |
Non-accelerated filer x |
Smaller reporting company x |
Emerging growth company ☐ |
|
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The aggregate market value of the registrant’s
common stock held by non-affiliates computed by reference to the closing price as of the last business day of the registrant’s
most recently completed final fiscal quarter (March 31, 2023) was approximately $25.2 million.
The number of shares outstanding of the registrant's common stock as of
July 13, 2023, was 28,899,402.
No
Documents Incorporated by Reference:
None
Explanatory Note
The purpose of this Amendment
No. 1 to Nemaura Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, filed with the Securities
and Exchange Commission on July 13, 2023 (the “Form 10-K”) is to correct a topographical error in Exhibit 23.1.
No other changes have
been made to the Original 10-K. This Amendment does not reflect subsequent events occurring after the filing date of the Original 10-K
or modify or update in any way disclosures made in the Original 10-K. This Amendment should be read in conjunction with the Original
10-K.
NEMAURA MEDICAL INC.
INDEX TO ANNUAL REPORT ON FORM 10-K
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this Annual Report that are
not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995,
and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because
they involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, or achievements
to differ materially from those expressed or implied. Any forward-looking statement speaks only as of the date made. We undertake no
obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.
The words "believe," "anticipate,"
"design," "estimate," "plan," "predict," "seek," "expect," "intend,"
"may," "could," "should," "potential," "likely," "projects," "continue,"
"will," and "would" and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These forward-looking statements are not guarantees of the future as there
are a number of meaningful factors that could cause Nemaura Medical Inc.’s (“Nemaura Medical”) actual results to vary
materially from those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience,
expected future developments and other factors Nemaura Medical believes are appropriate in the circumstances. Factors which could cause
actual results to differ from expectations, many of which are beyond Nemaura Medical’s control, include, but are not limited to,
obtaining regulatory approval for our sugarBEAT® device, conducting successful clinical trials, executing agreements required to successfully
advance the Company's objectives; retaining the management and scientific team to advance the product; overcoming adverse changes in market
conditions and the regulatory environment; obtaining and enforcing intellectual property rights; obtaining adequate financing in the future
through product licensing, public or private equity or debt financing or otherwise; dealing with general business conditions and competition;
and other factors referenced herein in “Risk Factors.” Except as required by law, we do not assume any obligation to
update any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise.
PART I
ITEM 1. BUSINESS.
Business Overview
We are a medical technology company that has developed sugarBEAT®,
a non-invasive, flexible, continuous glucose monitoring system, for adjunctive use by persons with diabetes, and any person wishing to
determine factors influencing their blood glucose profiles. SugarBEAT® consists of a disposable adhesive skin-patch containing a
sensor, which is connected to a rechargeable wireless transmitter. The sensor takes a measurement of the glucose reading every 5 minutes
and sends the data by low energy blue tooth to a smart device such as mobile phone (both android and iOS). An app on the smart device
uses a proprietary algorithm to display true glucose values, after the data is calibrated using a minimum of one finger stick calibration.
SugarBEAT® works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based
sensor. The data is recorded on the application and can be viewed in real time as well as storing all historic data for later evaluation
as desired. We believe sugarBEAT® may be utilized by any person with diabetes, whether Type 1 or Type 2 and also by any persons
wishing to determine factors affecting their blood glucose profiles, and therefore their state of metabolic health in terms of insulin
resistance.
On May 29, 2019, we announced that we had been awarded CE approval
to allow sugarBEAT® to be legally sold in the European Union. CE approval is disclosed by the use of the CE mark, a manufacturers'
declaration that the product meets the requirements of the applicable European laws. The European clinical trial program for sugarBEAT®
evaluated 525 patient days across 75 Type 1 and Type 2 diabetic patients and was completed in December 2017. CE approval is the process
to achieve a mandatory conformity marking for the sugarBEAT® device to allow it to be legally sold in the European Union. It is a
manufacturers' declaration that the product meets the requirements of the applicable European laws. This approval is subject to an annual
review of the underlying ISO 13485 accredited Quality Management System. The accreditation was successfully renewed in November 2021.
We also submitted a PMA (Premarket Approval) application to
the U.S. Food and Drug Administration (the “FDA”) with the same label claim as achieved for CE approval, an adjunct device
for glucose trending for persons with diabetes. The PMA is currently under review.
In July 2020, we filed a PMA application with the FDA to use
sugarBEAT® as an adjunct to finger prick testing for blood glucose trending. We, along with other applicants, were then informed
by the FDA that the approval process was subject to delays as a result of the FDA’s Center for Devices and Radiological Health
(“CDRH”) being actively engaged in responding to the COVID-19 pandemic, which resulted in staff being reallocated to other
approval requests associated with COVID-19. In April 2021 the FDA confirmed that it was recommencing its review of the PMA application,
and in December 2021, the FDA’s Bio-monitoring research division conducted an audit of the clinical program submitted in support
of the PMA application. A single 483 observation was raised, and the Company submitted a full response in January 2022. The FDA subsequently
scheduled a pre-market inspection for the second calendar quarter of 2022, intended to cover the FDA’s Quality System/Current Good
Manufacturing Practice regulations for Medical Devices (21 CFR Part 820).
In addition to this, Nemaura established that proBEATTM,
which is based on the sugarBEAT® platform, can be classified under the Wellness guidance when it is used according to the FDA Wellness
guidance notes, to provide prompts and educate users on factors affecting their blood sugar profiles.
We believe there are additional applications for sugarBEAT®
and the underlying BEAT technology platform, which may include:
| · | a web-server accessible by physicians and diabetes professionals to track
the condition remotely, thereby reducing healthcare costs and managing the condition more effectively; |
| · | a complete virtual doctor that monitors a person's vital signs and transmits
results via the web; |
| · | other
patches using the BEAT technology platform to measure alternative analytes, including lactate. This would be a step-change in the monitoring
of conditions, particularly in the hospital setting. Lactate monitoring is currently used to determine the relative fitness of professional
athletes and we completed preliminary studies demonstrating the application of the BEAT technology for continuous lactate monitoring; |
| · | a continuous temperature monitoring system which could have various applications. |
Our Business Strategy
We intend to lead in the
discovery, development and commercialization of innovative and targeted diagnostic medical devices, and data-driven digital platforms,
that improve disease monitoring, management and overall patient care in both the consumer well-being space and medical sector. Specifically,
we intend to focus on the monitoring of molecules that can be drawn out through the skin non-invasively using our technology platform.
In addition to glucose, such molecules may include lactic acid monitoring and the monitoring of prescription drugs and blood biomarkers
that may help in the diagnosis, prevention, or management of diseases, such as diabetes. We plan to take the following steps to implement
our broad business strategy. Our key commercial strategies post-approval will first be implemented in Europe and then in parts of the
Middle East and Asia, and then the U.S., as follows:
| - | Commercialize sugarBEAT® in the United Kingdom and Republic of Ireland.
We intend to commercialize sugarBEAT® in the United Kingdom, and Republic of Ireland with MySugarWatch Limited (previously known
as Dallas Burston Ethitronix Limited) (“MSW”), with whom we have an exclusive marketing rights agreement for these two countries.
We have also signed a full commercial agreement with MySugarWatch (Europe) Limited (previously known as Dallas Burston Ethitronix (Europe)
Limited) in May 2018 for all other European territories as part of an equal joint venture agreement. The joint venture intends to seek
sub-license rights opportunities to one or more leading companies in the diabetes monitoring space, to leverage their network,
infrastructure and resources. |
| - | Establish licensing or joint venture agreements with other parties to
market sugarBEAT® in other geographies. We are in detailed discussions and negotiations with several other parties
worldwide for licensing or joint venture agreements for the sale of the sugarBEAT® device and have signed commercial agreements with
TP MENA for the Gulf Cooperation Council. TP MENA have submitted an application to the Saudi Arabian Regulatory Agency for registration
of sugarBEAT in the KSA (Kingdom of Saudi Arabia). |
| - | Seek FDA PMA approval of sugarBEAT®. The PMA application is currently
in review by the FDA. |
| - | Expand the indications for which the sugarBEAT® device may
be used. We believe that the sugarBEAT® device may offer significant benefits as compared to those found in the non-acute setting
for the monitoring of other diseases. This includes monitoring of lactic acid for performance athletics, and the monitoring of drugs.
We have completed initial proof of concept for lactate monitoring and now plan to explore the route to commercialization for well-being
applications in athletic performance training, and plan to undertake further clinical programs to support clinical use of the device for
lactate monitoring. |
| - | Expand our product pipeline through our proprietary platform technologies,
acquisitions and strategic licensing arrangements. We intend to leverage our proprietary platform technologies to grow our portfolio
of product candidates for the diagnosis of diabetes and other diseases. This includes digital platforms driven by data gathered by our
sensors within the medical and wellbeing markets, such as for metabolic health monitoring. In addition, we intend to license our product
and acquire products and technologies that are consistent with our research and development and business focus and strategies. This may
include digital solutions for managing chronic disease conditions, supported with sensor data, drug delivery products for the improved
management of diabetes, for example improved insulin injector systems, and/or combination drug products for diabetes related drugs. |
Product Development
Management has extensive experience in regulatory and clinical
development of diagnostic medical devices. We intend to take advantage of this experience in the field of diagnostic medical devices
in an attempt to increase the probability of product approval in multiple territories. The overall regulatory process for diagnostic
medical devices for diabetes is currently similar to those governing other diagnostic devices. The timelines are shorter than, for example,
when new drugs or completely invasive diagnostic devices are trialed in clinics. We have successfully tested and evaluated the device
for its clinical output, in this case the accuracy and safety with which it can trend blood glucose levels, based on which CE approval
was granted by the Notified Body BSI. A PMA (pre-market approval) application was also submitted to the FDA and is currently under review.
We continue to seek collaborations with future licensees and marketing partners to achieve our commercial growth milestones.
Market Opportunity for the Company's Products
According to the International Diabetes Federation Atlas 10th
Edition 2021 (the "IDF"), there are approximately 537 million adults living with diabetes, representing 10.5% of the
world’s population in this age group. This number is predicted to rise to 643 million (11.3%) by 2030 and to 783 million (12.2%)
by 2045. Additionally an estimated 240 million people are living with undiagnosed diabetes worldwide, meaning almost one-in-two adults
with diabetes are unaware they have the condition. The IDF identifies that almost 90% of people with undiagnosed diabetes live in low-and-middle
income countries.
Statistics published by the IDF evidence
the fact that diabetes is a huge and growing problem, and that whilst the costs to society are already high, they continue to escalate.
In addition, the IDF also notes that Europe has the highest prevalence of children and adolescents with Type 1 diabetes, as well as the
highest incidence annually. Europe is also reported as having the second highest average cost per person with diabetes ($3,086), with
only North America and the Caribbean being higher ($8,208).
Statistical Data for Diabetes Globally
|
2021 |
2030 |
2045 |
Total world population |
7.9 billion |
8.6 billion |
9.5 billion |
Adult population (20-79 years) |
5.1 billion |
5.7 billion |
6.4 billion |
|
Diabetes (20 – 79 years) |
Prevalence (%) |
10.5% |
11.3% |
12.2% |
Number of people with diabetes |
536.6 million |
642.7 million |
783.2 million |
Total health expenditure due to diabetes (2021 $) |
$966 billion |
$1,028 billion |
$1,054 billion |
|
Impaired Glucose Tolerance “IGT” (20 – 79 years) |
Prevalence (%) |
10.6% |
11.0% |
11.4% |
Number of people with IGT |
541.0 million |
622.7 million |
730.3 million |
|
Type 1 diabetes (0 – 19 years) |
Number of children / adolescents with Type 1 diabetes |
1.2 million |
- |
- |
Number of newly diagnosed cases per year |
184,100 |
- |
- |
Type 1 diabetes, once known as juvenile diabetes or insulin-dependent
diabetes, is a chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow sugar (glucose) to enter
cells to produce energy. The far more common Type 2 diabetes occurs when the body becomes resistant to the effects of insulin or doesn't
make enough insulin.
Various factors may contribute to Type 1 diabetes including
genetics and exposure to certain viruses. Although Type 1 diabetes typically appears during childhood or adolescence, it also can develop
in adults.
Despite active research, Type 1 diabetes
has no cure, although it can be managed. With proper treatment, people who have Type 1 diabetes can expect to live longer, healthier lives
than they did in the past. Type 1 diabetes includes autoimmune Type 1 diabetes (Type 1a) which is characterized by having positive autoantibodies,
as well as idiopathic Type 1 diabetes (Type 1b) where autoantibodies are negative, and c-peptide is low. Patients with Type 1 diabetes
(insulin dependent) require long term treatment with exogenous insulin and these patients perform self-monitoring of blood glucose (SMBG)
to calculate the appropriate dose of insulin. SMBG is done by using blood samples obtained by finger sticks but frequent SMBG does not
detect all the significant deviations in blood glucose, specifically in patients who have rapidly fluctuating glucose levels.
Type 2 diabetes, once known as adult-onset or non-insulin-dependent
diabetes, is a chronic condition that affects the way your body metabolizes sugar (glucose), your body's main source of fuel. With Type
2 diabetes, your body either resists the effects of insulin, a hormone that regulates the movement of sugar into your cells or doesn't
produce enough insulin to maintain a normal glucose level. Untreated, Type 2 diabetes can be life-threatening.
More common in adults, Type 2 diabetes increasingly
affects children as childhood obesity increases. Whilst there is currently no acknowledged cure for Type 2 diabetes, there is increasing
evidence to suggest that it can be effectively managed by eating well, exercising and maintaining a healthy weight. If diet and exercise
don't control the blood sugar, diabetes medications or insulin therapy may be required.
Each year, millions of patients undergo diabetes testing in
the European Union and in the U.S. The main reason for this testing is to detect and evaluate diabetes in patients with symptoms of diabetes.
These studies provide clinical benefit in the initial evaluation of patients with suspected but unproven diabetes, and in those patients
in whom a diagnosis of diabetes has been established and information on prognosis or risk is required.
We believe that our market opportunity is
a direct function of the number of persons tested, diagnosed and treated for Type 2 diabetes. The IDF indicates that the total world market
opportunity for a continuous glucose monitoring device is in the billions of dollars and is projected to grow annually as incidences of
diabetes continue to grow.
We do not believe it is possible to estimate
the number of diabetes patients that undergo finger pricks or other types of invasive glucose monitoring. However, we are unaware of any
product currently on the market that may allow for non-invasive continuous glucose monitoring. We believe the sugarBEAT® device may
be readily adopted by the medical community for the assessment of a patient continuously.
We believe our non-invasive sugarBEAT®
device possesses many significant advantages and may represent an ideal device for the detection of discordances in an individual's blood
sugar levels. We believe the CE approved sugarBEAT® device may represent a best-in-class non-invasive continuous glucose monitoring
device to reach those afflicted with diabetes. While we cannot estimate the market share that our sugarBEAT® device may capture, we
believe that the sugarBEAT® device will capture a significant share of the non-invasive continuous glucose monitoring market, in-particular
the market that has been established by the Abbott Freestyle Libre device for glucose trending, as well as be adopted by non-insulin dependent
diabetics who have not historically used continuous glucose monitoring devices due to their invasiveness.
Commercialization Plan
Throughout the fiscal year ended March 31,
2023, we worked with our UK Licensee, MSW, to provide support in the development of their go-to-market strategy which incorporates the
utilization of our sugarBEAT® device into their own branded product offering. While COVID-19 did result in some short delays to MSW’s
user assessment program, the overall feedback was positive, albeit the anticipated timetable for purchase orders to be placed by MSW
was extended out, with the first order for 5,000 sugarBEAT® transmitters and 200,000 sugarBEAT® sensors placed in April 2021.
During the fiscal year to March 2023 our focus has been to support our licensee to gather user feedback to support an application of
reimbursement of the sensors and we continue to support these endeavors. We also took the following actions during the fiscal year ended
March 31, 2023:
| · | Increased headcount of production operatives to facilitate product manufacture |
| · | Started
to receive components / materials from forward orders previously placed for raw materials to support scale-up and secure inventory of
those items that are currently in short supply globally i.e. electronic components such as microprocessors, etc. |
| · | Continued to work with Benchmark Electronics Inc as our CMO partner to facilitate
future volume scale up of transmitter production via its FDA approved facility in Thailand, by undertaking electronic PCBA (Printed Circuit
Board Assembly) batch qualification runs |
| · | Completed phased delivery of transmitters against purchase order received
from MSW in December 2021 |
We also advanced our plans to develop our go-to-market
capabilities in the U.S., which included:
| · | In July 2020, we submitted a PMA application to the FDA for the sugarBEAT® device for glucose profiling
as an adjunct to a finger-stick measurement. We, along with other applicants, were then informed by the FDA that the approval process
was subject to delays as a result of the CDRH being actively engaged in responding to the pandemic caused by COVID-19 which resulted in
staff being reallocated to other approval requests associated with COVID-19. In April 2021, the FDA confirmed that it would recommence
its review of the PMA application. |
| · | In December 2021, the FDA’s Bio-monitoring research division conducted an audit of the clinical
program submitted in support of the PMA application. A single 483 observation was raised, and the Company submitted a full response in
January 2022. |
| · | The FDA subsequently conducted a pre-market inspection during the second calendar quarter of 2022,
covering the FDA’s Quality System / Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820). Once
again a single 483 observation was made, and this was responded to within the mandated time frame. The company continues its dialogue
with the FDA with respect to the PMA submission and plans to provide further material updates as they arise in due course. |
In addition to this, we
continue to explore commercialization opportunities in other key geographic markets and intend to provide material updates as they arise..
Competitive Landscape
To the best of our knowledge, there are
currently no other competing devices on the market that offer continuous glucose monitoring and profiling, non-invasively, with a single
day sensor wear. We believe this positions us uniquely in a market where we can target persons with diabetes as well as those that are
pre-diabetic. Additionally, we believe that this can also be used to improve outcomes in weight management and wellbeing markets. There
are companies, such as Dexcom and Abbott, that currently offer Continuous Glucose Monitoring (CGM) sensors with 10 and 14 continuous day
wear, respectively. These companies could be deemed future competitors were they to:
| – | develop and market products that are less expensive or more effective than
our current and/or future products; |
| – | operate larger research and development programs or have substantially greater
financial resources than we do; |
| – | initiate or withstand substantial price competition more successfully than
we can; |
| – | have greater success in recruiting skilled technical and scientific workers
from the limited pool of available talent; |
| – | more effectively negotiate third-party licenses and strategic relationships;
and |
| – | take advantage of acquisition or other opportunities more readily than we
can. |
We may compete for market share against
these companies and potential newcomers in this general field. These potential competitors, either alone or together with their partners,
may develop new products that will compete with ours, and these competitors may, and in certain cases do, operate larger research and
development programs, or have substantially greater financial resources than we do.
As noted, while it is difficult to analyze our major competitors
since currently there are no non-invasive diagnostic medical devices to continuously monitor blood glucose levels, we anticipate that
specific companies may compete with us in the future.
Regulatory Requirements
Our device has undergone the applicable
electrical safety testing and biocompatibility has been demonstrated against the relevant European Directives, Regulations and Standards.
If and when new materials are introduced, they will undergo a biocompatibility risk assessment, and further testing where necessary. Batches
of the device and patches were manufactured for human clinical studies that took place between November 2014 and December 2015. This was
a functional watch device with a wire connection to a skin adhered sensor and electrode. Subsequent to studies conducted in India the
device received a CE mark approval in February 2016. The device has since been upgraded to reduce it in size, include an enhanced sensor
system and allow wireless communication from a body worn transmitter. This miniaturized wireless device achieved CE approval in May 2019,
and a PMA was submitted to the U.S. FDA in July 2020 and is currently in review. An application for CE mark approval requires the Company
to have an ISO13485 Quality Management System, covering the design, development and manufacture of a medical device. Nemaura Medical does
not have this accreditation, and instead under the terms of a service contract dated April 4, 2018, with Nemaura Pharma Limited (“Pharma”),
Nemaura Medical has outsourced the CE approval registration process to Pharma. Pharma, a related company, is controlled by our Chief Executive
Officer, President, Chairman of the Board and majority shareholder, Dr D.F.H. Chowdhury. Under the terms of the service contract Pharma
has undertaken all required activities to register the product for CE approval under a fee for service arrangement, while Nemaura Medical
will retain full title and beneficial ownership of the CE mark, and all related intellectual property without any further payments or
royalties becoming due other than the fee for service.
Intellectual Property
We believe that clear and extensive intellectual
property relating to our technologies is central to long-term success and we intend to invest accordingly. This applies to both domestic
and international patent coverage, and trade secrets, and trademarks.
The sugarBEAT® technology is protected by our portfolio
of intellectual property comprised of issued and pending patents and trade secrets covering a range of claims, including the methods
and apparatus for measuring glucose extracted from human skin in a non-invasive manner, devices for extracting glucose from the skin
is a stable manner, devices for reducing background noise signals, algorithm for converting raw data in to glucose values to calibrate
the device, and the formulation and process for preparation of the enzyme solution used in the sensor.
On May 8, 2014, NDM Technologies Limited,
a related company, assigned the UK patent application 1208950.4 and International (PCT) patent application PCT/GB2013/051322 entitled
"Cumulative Measurement of an Analyte" to Dermal Diagnostics Limited (“DDL”) for a nominal consideration.
Additional patents are intended to be filed
in the future relating to the device and sensor, providing new intellectual property protection. Some of the recently filed patents and
future patents may supersede previous intellectual property.
Additionally, we retain substantial
trade secrets relating to aspects of the sensor manufacture process and the sensor formulation, which have taken
several years to develop, and will prove challenging to reverse engineer as it consists of formulation components in addition to processing
methods in complex combinations that are unique to the final functional sensor. Patents will not be filed on this aspect of the technology
to avoid any public dissemination of the know-how.
These patents and know-how cover aspects
of the technology platform. Furthermore, the trademarks BEAT® and sugarBEAT® have been registered in multiple key global territories.
Accordingly, all intellectual property essential to the sugarBEAT® product is owned by us, and not subject to royalty payments.
We intend to take the lead in the preservation and/or prosecution of these patents and patent applications going forward as required.
We intend to file additional patents as the development progresses, where deemed to be of value to protecting the technology platform
and future modifications and improvements. Where patents cannot be secured, or existing patents are superseded by new know-how or technical
developments that cannot be patented the intellectual property will be limited to know-how and trade secrets, and these will be diligently
guarded.
Trade Secrets, Trademarks, and Patents Filed, Granted and
Pending
IP: Patent (Core Claim),
Know-how, Trademark |
|
Expiration Date |
|
Jurisdictions in which
Granted / Issued |
|
Jurisdictions in which
Pending |
|
Ongoing Royalty or Milestone
Payments |
|
|
|
|
|
|
|
|
|
Patent: Cumulative Measurement of an Analyte (1) |
|
May 20, 2033 |
|
Australia, France, Germany, Italy, Poland, Spain, Netherlands, UK, China, Japan, USA, Canada, UAE, Brazil |
|
Qatar |
|
None. Internal development |
Skin Prep Patch (2) |
|
December 2, 2039 |
|
UK |
|
Europe, USA |
|
None. Internal development |
Know-how: Sensor Formulation and manufacture processes |
|
N/A |
|
Trade Secret |
|
N/A |
|
None. Internal development |
Trademark:
BEAT |
|
Renewal due in 2026 |
|
UK, Canada, China, EU, India, Japan, Norway, Russia, Singapore |
|
Malaysia, Brazil, Mexico, Switzerland, Turkey |
|
None. Internal development |
Trademark: sugarBEAT |
|
Renewal due in 2025 |
|
UK, Canada, Australia, Switzerland, China, Egypt, EU, Israel, India, Iran, Japan, North Korea, Morocco, Mexico, Norway, New Zealand, Russia, Singapore, Tunisia, Turkey, USA |
|
N/A |
|
None. Internal development |
Sensors for metabolic health (3)
|
|
December 7, 2041 |
|
N/A |
|
UK |
|
None. Internal development |
(1) This patent provides a formula for
calculating the amount of glucose extracted over a defined period of time by deducting the difference between two readings to allow rapid
sensing without needing to deplete the analyte being measured.
(2) This patent describes a device and
method for preparing the skin for extraction of glucose.
Clinical Trials
Our clinical testing have been conducted
by contract clinical research organizations in various centers around the world to cover a wide demographic – including Asia and
Europe – and is managed by our in-house management team.
We had 2 pre-submission meetings with the
FDA in June 2016, to define the clinical roadmap. As a result, a detailed clinical plan was developed and approved internally and a clinical
site in Europe was selected and audited and approved for commencement of clinical studies using the body worn transmitter device version
of the sugarBEAT®. The study was completed, and a PMA application submitted to the FDA in July 2020.
The data from these studies was also submitted
as part of the CE approval in Europe was received in May 2019.
Research and development
We spent $1,538,615 and $1,556,988 during the
fiscal years ended March 31, 2023 and 2022, respectively, on research and development; management currently anticipated that spend in
this area will remain reasonably consistent in the coming fiscal year.
Manufacturing
The manufacture and sale of CE certified
medical devices are controlled and governed by guidelines stipulated in the International Organization for Standardization (ISO), more
specifically ISO13485; sugarBEAT® will be manufactured and marketed according to ISO13485 quality standards.
In support of commercial sales of sugarBEAT®
in the UK and EU we have worked with our manufacturing partner Nemaura Pharma, to scale-up manufacturing of the various sugarBEAT®
components alongside facilities for final assembly and packaging. As part of this process, we have expanded our manufacturing and assembly
capabilities by occupying additional space within our existing headquarters site at Loughborough University Science and Enterprise Park
(LUSEP) in the UK.
We have entered into the following types
of agreements with various manufacturing partners:
| – | Manufacturing agreements for the sensor manufacture |
| – | Manufacturing agreements for the patch manufacture |
| – | Manufacturing agreements for the CGM transmitter device and re-charging
station manufacture |
Sales and Marketing
An Exclusive Marketing Rights agreement
for the UK and Republic of Ireland was signed on March 31, 2014 with Dallas Burston Pharma, a Jersey (Channel Island) based company (“DB
Pharma”) (subsequently updated in 2018 and again in 2021 to include a change in the company name to MySugarWatch Limited “MSW”),
who has pharmaceutical product marketing operations in the UK and has demonstrated a very successful model for the marketing of prescription
medical products directly to general practitioners. We received a non-refundable upfront payment of £1 million ($1.67 million at
the then exchange rate) in return for providing MSW with the exclusive right to sell the sugarBEAT® device in the UK and Republic
of Ireland, both direct to consumer and through prescriptions by general practitioners. The key terms of the Exclusive Marketing Rights
Agreement were concluded in a Commercial Agreement signed in August 2015. This agreement was updated and re-issued in October 2019 to
cover new IP / improvements to the technology.
In addition, a joint venture agreement was entered into with
MySugar Watch (Europe) Limited (previously known as Dallas Burston Ethitronix (Europe) Limited) in May 2018, whereby we will share equally
the costs and net profits of the sales of our sugarBEAT® system in all territories in Europe, with the exception of the United Kingdom,
which is the subject of a separate agreement with MSW. This agreement was updated and re-issued in October 2019 to cover new IP/ improvements
to the technology. Commercial agreements were signed in 2018 with TPMENA and Al-Danah Medical, for the Gulf Region (GCC) and Qatar respectively.
Regulatory matters
Government Regulation
Our business is subject to extensive federal, state, local
and foreign laws and regulations, including those relating to the protection of the environment, and health and safety. Some of the pertinent
laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of
subjective interpretations. In addition, these laws and their interpretations are subject to change, or new laws may be enacted.
Both federal and state governmental agencies continue to subject
the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. We believe that
we have structured our business operations to comply with all applicable legal requirements. However, it is possible that governmental
entities or other third parties could interpret these laws differently and assert otherwise. We discuss below the statutes and regulations
that are most relevant to our business.
United Kingdom and Wales and the European Union regulations
Government authorities in the United Kingdom
and Wales and the European Union as well as other foreign countries extensively regulate, among other things, the research, development,
testing, manufacture, labelling, promotion, advertising, distribution, sampling, marketing and import and export of medical devices, including
patches and other pharmaceutical products. Our body worn transmitter devices in the United Kingdom and Wales will be subject to strict
regulation and require regulatory approval prior to commercial distribution. The process of obtaining governmental approvals and complying
with ongoing regulatory requirements requires the expenditure of substantial time and financial resources. In addition, statutes, rules,
regulations and policies may change and new legislation or regulations may be issued that could delay such approvals. If we fail to comply
with applicable regulatory requirements at any time during the product development process, approval process, or after approval, we may
become subject to administrative or judicial sanctions. These sanctions could include the authority's refusal to approve pending applications,
withdrawals of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of our operations,
injunctions, fines, civil penalties or criminal prosecution. Any agency enforcement action could have a material adverse effect on us.
The European Commission on Public Health
(the "ECPH") provides the regulation for the development and commercialization of new medical diagnostic devices. Any medical
device placed on the European market must comply with the relevant legislation, notably with Directive 93/42/EEC for medical devices,
with the active implantable devices Directive (90/385/EEC) or with the in vitro devices Directive (98/79/EC). From 26th
May 2021, all newly approved medical devices must comply with the Medical Device Regulation (2017/745). Before manufacture / import, it
must be determined whether the device in question falls under any of these Directives. All medical devices must fulfil the essential requirements
set out in the above-mentioned directives. Where available, relevant standards may be used to demonstrate compliance with the essential
requirements defined in the devices Directives.
Manufacturers also need to determine the
appropriate conformity assessment route. For devices falling under Directive 93/42/EEC / Regulation 2017/745, other than custom-made devices
and devices intended for clinical investigation, the conformity assessment route depends on the class of the device, to be determined
in accordance with certain rules set forth in the directives / regulations. Once the applicable class or list has been determined, manufacturers
need to follow the appropriate conformity assessment procedure. Subject to the type of the device, this may require manufacturers to have
their quality systems and technical documentation reviewed by a Notified Body before they can place their products on the market. A Notified
Body is a third-party body that can carry out a conformity assessment recognized by the European Union. The Notified Body will need to
assure itself that relevant requirements have been met before issuing relevant certification. Manufacturers can then place the CE marking
on their products to demonstrate compliance with the requirements.
The CE approval is the process of achieving
a mandatory conformity marking for the sugarBEAT® device to allow it to be legally sold in the European Union. It is a manufacturers'
declaration that the product meets the requirements of the applicable European laws. The process for the sugarBEAT® device CE submission
and approval involved the following:
1. The device is classified depending
on certain categories described by the European Directive with Class I products being low risk (e.g., band aid plasters), with Class III
devices being the highest risk. The classes are Class I, IIa, IIb and III. Risk is based upon the potential harm to the patient should
a problem arise with a product or its use. The sugarBEAT® device is classified as a IIb device.
2. A 'technical file' containing all of
the information required to demonstrate that the product meets the essential requirements of the European directive will be prepared.
This includes information relating to performance and safety of the device such as product specifications, labelling, instructions for
use, risk analysis and specific test information/clinical evidence relating to the product that support the claims being made for the
product.
3. Clinical evidence included in the technical
file is expected to demonstrate that the device is safe and meets defined performance requirements. This clinical evidence can be in the
form of literature data where substantial published data exists that utilizes the same technique for glucose extraction and measurement
(albeit in a different device format), or data from actual clinical studies performed using the sugarBEAT® device. The first CE mark
submission was based on literature evaluation of 3rd party published clinical data available in the public domain. The final
CE mark submission has claims based on the clinical performance of the device, based on clinical studies described earlier herein. The
clinical data showed that the sugarBEAT® device can trend blood glucose levels in a human subject by taking measurements every 5 minutes.
The clinical trial data demonstrates the sugarBEAT® device blood glucose trend can be used to supplement normal finger prick measurements.
4. The technical file has been assessed
by an independent inspector (the Notified Body), regulated by the competent authority, (Medicines and Healthcare products Regulatory Agency,
MHRA in the United Kingdom). The Notified Body (an organization in the European Union that has been accredited by a member state to determine
whether a medical device complies with the European medical device directives), will then notify The European Commission on Public Health
(the "ECPH") of the approval and a certificate will be issued to the Company by the notified body and we will then be able to
apply the CE mark to the device, and legally offer the product for sale in the European Economic Area (EEA). The CE mark has been issued
as of May 2019 and the company is now able to offer the device for commercial sale in the EU.
5. The review of the technical file commenced
in August 2018, and the final review and sign off was received in May 2019. Since the CE mark was approved, we have undergone routine
inspections of our ISO 13485 Quality Management System in order to maintain our CE mark accreditation. An addendum was also submitted
to the notified body and approval obtained, to include within the approved CE marked device, the iOS version of the smart device app that
the transmitter connects to.
U.S. Food and Drug Administration regulation of medical
devices
The US Food, Drug, and Cosmetic Act (the “FDCA”)
and FDA regulations establish a comprehensive system for the regulation of medical devices intended for human use. sugarBEAT® is
a medical device that is subject to these, as well as other federal, state, local and foreign, laws and regulations. The FDA is responsible
for enforcing the laws and regulations governing medical devices in the United States.
The FDA classifies medical devices into one of three classes
(Class I, Class II, or Class III) depending on their level of risk and the types of controls that are necessary to ensure device safety
and effectiveness. The class assignment is a factor in determining the type of premarketing submission or application, if any, that will
be required before marketing in the United States. SugarBEAT® falls under Class III.
| – | Class I devices present a low risk and are not life-sustaining
or life-supporting. The majority of Class I devices are subject only to "general controls" (e.g., prohibition against adulteration
and misbranding, registration and listing, good manufacturing practices, labelling, and adverse event reporting. General controls are
baseline requirements that apply to all classes of medical devices.) |
| – | Class II devices present a moderate risk and are devices
for which general controls alone are not sufficient to provide a reasonable assurance of safety and effectiveness. Devices in Class II
are subject to both general controls and "special controls" (e.g., special labelling, compliance with performance standards,
and post market surveillance. Unless exempted, Class II devices typically require FDA clearance before marketing, through the premarket
notification (510(k)) process.) |
| – | Class III devices present the highest risk. These
devices generally are life-sustaining, life-supporting, or for a use that is of substantial importance in preventing impairment of human
health or present a potential unreasonable risk of illness or injury. Class III devices are devices for which general controls, by themselves,
are insufficient and for which there is insufficient information to determine that application of special controls would provide a reasonable
assurance of safety and effectiveness. Class III devices are subject to general controls and typically require FDA approval of a PMA application
before marketing. |
Unless it is exempt from premarket review requirements, a medical
device must receive marketing authorization from the FDA prior to being commercially marketed, distributed or sold in the United States.
The most common pathways for obtaining marketing authorization are 510(k) clearance and PMA. After preliminary discussions with
the FDA in June 2016 as part of a pre-submission meeting it was determined that the pathway for sugarBEAT® would be a PMA approval.
Premarket approval pathway
The PMA approval process requires an independent demonstration
of the safety and effectiveness of a device. PMA is the most stringent type of device marketing application required by the FDA. PMA
approval is based on a determination by the FDA that the PMA contains sufficient valid scientific evidence to ensure that the device
is safe and effective for its intended use(s). A PMA application generally includes extensive information about the device including
the results of clinical testing conducted on the device and a detailed description of the manufacturing process.
After a PMA application is accepted for review, the FDA begins
an in-depth review of the submitted information. FDA regulations provide 180 days to review the PMA and make a determination; however,
in reality, the review time is normally longer (e.g., 1-3 years). During this review period, the FDA may request additional information
or clarification of information already provided. Also, during the review period, an advisory panel of experts from outside the FDA may
be convened to review and evaluate the data supporting the application and provide recommendations to the FDA as to whether the data
provides a reasonable assurance that the device is safe and effective for its intended use. In addition, the FDA generally will conduct
a preapproval inspection of the manufacturing facility to ensure compliance with Quality System Regulation, which imposes comprehensive
development, testing, control, documentation and other quality assurance requirements for the design and manufacturing of a medical device.
Based on its review, the FDA may (i) issue
an order approving the PMA, (ii) issue a letter stating the PMA is "approvable" (e.g., minor additional information is needed),
(iii) issue a letter stating the PMA is "not approvable," or (iv) issue an order denying PMA. A company may not market a device
subject to PMA review until the FDA issues an order approving the PMA. As part of a PMA approval, the FDA may impose post-approval conditions
intended to ensure the continued safety and effectiveness of the device including, among other things, restrictions on labelling, promotion,
sale and distribution, and requiring the collection of additional clinical data. Failure to comply with the conditions of approval can
result in materially adverse enforcement action, including withdrawal of the approval.
Most modifications to a PMA approved device,
including changes to the design, labelling, or manufacturing process, require prior approval before being implemented. Prior approval
is obtained through submission of a PMA supplement. The type of information required to support a PMA supplement and the FDA's time for
review of a PMA supplement vary depending on the nature of the modification.
In February
2020 Nemaura announced that following discussions with the FDA, it was established that Nemaura may sell its CGM product with a digital
service offering in the U.S. without FDA approval as a non-medical wellbeing application. Nemaura further announced that it intended to
launch this product under the brand proBEATÔ in the
U.S. in October to December 2020. The product enables users to wear the CGM device from which data will be sent to Nemaura’s servers
in the cloud, from where data will be processed to provide users with educational material and insights into factors that can affect their
sugar levels and tips for healthy lifestyle and diet, with a view to helping pre-diabetics and diabetics alike live healthier lives. A
limited product launch commenced in the U.S. in December 2020 to enabled potential customers to register their interest utilizing proBEAT™
in conjunction with a digital program for weight loss targeted at persons with diabetes, under the brand
BEATdiabetes.life.
Clinical trials
Clinical trials of medical devices in the U.S. are governed
by the FDA's Investigational Device Exemption ("IDE") regulation. This regulation places significant responsibility on the
sponsor of the clinical study including, but not limited to, choosing qualified investigators, monitoring the trial, submitting required
reports, maintaining required records, and assuring investigators obtain informed consent, comply with the study protocol, control the
disposition of the investigational device, submit required reports, etc.
Clinical trials of significant risk devices (e.g., implants,
devices used in supporting or sustaining human life, devices of substantial importance in diagnosing, curing, mitigating or treating
disease or otherwise preventing impairment of human health) require FDA and Institutional Review Board ("IRB") approval prior
to starting the trial. FDA approval is obtained through submission of an IDE application. Clinical trials of non-significant risk ("NSR")
devices (i.e., devices that do not meet the regulatory definition of a significant risk device) only require IRB approval before starting.
The clinical trial sponsor is responsible for making the initial determination of whether a clinical study is significant risk or NSR;
however, a reviewing IRB and/or FDA may review this decision and disagree with the determination.
An IDE application must be supported by appropriate data, such
as performance data, animal and laboratory testing results, showing that it is safe to evaluate the device in humans and that the clinical
study protocol is scientifically sound. There is no assurance that submission of an IDE will result in the ability to commence clinical
trials. Additionally, after a trial begins, the FDA may place it on hold or terminate it if, among other reasons, it concludes that the
clinical subjects are exposed to an unacceptable health risk.
As noted above, the FDA may require a company to collect clinical
data on a device in the post-market setting.
The collection of such data may be required as a condition
of PMA approval. The FDA also has the authority to order, via a letter, a post-market surveillance study for certain devices at any time
after they have been cleared or approved.
Pervasive and continuing FDA regulation
After a device is placed on the market,
regardless of its classification or premarket pathway, numerous additional FDA requirements generally apply. These include, but are not
limited to:
| – | Establishment registration and device listing requirements; |
| – | Quality System Regulation ("QSR"), which
governs the methods used in, and the facilities and controls used for, the design, manufacture, packaging, labelling, storage, installation,
and servicing of finished devices; |
| – | Labelling requirements, which mandate the inclusion
of certain content in device labels and labelling, and generally require the label and package of medical devices to include a unique
device identifier ("UDI"), and which also prohibit the promotion of products for uncleared or unapproved, i.e., "off-label,"
uses; |
| – | Medical Device Reporting ("MDR") regulation,
which requires that manufacturers and importers report to the FDA if their device may have caused or contributed to a death or serious
injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and |
| – | Reports of Corrections and Removals regulation, which
requires that manufacturers and importers report to the FDA recalls (i.e., corrections or removals) if undertaken to reduce a risk to
health posed by the device or to remedy a violation of the Federal Food, Drug and Cosmetic Act that may present a risk to health; manufacturers
and importers must keep records of recalls that they determine to be non-reportable. |
The FDA enforces these requirements by inspection
and market surveillance. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which
may include, but is not limited to, the following sanctions:
| – | Untitled letters or warning letters; |
| – | Fines, injunctions and civil penalties; |
| – | Recall or seizure of our products; |
| – | Operating restrictions, partial suspension or total
shutdown of production; |
| – | Refusing a request for 510(k) clearance or premarket
approval of new products; |
| – | Withdrawing 510(k) clearance or premarket approvals
that are already granted; and |
We would be subject to unannounced device inspections by the
FDA, as well as other regulatory agencies overseeing the implementation of and compliance with applicable state public health regulations.
These inspections may include our suppliers' facilities.
Other Regulation in the United Kingdom
and Wales and the EU
Healthcare Reimbursement
Government and private sector initiatives
to limit the growth of healthcare costs, including price regulation, competitive pricing, coverage and payment policies, and managed-care
arrangements, are continuing in many countries where we do business, including the United Kingdom and Wales. These changes are causing
the marketplace to put increased emphasis on the delivery of more cost-effective medical products. Government programs, private healthcare
insurance and managed-care plans have attempted to control costs by limiting the amount of reimbursement they will pay for particular
procedures or treatments. This has created an increasing level of price sensitivity among customers for products. Some third-party payers
must also approve coverage for new or innovative devices or therapies before they will reimburse healthcare providers who use the medical
devices or therapies. Even though a new medical product may have been cleared for commercial distribution, we may find limited demand
for the product until reimbursement approval has been obtained from governmental and private third-party payers.
Environmental Regulation
We are also subject to various environmental laws and regulations
both within and outside the United Kingdom and Wales. Like many other medical device companies, our operations involve the use of substances,
including hazardous wastes, which are regulated under environmental laws, primarily manufacturing and sterilization processes. We do
not expect that compliance with environmental protection laws will have a material impact on our consolidated results of operations,
financial position or cash flow. These laws and regulations are all subject to change, however, and we cannot predict what impact, if
any, such changes might have on our business, financial condition or results of operations.
Foreign Regulation
Whether or not we obtain regulatory approval
for a product, we must obtain approval from the comparable regulatory authorities of foreign countries before we can commence clinical
trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer
or shorter than that required for EC approval. The requirements governing the conduct of clinical trials, product licensing, pricing and
reimbursement also vary greatly from country to country.
In addition, regulatory approval of prices is required in most
countries other than the United States. We face the risk that the prices which result from the regulatory approval process would be insufficient
to generate an acceptable return to us or our collaborators.
EU General Data Protection Regulation
The EU General Data Protection Regulation
(the “GDPR”) came into force in all EU Member States from May 25, 2018 and replaced previous EU data privacy laws. Although
a number of basic existing principles will remain the same, the GDPR introduces new obligations on data controllers and rights for data
subjects, including, among others:
| – | accountability and transparency requirements, which will require data controllers
to demonstrate and record compliance with the GDPR and to provide more detailed information to data subjects regarding processing; |
| – | enhanced data consent requirements, which includes “explicit”
consent in relation to the processing of sensitive data; |
| – | obligations to consider data privacy as any new products or services are
developed and limit the amount of information collected, processed, stored and its accessibility; |
| – | constraints on using data to profile data subjects; |
| – | providing data subjects with personal data in a useable format on request
and erasing personal data in certain circumstances; and |
| – | reporting of breaches without undue delay (72 hours where feasible). |
The GDPR also introduced new fines and penalties
for a breach of requirements, including fines for serious breaches of up to the higher of 4% of annual worldwide revenue or €20m
and fines of up to the higher of 2% of annual worldwide revenue or €10m (whichever is highest) for other specified infringements.
The GDPR identifies a list of points to consider when imposing fines (including the nature, gravity and duration of the infringement).
The Company has assessed the implications
of the GDPR on all personal data it holds and has implemented measures to ensure that personal data shall be:
| - | Processed lawfully, fairly and
in a transparent manner in relation to the data subject. |
| - | Collected for a specified, explicit
and legitimate purpose and not further processed in a manner that is incompatible with those purposes. |
| - | Adequate, relevant and limited
to what is necessary in relation to the purposes for which they are processed. |
| - | Kept in a form which permits
identification of data subjects for no longer than is necessary for the purposes for which the personal data is processed. |
| - | Processed in a manner that ensures
appropriate security of the personal data, including protection against unauthorised or unlawful processing and against accidental loss,
destruction or damage, using appropriate technical or organisational measures. |
| - | Maintained accurately and up
to date and that every reasonable step is taken to ensure that personal data that is inaccurate, having regard to the purposes for which
they are processed, are erased or rectified without delay. |
At the current stage of the Company’s
development and, with being pre-revenue at this stage, the scope of data held, and consequently the impact of GDPR, is limited. Increased
application of GDPR will be assessed and implemented prior to further Company developments that warrant additional GDPR measures. As the
Company progresses with product commercialization, the extent to which GDPR will affect the Company will increase, which will require
additional changes to the Company’s procedures and policies which could adversely impact operational and compliance costs. Further,
there is a risk that the measures will not be implemented correctly or that individuals within the business will not be fully compliant
with the new procedures. If there are breaches of these measures, the Company could face significant administrative and monetary sanctions
as well as reputational damage which may have a material adverse effect on its operations, financial condition, and prospects.
Corporate Information
Our principal executive offices are located
at 57 West 57th Street New York, NY 10019. Our website is located at www.nemauramedical.com and our telephone number is + 1
646-416-7912. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report,
and you should not consider it part of the Annual Report.
Human Capital Management
We believe that a diverse workforce is important
to our success. We will continue to focus on the hiring, retention and advancement of women and underrepresented populations, and to cultivate
an inclusive and diverse corporate culture. In the future, we intend to continue to evaluate our use of human capital measures or objectives
in managing our business such as the factors we employ or seek to employ in the development, attraction and retention of personnel and
maintenance of diversity in our workforce.
The success of our business is fundamentally
connected to the well-being of our people. Accordingly, we are committed to the health, safety, and wellness of our employees. We provide
our employees with access to a variety of flexible and convenient health and wellness programs, including benefits that provide protection
and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being;
that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and
encourage engagement in healthy behaviors; and that offer choice where possible so they can customize their benefits to meet their needs
and the needs of their families.
We also provide robust compensation and
benefits programs to help meet the needs of our employees. We believe that we maintain a satisfactory working relationship with our employees
and have not experienced any labor disputes. As of March 31, 2023, we had 38 personnel employed on our payroll, which equates to approximately
36 full-time equivalents.
Corporate History and Restructuring
We are a holding corporation that owns 100% of a diagnostic
medical device company specializing in discovering, developing, and commercializing specialty medical devices. We were organized on December
24, 2013, under the laws of the State of Nevada. We own 100% of Dermal Diagnostic (Holdings) Limited, an England and Wales corporation
formed on December 11, 2013. Dermal Diagnostics (Holdings) Limited owns 100% of the stock in Dermal Diagnostics Limited (“DDL”),
an England and Wales corporation formed on January 20, 2009, and 100% of the stock in Trial Clinic Limited (“TCL”), an England
and Wales corporation formed on January 12, 2011.
During the fiscal year ended March 31, 2021, the Board of Directors
assessed the adequacy of the group’s organizational structure and concluded that an intermediary holding company, Region Green
Limited, was no longer required as the entity had been effectively dormant since inception and no longer represented a requirement to
be maintained. It was therefore determined that Region Green Limited should be unwound, with the assets held by Region Green Limited
being transferred up to Nemaura Medical Inc. following which Region Green Limited would be dissolved.
The transfer of assets took place on March
5, 2021 and Region Green Limited was formally dissolved as of April 23, 2021.
In December 2013, we restructured the Company
and re-domiciled as a domestic corporation in the United States. The corporate re-organization was accomplished to preserve the tax advantages
under the laws of the England and Wales tax laws for the benefit of the shareholders of both Dermal Diagnostics Limited and Trial Clinic
Limited.
DDL is a diagnostic medical device company
headquartered in Loughborough, Leicestershire, England. DDL was founded on January 20, 2009, to engage in the discovery, development and
commercialization of diagnostic medical devices. The Company’s initial focus has been on the development of a novel CGM device.
ITEM 1A. — RISK FACTORS
Investing
in our securities is highly speculative and involves a high degree of risk. You should carefully consider the following risks and other
information in this Annual Report on Form 10-K and our other SEC filings before deciding to invest. Additional risks and uncertainties
that we are unaware of may become relevant to us. Any of the following risks could materially and adversely affect our business, results
of operations or financial condition. In that event, the trading price of our common stock and warrants may decline, and you could lose
all or part of your investment.
We will need to raise additional funds in order to finance
the anticipated commercialization of our product by incurring indebtedness, through collaboration and licensing arrangements, or by issuing
securities which may cause dilution to existing stockholders, or require us to relinquish rights to our technologies and our product.
Developing our product, conducting clinical trials, establishing
manufacturing facilities and developing marketing and distribution capabilities is expensive. We will need to finance future cash needs
through additional public or private equity offerings, debt financings or corporate collaboration and licensing arrangements. We cannot
be certain that additional funding will be available to us on acceptable terms, or at all. If adequate funds are not available, we may
be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization
efforts. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience dilution. To the
extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights
to our technologies or our product or grant licenses on terms that are not favorable to us.
We have a limited operating history, and you should not rely
on our historical financial data as an indicator of our future financial performance.
We have a limited operating history in the medical device industry.
You should consider our business and prospects in light of the risks and difficulties we face with our limited operating history and
should not rely on our past results as an indication of our future performance. In particular, we may face challenges in planning our
growth strategy and forecasting market demand accurately as a result of our limited historical data and limited experience in implementing
and evaluating our business strategies. If we are unable to successfully address these risks, difficulties and challenges as a result
of our limited operating history, our ability to implement our strategic initiatives could be adversely affected, which may in turn have
a material adverse effect on our business, financial condition, results of operations and prospects.
We have a history of losses and may not achieve or maintain profitability.
We have incurred net losses every year since our inception
in 2009 and have generated minimal revenue from the period of our inception from product sales or licenses to date. As of March 31, 2023,
we had an accumulated deficit of approximately $52.5 million. We expect to incur losses until our product is successfully launched and
cannot be certain that we will ever achieve profitability. As a result, our business is subject to all of the risks inherent in the development
of a new business enterprise, such as the risk that we may not obtain substantial additional capital needed to support the expenses of
developing our technology and commercializing our potential products; develop a market for our potential products; successfully transition
from a company with a research focus to a company capable of either manufacturing and selling potential products or profitably licensing
our potential products to others; and/or attract and retain qualified management, technical and scientific staff.
There is substantial doubt about our ability to
continue as a going concern, which may hinder our ability to obtain future financing.
For the year ended March 31, 2023, the Company
recorded a net loss of $14,143,735 and used cash in operations of $8,451,781. These factors raise substantial doubt about the Company’s
ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements
do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. In addition, the Company’s
independent registered public accounting firm, in their report on the Company’s March 31, 2023 audited financial statements, raised
substantial doubt about the Company’s ability to continue as a going concern.
In evaluating the going concern
position of the company, management has considered potential funding providers and believes that financing to fund future operations could
be provided by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions
on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.
Revenue generation from product sales has only commenced in the current fiscal
year and may never become profitable.
To date, we have generated revenue for the
first time in the current fiscal period for product sales. Our ability to generate and grow revenue depends on several factors, including
our ability to support the market launch of our UK Licensee, successfully obtain regulatory approval in all key markets identified to
commercialize our product pipeline. Even then, we will need to establish and maintain sales, marketing, distribution and to the extent
we do not outsource manufacturing, manufacturing capabilities. We plan to rely on one or more strategic collaborators to help generate
revenues in markets outside of Great Britain however, we cannot be sure that our collaborators, if any, will be successful. Our ability
to generate revenue will also be impacted by certain challenges, risks and uncertainties frequently encountered in the establishment of
new technologies and products in emerging markets and evolving industries. These challenges include our ability to:
| – | execute our business model; |
| – | create brand recognition; |
| – | manage growth in our operations; |
| – | create a customer base cost-effectively; |
| – | access additional capital when required; and |
| – | attract and retain key personnel. |
We cannot be certain that our business model
will be successful or that it will successfully address these and other challenges, risks, and uncertainties. If we are unable to generate
significant revenue, we may not become profitable, and we may be unable to continue our operations. Even if we are able to commercialize
the sugarBEAT® device, we may not achieve profitability for at least several years, if at all, after generating material revenue.
Our substantial
amount of indebtedness may adversely affect our cash flow and our ability to operate our business, remain in compliance with debt covenants
and make payments on our indebtedness.
Our substantial
level of indebtedness increases the possibility that we may be unable to generate cash sufficient to pay, when due, the principal or interest
on or other amounts due with respect to our indebtedness. Our indebtedness could have other important consequences to you as a stockholder.
For example, it could:
| – | make it more difficult for us to satisfy our obligations with respect to our indebtedness and any failure
to comply with the obligations of any of our debt instruments, including financial and other restrictive covenants, could result in an
event of default under the senior secured credit facility and the senior subordinated note; |
| – | make is more vulnerable to adverse changes in general economic, industry and competitive conditions
and adverse change in government regulation; |
| – | require us to dedicate a substantial portion of our cashflow from operations to payments on our indebtedness,
thereby reducing the availability of our cashflows to fund working capital, capital expenditures, acquisitions and other general corporate
purposes; |
| – | limit our flexibility in planning for, or reacting to, changes in our business and the industry in which
we operate; |
| – | place us at a competitive disadvantage compared to our competitors that have less debt; and |
| – | limit our ability to borrow amounts for working capital, capital expenditures, acquisitions, debt service
requirements, execution of our business strategy or other purposes. |
Risks Related to Our Product Candidate
and Operations
We are largely dependent on the success
of our sole product candidate, the sugarBEAT® device, and we may not be able to successfully commercialize this potential product.
We have incurred and will continue to incur
significant costs relating to the development and marketing of our sole product candidate, the sugarBEAT® device. We have obtained
approval to market this product in the EU, but it is not guaranteed that we will achieve this in any jurisdiction and we may never be
able to obtain approval or, if approvals are obtained, to commercialize this product successfully in other territories.
If we fail to successfully commercialize
our product(s) in multiple territories, we may be unable to generate sufficient revenue to sustain and grow our business, and our business,
financial condition and results of operations will be adversely affected.
If we fail to obtain regulatory approval
of the sugarBEAT® device or any of our other future products, we will be unable to commercialize these potential products.
The development, testing, manufacturing
and marketing of our product is subject to extensive regulation by governmental authorities in Great Britain and the European Union. In
particular, the process of obtaining CE approval by a Notified Body, a third party that can carry out a conformity assessment recognized
by the European Union, is costly and time consuming, and the time required for such approval is uncertain. Our product must undergo rigorous
preclinical and clinical testing and an extensive regulatory approval process mandated for the CE. Such regulatory review includes the
determination of manufacturing capability and product performance. CE approval was granted by the European Notified Body BSI in May 2019,
allowing the product to be made available for commercial sale. This approval is subject to an annual review of the underlying ISO 13485
accredited Quality Management System. The accreditation was successfully renewed in November 2021.
There can be no assurance that all necessary
approvals will be granted for future products or that CE review or actions will not involve delays caused by requests for additional information
or testing that could adversely affect the time to market for and sale of our product. Further failure to comply with applicable regulatory
requirements can, among other things, result in the suspension of regulatory approval as well as possible civil and criminal sanctions.
Failure to enroll patients in future clinical trials may cause delays in developing the sugarBEAT® device or any of our future products.
We may encounter delays in the development
and commercialization, or fail to obtain marketing approval, of the sugarBEAT® device or any other future products if we are unable
to enroll enough patients to complete clinical trials. Our ability to enroll sufficient numbers of patients in our clinical trials depends
on many factors, including the severity of illness of the population, the size of the patient population, the nature of the clinical protocol,
the proximity of patients to clinical sites, and the eligibility criteria for the trial and competing clinical trials. Delays in any possible
future patient enrolment, based on request by local regulatory agencies to conduct studies in their territory, may result in increased
costs and harm our ability to complete our clinical trials and obtain regulatory approval.
Delays in clinical testing could result
in increased costs to us and delay our ability to generate revenue.
Significant delays in clinical testing could
materially, adversely impact our product development costs. We do not know whether planned clinical trials will begin on time, will need
to be restructured or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays
in obtaining regulatory approval to commence and continue a study, delays in reaching agreement on acceptable clinical study terms with
prospective sites, delays in obtaining institutional review board approval to conduct a study at a prospective site and delays in recruiting
patients to participate in a study.
Significant delays in testing or regulatory approvals for any
of our current or future products, including the sugarBEAT® device, could prevent or cause delays in the commercialization of such
product candidates, reduce potential revenues from the sale of such product candidates and cause our costs to increase.
Further clinical trials for any of our current or future
products may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical
and/or preclinical testing for these products or cease our trials.
We will only receive regulatory approval
to commercialize a product candidate if we can demonstrate to the satisfaction of the applicable regulatory agency that the product is
safe and effective. We do not know whether our future clinical trials will demonstrate safety and efficacy sufficiently to result in marketable
products. Because our clinical trials for the sugarBEAT® device may produce negative or inconclusive results, we may decide, or regulators
may require us, to conduct additional clinical and/or preclinical testing for this product or cease our clinical trials. If this occurs,
we may not be able to obtain approval for this product or our anticipated time to market for this product may be substantially delayed
and we may also experience significant additional development costs. We may also be required to undertake additional clinical testing
if we change or expand the indications for our product.
If approved, the commercialization of
our product, the sugarBEAT® device, may not be profitable due to the need to develop sales, marketing and distribution capabilities,
or make arrangements with a third party to perform these functions.
In order for the commercialization of our potential product
to be profitable, our product must be cost-effective and economical to manufacture on a commercial scale. Subject to regulatory approval,
we expect to incur significant sales, marketing, distribution, and to the extent we do not outsource manufacturing, manufacturing expenses
in connection with the commercialization of the sugarBEAT® device and our other potential products. We do not currently have a dedicated
sales force and our current manufacturing capability has limited capacity, we also have limited experience in the sales, marketing and
distribution of medical diagnostic device products. In order to commercialize the sugarBEAT® device or any of our other potential
products that we may develop, we must develop sales, marketing and distribution capabilities or make arrangements with a third party
to perform these functions. Developing a sales force is expensive and time-consuming, and we may not be able to develop this capacity.
If we are unable to establish adequate sales, marketing and distribution capabilities, independently or with others, we may not be able
to generate significant revenue and may not become profitable. Our future profitability will depend on many factors, including, but not
limited to:
| – | the costs and timing of developing a commercial scale manufacturing facility
or the costs of outsourcing the manufacturing of the sugarBEAT® device; |
| – | receipt of regulatory approval of the sugarBEAT® device; |
| – | the terms of any marketing restrictions or post-marketing commitments imposed
as a condition of approval by regulatory authorities; |
| – | the costs of filing, prosecuting, defending and enforcing any patent claims
and other intellectual property rights; |
| – | costs of establishing sales, marketing and distribution capabilities; |
| – | the effect of competing technological and market developments; and |
| – | the terms and timing of any collaborative, licensing and other arrangements
that we may establish. |
Even if we receive regulatory approval for
the sugarBEAT® device or any other product candidates, we may never receive significant revenues from any of them. To the extent that
we are not successful in commercializing our potential products, we will incur significant additional losses.
Our proprietary rights may not adequately protect our intellectual property
and product and if we cannot obtain adequate protection of our intellectual property and product, we may not be able to successfully
market our product.
Our commercial success will depend in part
on obtaining and maintaining intellectual property protection for our technologies and product. We will only be able to protect our technologies
and product from unauthorized use by third parties to the extent that valid and enforceable patents cover them, or that other market exclusionary
rights apply. While we have issued enforceable patents covering the sugarBEAT® device, the patent positions of companies like ours
can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent
policy regarding the breadth of claims allowed in such companies’ patents has emerged to date in Great Britain and the European
Union. The general patent environment outside the United States involves significant uncertainty. Accordingly, we cannot predict the breadth
of claims that may be allowed or that the scope of these patent rights would provide a sufficient degree of future protection that would
permit us to gain or keep our competitive advantage with respect to this product and technology. Additionally, companies like ours are
dependent on creating a pipeline of products. We may not be able to develop additional proprietary technologies or products that produce
commercially viable products or that are themselves patentable.
Our issued patents may be subject to challenge
and possibly invalidated by third parties. Changes in either the patent laws or in the interpretations of patent laws in Great Britain
or the European Union or other countries may diminish the market exclusionary ability of our intellectual property.
In addition, others may independently develop
similar or alternative technologies that may be outside the scope of our intellectual property. Should third parties obtain patent rights
to similar technology, this may have an adverse effect on our business. Similarly future developments and improvements could lead to our
existing patents becoming obsolete and leaving intellectual property secured primarily in the form of know-how.
To the extent that consultants or key employees
apply technological information independently developed by them or by others to our product, disputes may arise as to the proprietary
rights of the information, which may not be resolved in our favor. Consultants and key employees that work with our confidential and proprietary
technologies are required to assign all intellectual property rights in their discoveries to us. However, these consultants or key employees
may terminate their relationship with us, and we cannot preclude them indefinitely from dealing with our competitors. If our trade secrets
become known to competitors with greater experience and financial resources, the competitors may copy or use our trade secrets and other
proprietary information in the advancement of their products, methods or technologies. If we were to prosecute a claim that a third party
had illegally obtained and was using our trade secrets, it would be expensive and time consuming and the outcome would be unpredictable.
In addition, courts in Great Britain and the European Union are sometimes less willing to protect trade secrets than courts in the United
States. Moreover, if our competitors independently develop equivalent knowledge, we would lack any contractual claim to this information,
and our business could be harmed.
Our ability to commercialize our product
will depend on our ability to sell such products without infringing the patent or proprietary rights of third parties. If we are sued
for infringing intellectual property rights of third parties, such litigation will be costly and time consuming and an unfavorable outcome
would have a significant adverse effect on our business.
Our ability to commercialize our product
will depend on our ability to sell such products without infringing the patents or other proprietary rights of third parties. Third-party
intellectual property in the field of diagnostic medical devices is complicated, and third-party intellectual property rights in this
field are continuously evolving. We have not performed searches for third-party intellectual property rights that may raise freedom-to-operate
issues, and we have not obtained legal opinions regarding commercialization of our product other than patent research prior to the filing
of our patent applications, and search and examination reports from the respective patent examination offices.
In addition, because patent applications are published months
after their filing, and because applications can take several years to issue, there may be currently pending third-party patent applications
that are unknown to us, which may later result in issued patents. If a third-party claim that we infringe on its patents or other proprietary
rights, we could face a number of issues that could seriously harm our competitive position, including:
| – | infringement claims that, with or without merit, can be costly and time
consuming to litigate, can delay the regulatory approval process and can divert management’s attention from our core business strategy; |
| – | substantial damages for past infringement which we may have to pay if a
court determines that our products or technologies infringe upon a competitor’s patent or other proprietary rights; |
| – | if a license is available from a holder, we may have to pay substantial
royalties or grant cross licenses to our patents or other proprietary rights; and |
| – | Re-designing our process so that it does not infringe the third-party intellectual
property, which may not be possible, or which may require substantial time and expense including delays in bringing our own products to
market. |
Such actions could harm our competitive
position and our ability to generate revenue and could result in increased costs.
If our product, the sugarBEAT®
device, does not gain market acceptance among physicians, patients and the medical community, we will be unable to generate significant
revenue, if any.
The sugarBEAT® device that we developed may not achieve
market acceptance among physicians, patients, third-party payers and others in the medical community. If we receive the regulatory approvals
necessary for commercialization, the degree of market acceptance will depend upon a number of factors, including:
| – | limited indications of regulatory approvals; |
| – | the establishment and demonstration in the medical community of the clinical efficacy and safety of
our product and its potential advantages over existing diagnostic medical devices; |
| – | the prevalence and severity of any side effects; |
| – | our ability to offer our product at an acceptable price; |
| – | the relative convenience and ease of use of our product; |
| – | the strength of marketing and distribution support; and |
| – | sufficient third-party coverage or reimbursement. |
The market may not accept the sugarBEAT® device based on
any number of the above factors. If the sugarBEAT® device is approved, there may be other therapies available which directly compete
for the same target market. The market may choose to continue utilizing the existing products for any number of reasons, including familiarity
with or pricing of these existing products. The failure of any of our products to gain market acceptance could impair our ability to
generate revenue, which could have a material adverse effect on our future business.
We have outsourced the bulk of the commercial manufacturing
operations for the various components of the sugarBEAT®, with the exception of the Sensor chemistry which is being conducted
in-house. The failure to find manufacturing partners or expand our internal manufacturing facility could have an adverse impact on our
ability to grow our business.
We are largely dependent on third parties
to supply our product according to our specifications, in sufficient quantities, on time, in compliance with appropriate regulatory standards
and at competitive prices. We cannot be sure that we will be able to obtain an adequate supply of our product candidates on acceptable
terms, or at all.
Manufacturers supplying diagnostic medical devices must comply
with regulations which require, among other things, compliance with evolving regulations under Medical Device Directives stipulated under
ISO13485. The manufacturing of products at any facility will be subject to strict quality control, testing and record keeping requirements,
and continuing obligations regarding the submission of safety reports and other post-market information. Both the sensor and patch manufacturing
facilities for the sugarBEAT® device are currently ISO13485 certified. We cannot guarantee that the facilities will continue to pass
regulatory inspection, or that future changes to ISO13485 standards will not also affect the manufacture of the sensors and patches.
If we fail to attract and retain senior
management, consultants, advisors and scientific and technical personnel, our product development and commercialization efforts could
be impaired.
Our performance is substantially dependent
on the performance of our senior management and key scientific and technical personnel, particularly Dr. Dewan Fazlul Hoque Chowdhury,
President, Chairman and Chief Executive Officer. The loss of the services of any member of our senior management or our scientific or
technical staff may significantly delay or prevent the development of our product and other business objectives by diverting management’s
attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business,
operating results and financial condition.
We also rely on consultants and advisors
to assist us in formulating our research and development strategy. All of our consultants and advisors are either self-employed or employed
by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other
organizations, that may affect their ability to contribute to us.
In addition, we believe that we will need
to recruit additional executive management and scientific and technical personnel. There is currently intense competition for skilled
executives and employees with relevant scientific and technical expertise, and this competition is likely to continue. The inability to
attract and retain sufficient scientific, technical and managerial personnel could limit or delay our product development efforts, which
would adversely affect the development of our product and commercialization of our potential product and growth of our business.
We expect to expand our marketing capabilities and, as a result of which we may
encounter difficulties in managing our growth, which could disrupt our operations.
We expect to have growth in expenditures, the number of our
employees and the scope of our operations, in particular with respect to those potential products that we elect to commercialize independently
or together with others. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational
and financial systems, expand our facilities and continue to train qualified personnel. Due to our limited resources, we may not be able
to effectively manage the expansion of our operations or train additional qualified personnel. The physical expansion of our operations
may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could
delay the execution of our business plan or disrupt our operations.
Fluctuations in foreign exchange rates may adversely affect our financial condition
and results of operations.
Our functional currency is the Great Britain
Pound Sterling (“GBP”). The reporting currency is the United States dollar (U.S.$). Income and expenditures are translated
at the appropriate weighted average exchange rates prevailing during the reporting period. Assets and liabilities are translated at the
exchange rates as of balance sheet date. Stockholders’ equity is translated into United States dollars from GBP at historical exchange
rates. Currency fluctuations and restrictions on currency exchange may adversely affect our business, including limiting our ability to
convert GBP into foreign currencies and, if the GBP were to decline in value, reducing our revenue in U.S. dollar terms. To the extent
the U.S. dollar strengthens against foreign currencies, the translation of these foreign currencies denominated transactions results in
reduced revenue, operating expenses and net income for our international operations. Similarly, to the extent the U.S. dollar weakens
against foreign currencies, the translation of these foreign currency denominated transactions results in increased revenue, operating
expenses and net income for our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the
financial statements of our foreign subsidiaries into U.S. dollars in consolidation. If there is a change in foreign currency exchange
rates, the conversion of the foreign subsidiaries’ financial statements into U.S. dollars will lead to a translation gain or loss
which is recorded as a component of other comprehensive income (loss). We have not entered into agreements or purchased instruments to
hedge our exchange rate risks. The availability and effectiveness of any hedging transaction may be limited, and we may not be able to
successfully hedge our exchange rate risks.
In addition, a number of events have occurred
in recent years, including the UK’s Brexit vote to leave the EU, the impact of Covid-19, and the invasion of Ukraine by Russia,
that have had significant and potentially lasting effect of both the global economic outlook as well as a weakening of GBP against many
currencies. We expect to have to pay some of our service providers and vendors in U.S.$ which given the exchange rate impact and knock
on inflationary pressure, will represent a significant increase in costs to the business compared to prior years. The currency exchange
rate continues to be very unstable and therefore the future impact or further weakening of GBP is not known at this time.
Our business, financial condition and results of operations
may be materially adversely affected by global health epidemics, including the COVID-19 pandemic.
A regional or global
health pandemic, including COVID-19, could severely affect our business, results of operations and financial condition. A regional or
global health pandemic, depending upon its duration and severity, could have a material adverse effect on our business. For example, the
COVID-19 pandemic has had numerous effects on the global economy and governmental authorities around the world have implemented measures
to reduce the spread of COVID-19. These measures, including shutdowns and “shelter-in-place” orders suggested or mandated
by governmental authorities or otherwise elected by companies as a preventive measure, have adversely affected workforces, customers,
consumer sentiment, economies and financial markets, and, along with decreased consumer spending, have led to an economic downturn in
many of our markets.
As a result of
the COVID-19 pandemic, we evaluated and executed the steps available to us to ensure we were able to provide protection of our employees
and instigated remote working where possible combined with following all government advice and guidance regarding any engagement within
the workplace that could not be completed remotely. To date this transition has had little impact on our employee productivity and has
caused limited interruption to our business. Whilst restrictions associated with COVID-19 have largely been removed, we will continue
to assess the situation, including abiding by any government-imposed restrictions, as and where relevant.
At this point in
time, there remains some uncertainty relating to the potential effect of COVID-19 on our business. As infections may continue to become
more widespread, we could experience a severe negative impact on our business, financial condition, and results of operations. To the
extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of
the other risks described in this “Risk factors” section.
Risks Related to Our Industry
Our competitors may develop products that are less expensive,
safer or more effective, which may diminish or eliminate the commercial success of any potential products that we may commercialize.
If our competitors market products that
are less expensive, safer or more effective than our future products developed from our product candidates, or that reach the market before
our products, we may not achieve commercial success. For example, if approved, the sugarBEAT® device’s primary competition in
the glucose monitoring device setting will be companies such as Dexcom, Abbott, and Senseonics who produce glucose monitoring devices.
The market may choose to continue utilizing the existing products for any number of reasons, including familiarity with or pricing
of these existing products. The failure of our product to compete with products marketed by our competitors would impair our ability to
generate revenue, which would have a material adverse effect on our future business, financial condition and results of operations.
We expect to compete with several companies including Dexcom,
Abbott, and Senseonics, and our competitors may:
| – | develop and market products that are less expensive or more effective than
our future product; |
| – | commercialize competing products before we can launch any products developed
from our product candidate; |
| – | operate larger research and development programs or have substantially greater
financial resources than we do; |
| – | initiate or withstand substantial price competition more successfully than
we can; |
| – | have greater success in recruiting skilled technical and scientific workers
from the limited pool of available talent; |
| – | more effectively negotiate third-party licenses and strategic relationships;
and |
| – | take advantage of acquisition or other opportunities more readily than we
can. |
We expect to compete for market share against
large medical diagnostic device manufacturing companies, smaller companies that are collaborating with larger companies, new companies,
and other public and private research organizations.
In addition, our industry is characterized by rapid technological
change. Because our research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes in
each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors
may render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches,
potentially eliminating the advantages in our product discovery process that we believe we derive from our research approach and proprietary
technologies.
The use of hazardous materials in our operations may subject
us to environmental claims or liabilities.
Our research and development activities
involve the use of hazardous chemical materials. Injury or contamination from these materials may occur and we could be held liable for
any damages, which could exceed our available financial resources. This liability could materially adversely affect our business, financial
condition and results of operations.
We are subject to laws and regulations governing the use, manufacture,
storage, handling and disposal of hazardous materials and waste products. We may be required to incur significant costs to comply with
environmental laws and regulations in the future that could materially adversely affect our business, financial condition and results
of operations.
If we fail to comply with extensive regulations
enforced by regulatory agencies with respect to diagnostic medical device products, the commercialization of our product could be prevented,
delayed or halted.
Research, preclinical development, clinical
trials, manufacturing and marketing of our product is subject to extensive regulation by various government authorities. We have not received
marketing approval for the sugarBEAT® device in all of our target markets. The process of obtaining the required regulatory approvals
is lengthy and expensive, and the time required for such approvals is uncertain. The approval process is affected by such factors as:
| – | the indication and claims of the diagnostic device; |
| – | the quality of submission relating to the product; |
| – | the product’s clinical efficacy and safety; |
| – | the manufacturing facility compliance; |
| – | the availability of alternative devices; |
| – | the risks and benefits demonstrated in clinical trials; and |
| – | the patent status and marketing exclusivity rights of certain innovative
products. |
Any regulatory approvals that we or our
partners receive for our product may also be subject to limitations on the indicated uses for which the product may be marketed or contain
requirements for potentially costly post-marketing follow-up studies. The subsequent discovery of previously unknown problems with the
product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product and
withdrawal of the product from the market.
Manufacturing, labelling, storage and distribution
activities also are subject to strict regulation and licensing by government authorities. The manufacturing facilities for our product
will be subject to periodic inspection by the regulatory authorities and from time to time, these agencies may send notice of deficiencies
as a result of such inspections. Our failure, or the failure of our manufacturing facilities, to continue to meet regulatory standards
or to remedy any deficiencies could result in corrective action by the authorities, including the interruption or prevention of marketing,
closure of our manufacturing facilities, and fines or penalties.
Regulatory authorities also will require
post-marketing surveillance to monitor and report potential adverse effects of our product. If approved, any of our products’ subsequent
failure to comply with applicable regulatory requirements could, among other things, result in warning letters, fines, suspension or revocation
of regulatory approvals, product recalls or seizures, operating restrictions, injunctions and criminal prosecutions.
Government policies may change, and additional
government regulations may be enacted that could prevent or delay regulatory approval of our product. We cannot predict the likelihood,
nature or extent of adverse government regulation that may arise from future legislation or administrative action. If we are not able
to maintain regulatory compliance, we might not be permitted to market our product and our business could suffer.
In the future, we hope to distribute
and sell our product outside of the United Kingdom and the European Union, which will subject us to further regulatory risk.
In addition to maintaining approval from
the United Kingdom and the European Union for the sugarBEAT® device, we may seek regulatory approval from Saudi Arabia and the United
Arab Emirates, Hong Kong, Australia, and the U.S., to market the sugarBEAT® device, however, there is no guarantee we will do so.
We may in the future also seek approvals for additional countries. The regulatory review process varies from country to country, and approval
by foreign government authorities is unpredictable, uncertain and generally expensive. The ability to market our product could be substantially
limited due to delays in receipt of, or failure to receive, the necessary approvals or clearances. Marketing of our product in these countries,
and in most other countries, is not permitted until we have obtained required approvals or exemptions in each individual country. Failure
to obtain necessary regulatory approvals could impair our ability to generate revenue from international sources.
Market acceptance of our product will
be limited if users are unable to obtain adequate reimbursement from third-party payers.
Government health administration authorities,
private health insurers and other organizations generally provide reimbursement for products like our product and our commercial success
will depend in part on these third-party payers agreeing to reimburse patients for the costs of our product. Even if we succeed in bringing
our product to market, we cannot assure you that third-party payers will consider our product cost effective or provide reimbursement
in whole or in part for its use.
Significant uncertainty exists as to the
reimbursement status of newly approved health care products. Our product is intended to replace or alter existing therapies or procedures.
These third-party payers may conclude that our product is less safe, effective or cost-effective than existing therapies or procedures.
Therefore, third-party payers may not approve our product for reimbursement.
If third-party payers do not approve our
product for reimbursement or fail to reimburse for them adequately, sales will suffer as some physicians, or their patients will opt for
a competing product that is approved for reimbursement or is adequately reimbursed. Even if third-party payers make reimbursement available,
these payers’ reimbursement policies may adversely affect our ability and the ability of our potential collaborators to sell our
product on a profitable basis.
The trend toward managed healthcare, the
growth of organizations such as health maintenance organizations and legislative proposals to reform healthcare and government insurance
programs could significantly influence the purchase of healthcare services and products, resulting in lower prices and reduced demand
for our product which could adversely affect our business, financial condition and results of operations.
In addition, legislation and regulations
affecting the pricing of our product may change in ways adverse to us before or after the regulatory agencies approve our product for
marketing. While we cannot predict the likelihood of any of these legislative or regulatory proposals, if any government or regulatory
agencies adopt these proposals, they could materially adversely affect our business, financial condition and results of operations.
Product liability claims may damage our
reputation and, if insurance proves inadequate, the product liability claims may harm our business.
As with other companies in our field, we
may be exposed to the risk of product liability claims that is inherent in the diagnostic medical device sector. A product liability claim
may damage our reputation by raising questions about our product’s safety and efficacy and could limit our ability to sell our product
by preventing or interfering with commercialization of our product.
In addition, product liability insurance
for our industry is generally expensive to the extent it is available at all. There can be no assurance that we will be able to maintain
such insurance on acceptable terms or that we will be able to secure increased coverage as the commercialization of our product progresses,
or that future claims against us will be covered by our product liability insurance. Moreover, there can be no assurance that any product
liability coverage from any insurance policy and/or any rights of indemnification and contribution that we have in place currently will
offset any / all future claims. A successful claim against us with respect to uninsured liabilities and not subject to any indemnification
or contribution could have a material adverse effect on our business, financial condition, and results of operations.
We could be negatively impacted by the
application or enforcement of fraud and abuse laws, including anti-kickback laws and other anti-referral laws.
We are not aware of any current business
practice which is in violation of any fraud and abuse law. However, continued vigilance to assure compliance with all potentially applicable
laws will be a necessary expense associated with product development. For example, all product marketing efforts must be strictly scrutinized
to assure that they are not associated with improper remunerations to referral sources in violation of any anti-kickback statutes. Remunerations
may include potential future activities for our product, including discounts, rebates and bundled sales, which must be appropriately structured
to take advantage of statutory and regulatory “safe harbors”. From time to time we may engage physicians in consulting activities.
In addition, we may decide to sponsor continuing medical education activities for physicians or other medical personnel. We may also award
or sponsor study grants to physicians from time to time. All relationships with physicians, including consulting arrangements, continuing
medical education and study grants, must be similarly reviewed for compliance with any anti-kickback statute to assure that remuneration
is not provided in return for referrals. Patient inducements may also be unlawful. Inaccurate reports of product pricing, or a failure
to provide a product at an appropriate price to various governmental entities, could also serve as a basis for an enforcement action under
various theories.
Claims which are “tainted” by
virtue of kickbacks or a violation of self-referral rules may be alleged as false claims if other elements of a violation are established.
Because our potential customers may seek payments from healthcare programs for our product, even during the clinical trial stages, we
must assure that we take no actions which could result in the submission of false claims. For example, free product samples which are
knowingly or with reckless disregard billed to healthcare programs could constitute false claims. If the practice was facilitated or fostered
by us, we could be liable. Moreover, inadequate accounting for or a misuse of grant funds used for product research and development could
be alleged as a violation of relevant statutes.
The risk of our being found in violation of these laws is increased
by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open
to a variety of interpretations, and additional legal or regulatory change.
Risks Related to Our Common Stock
Our stock price may be volatile.
The stock market, particularly in recent
years, has experienced significant volatility with respect to pharmaceutical, biotechnology and other diagnostic medical device company
stocks. The volatility of pharmaceutical, biotechnology and other diagnostic medical device company stocks often does not relate to the
operating performance of the companies represented by the stock. Factors that could cause this volatility in the market price of our common
stock include:
| – | results from and any delays in our clinical trials; |
| – | failure or delays in entering our product into clinical trials; |
| – | failure or discontinuation of any of our research programs; |
| – | delays in establishing new strategic relationships; |
| – | delays in the development or commercialization of our product; |
| – | market conditions in the diagnostic medical device sectors and issuance
of new or changed securities analysts’ reports or recommendations; |
| – | actual and anticipated fluctuations in our financial and operating results; |
| – | developments or disputes concerning our intellectual property or other proprietary
rights; |
| – | introduction of technological innovations or new commercial products by
us or our competitors; |
| – | issues in manufacturing our product; |
| – | market acceptance of our product; |
| – | third-party healthcare reimbursement policies; |
| – | regulatory actions affecting us or our industry; |
| – | litigation or public concern about the safety of our product; and |
| – | additions or departures of key personnel. |
These and other external factors may cause the market price
and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of
common stock and may otherwise negatively affect the liquidity of our common stock. In the past, when the market price of a stock has
been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If
any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also
divert the time and attention of our management.
We have not paid and may not pay any
dividends on our common stock.
We have paid no dividends on our common
stock to date and may not pay dividends to holders of our common stock in the foreseeable future. While our future dividend policy will
be based on the operating results and capital needs of the business, it is currently anticipated that any earnings will be retained to
finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a
lack of a dividend can further affect the market value of our stock and could significantly affect the value of any investment in our
Company.
We are subject to the reporting requirements
of federal securities laws. This can be expensive and may divert resources from other projects, and thus impairing our ability to grow.
We are subject to the information and reporting
requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and other federal securities laws, including
compliance with the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). The costs of preparing and filing annual and quarterly
reports, proxy statements and other information with the Securities and Exchange Commission (“SEC”) (including reporting of
any Merger that may occur in the future) and furnishing audited reports to stockholders will cause our expenses to be higher than they
would have been if we had remained privately held.
If we fail to establish and maintain
an effective system of internal control, we may not be able to report our financial results accurately or to prevent fraud. Any inability
to report and file our financial results accurately and timely could harm our reputation and adversely impact the trading price of our
common stock.
We are subject to reporting obligations
under the U.S. securities laws. The SEC, as required by Section 404 of the Sarbanes- Oxley Act (“SOX”), adopted rules requiring
every public company to include a management report on such company’s internal control over financial reporting in its annual report,
which contains management’s assessment of the effectiveness of the company’s internal control over financial reporting.
Public company compliance may make it
more difficult to attract and retain officers and directors.
The Sarbanes-Oxley Act and rules subsequently
implemented by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these
rules and regulations to increase our compliance costs and to make certain activities more time consuming and costly.
As a public company, we also expect that these rules and regulations may make it more difficult and expensive for us to obtain director
and officer liability insurance in the future and we may be required to accept reduced policy limits and coverage or incur substantially
higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified persons
to serve on our board of directors or as executive officers.
If our common stock is deemed a “penny
stock,” it will make it more difficult for our investors to sell their shares.
Our common stock will be subject to the
“penny stock” rules adopted under Section 15(g) of the Exchange Act. The penny stock rules generally apply to companies whose
common stock is not listed on The Nasdaq Stock Market or other national securities exchange and trades at less than $5.00 per share, other
than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible net worth of at least
$5,000,000 ($2,000,000 if the company has been operating for three or more years). These rules require, among other things, that brokers
who trade penny stock to persons other than “established customers” complete certain documentation, make suitability inquiries
of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document and
quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the requirements of the
penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities is limited. If we
remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market, if any, for our securities.
If our securities are subject to the penny stock rules, investors will find it more difficult to dispose of our securities.
Offers or availability for sale of a
substantial number of shares of our common stock may cause the price of our common stock to decline.
If our stockholders sell substantial amounts of our common
stock in the public market upon the expiration of any statutory holding period, under Rule 144, or issued upon the exercise of outstanding
options or warrants, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the
market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also
could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future
at a time and price that we deem reasonable or appropriate.
The interests of Dr D.F.H. Chowdhury,
or the controlling shareholders, may not always coincide with the interests of us and our other shareholders, and the controlling shareholders
may exert significant control or substantial influence over us and may take actions that are not in, or may conflict with, public shareholders’
best interests.
The controlling shareholders control the
exercise of voting rights of over 50% of the shares eligible to vote in any of our annual or special meetings. Therefore, these controlling
shareholders will be able to exercise significant influence over all matters that require us to obtain shareholder approval, including
the election of directors to our board and approval of significant corporate transactions that we may consider, such as a merger or other
sale of our company or its assets. The controlling shareholders may cause us to take actions that are not in, or may conflict with, the
interests of us or the public shareholders. In the case where the interests of the controlling shareholders conflict with those of our
other shareholders, or if the controlling shareholders choose to cause us to pursue objectives that would conflict with the interests
of our other shareholders, such other shareholders could be left in a disadvantageous position by such actions caused by the controlling
shareholders and the price of our common stock could be adversely affected.
We are subject to the anti-takeover provisions
of the Nevada Revised Statutes governing business combinations and control share acquisitions.
Applicability of the Nevada business combination
statute would discourage parties interested in taking control of our company if they cannot obtain the approval of our board of directors.
These provisions could prohibit or delay a merger or other takeover or change in control attempt and, accordingly, may discourage attempts
to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.
The effect of the Nevada control share statute
is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting of the stockholders. The Nevada control share
law, if applicable, could have the effect of discouraging takeovers of our company based on our organizational structure.
We are subject to compliance with multiple
tax jurisdictions.
As we transact out of both the UK and United
States, we must comply with tax filing requirements in both jurisdictions.
ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.
ITEM 2. PROPERTIES.
We have registered corporate offices in
the U.S. at 57 West 57th Street, Manhattan, NY 10019. We have offices and laboratories located across two locations on the
Loughborough University Science and Enterprise Park (LUSEP), Loughborough, Leicestershire, United Kingdom. The aggregate monthly rent
is approximately $51,000. All leases are currently operated on rolling 12-month terms. The terms of the different leases provide break
options allowing both landlord and tenant to terminate on provision of not less than one month’s prior written notice.
ITEM 3. LEGAL PROCEEDINGS.
We do not know of any material, active, pending or threatened
proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding
or pending litigation.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable
PART II
ITEM 5. MARKET FOR REGISTRANT’S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Market Information
Our common stock is traded on the NASDAQ Capital Market under
the trading symbol, “NMRD”. On July 12, 2023, the closing price for our common stock as reported on the NASDAQ Capital Market
was $0.9901.
As of July 12, 2023, we had 80 holders on
record of our common stock. The number of record holders does not include beneficial owners of common stock whose shares are held in the
names of banks, brokers, nominees or other fiduciaries.
Dividends
Since incorporation, we have not paid any
dividend on any class of equity securities. We anticipate that for the foreseeable future all earnings will be retained for use in our
business and no cash dividends will be paid to stockholders. Any payment of cash dividends in the future on the Company’s common
stock or preferred stock, will be dependent upon our financial condition, results of operations, current and anticipated cash requirements,
plans for expansion, as well as other factors that the Board of Directors deems relevant. The ability to pay dividends will be reliant
on the ability of DDL, the UK trading entity, to pay dividends to the Company and satisfying the capital maintenance requirements of UK
company’s legislation in line with statutory and company law.
Securities Authorized for Issuance Under
Equity Compensation Plans
We approved the adoption of an employee equity compensation
plan at our Annual General Meeting (“AGM”) on May 15, 2020. No awards have been made to date.
Unregistered Sales of Securities
None.
Purchases of Equity Securities by the Registrant and Affiliated Purchasers
We have not repurchased any shares of our common stock during the fiscal year
ended March 31, 2023.
ITEM 6. [RESERVED]
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the notes to those statements
included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, this discussion and analysis
contains forward-looking statements that reflect our plans, estimates and beliefs. You should not place undue reliance on these forward-looking
statements, which involve risks and uncertainties. As a result of many factors, including but not limited to those set forth under ‘‘Risk
Factors,’’ our actual results may differ materially from those anticipated in these forward-looking statements. See “Cautionary
Note Regarding Forward-Looking Statements.”.
Overview
Business Review and Outlook
It is management’s view that the Company
has made good progress during the fiscal year ended March 31, 2023, and some of the key developments are listed as follows:
| 1. | The
company continued to support its UK licensee with its endeavours to obtain reimbursement
for the sensors in the UK. |
| 2. | Advanced
development of its BEATdiabetes offering in readiness for a commercial launch in due course.
|
| 3. | Entered
in to a term sheet with Eversana, an organisation with expertise in taking medicines, devices
and digital healthcare products to market, with a view to entering in to a future commercial
agreement to support its launch of BEATdiabetes in the USA using proBEAT sensors. |
| 4. | Continued
development of its consumer metabolic health platform and potential deployment as a bolt-on
service into existing metabolic and wellness programs. |
| 5. | Supported
its partner TP-MENA with the submission for registration of sugarBEAT in the Kingdom of Saudi
Arabia (KSA). |
| 6. | Received
a provisional purchase order for 1.7 million sensors from its partner TPMENA in anticipation
of product registration in the KSA. |
Management is working towards fulfilling the remainder
of the UK licensees’ initial orders and supporting MSW’s UK launch plans, and for potential supplies to fulfill the provisional
purchase order for the KSA from TPMENA.The company continues to also develop capabilities to develop and service new channels of business
across other geographic markets via the use of our BEAT platform. To this end the company is now actively planning product launch in
other territories that accept the CE mark registration. In addition, the company is seeking to exploit its product platform in the consumer
space. All of these avenues are expected to strengthen revenue generation in future periods.
In line with this view, the Company has taken the following
actions during the fiscal year ended March 31, 2023:
- Increased headcount of production operatives; this will
be phased in line with the volume forecasts currently available, however the Company has also factored in an ability to scale further
and faster should this be required.
- Moved forward with placing phased orders for raw materials
to ensure future product availability to support both our UK Licensee while also providing for capacity to flex up further as other routes
to market materialize in line with management’s commercialization program.
- Engaged with external third-party manufacturers with the
ability to provide significant scale up services for product manufacture moving forward.
Affiliated Company Relationships
Pharma was incorporated in November 2005.
Through October 2013, all technology development and related transactions were incurred by Pharma. As new technology platforms were invented
and developed, additional companies were set up to contain these new technology platforms, and to aid in the process of raising further
investments to progress the development of these subsequent technologies. However, due to the small size of the operations, low number
of employees and laboratory and office space required, initially, certain costs were borne by Pharma and charged to DDL as required. On
April 4, 2018, a service agreement was put into place between Pharma and DDL which covered the development of sugarBEAT® under
Pharma’s ISO13485 Accreditation. In lieu of these services, Pharma invoices DDL on a periodic basis for said services. Services
are provided at cost plus a service surcharge amounting to less than 10% of the total costs incurred. This agreement includes all
aspects of the development, registration and manufacture of sugarBEAT®.
Full legal title and beneficial ownership
of the CE mark and all related intellectual property remains with Nemaura Medical under the terms of the service contract.
Dr. D.F.H. Chowdhury and Mr. Bashir Timol are officers of Pharma.
The current management at DDL, including Dr. D. F. H. Chowdhury allocate 15% - 20% of their time to oversee the current operations at
Pharma and will in due course implement a new management team in Pharma, and provide ongoing support in an advisory role. Pharma is a
drug delivery company, which means that its activities are entirely related to the administration of drugs to the body of a human or
animal subject. DDL is a diagnostic company, which means it is entirely focused on extracting molecules from the human or animal subject
and analyzing it to make a diagnosis or to monitor the level of a particular molecule such as glucose. These are two independent businesses
engaged in different activities, therefore there is no conflict of interest between the two and management does not see any conflicts
arising from the allocations of some of DDL management time to overseeing the operations of Pharma.
Payments made solely for work that Dr. D.
F. H. Chowdhury performs for Pharma in his capacity as manager are not charged to Nemaura Medical Inc. and are not included in our consolidated
financial statements.
RESULTS OF OPERATIONS
Management’s plans and basis of
presentation
The Company has experienced recurring losses
and negative cash flows from operations. On March 31, 2023, the Company had total stockholders’ deficit
of $(11,814,198) and an accumulated deficit of $51,875,211. To date, the Company has in large part relied on equity financing to fund
its operations. Initially additional funding also came from related party contributions. The Company expects to continue to incur
losses from operations for the near-term and these losses could be significant as the Company implements and scales its product commercialization
strategy.
Management’s strategic assessment
includes the following potential options:
| – | support the UK and EU launch of sugarBEAT®; |
| – | obtaining further regulatory approval for the sugarBEAT® device in other
countries such as the U.S.; |
| – | exploring licensing and partnership opportunities in other territories; |
| – | developing the sugarBEAT® device for commercialization for other applications;
and |
| – | considering whether additional future capital raises can further enhance
and accelerate the delivery of the Company’s strategic growth objectives. |
Results of Operations
Fiscal Year Ended March 31, 2023 Compared to Fiscal Year
Ended March 31, 2022
Revenue
Sales of $77,044 were recognised during the
2023 fiscal year, compared to $503,906 during fiscal year 2022..
December 2021 marked a pivotal milestone
for the Company as the Company commenced deliveries of sugarBEAT® to MSW pursuant to the initial order placed in April 2021. These
deliveries continued in line with the schedule agreed with MSW during the remainder of this fiscal year.
While the majority of the revenue recognized in 2022
related to the delivery of goods, revenue recognized in 2022 also included the recognition a proportion the GBP 1 million
(approximately $1.32 million), that was previously received and held within deferred revenue, relating to the exclusive Marketing
Rights Agreement that was signed with MSW. We expect to record the remainder of the revenue over an approximately 10-year term from
the date sales to MSW commenced.
Gross profit (loss)
Gross loss was $(1,476,392) compared to gross profit of $159,606
for the fiscal years ended March 31, 2023 and 2022, respectively. Cost of sales for fiscal year 2023 has been impacted by the impairment
of older inventory of $1,478,107.
Research and Development Expenses
Research and development expenses were $1,538,615
and $1,556,988 for the fiscal years ended March 31, 2023 and 2022, respectively. The stabilization in costs here being established as
the Company’s historically more significant research and development expenditure relating to clinical trials and improvements made
to the sugarBEAT® device started to flatten out over the year. We expect that the sugarBEAT® related research and development
expenses will reduce in future periods as the product is launched, however the Company expects to continue to incur research and development
costs to both enhance, refine and extend the platform capabilities for alternative applications.
General and Administrative Expenses
General and administrative expenses were
$6,580,227 and $6,173,049 for the fiscal years ended March 31, 2023 and 2022, respectively. These consisted of fees for legal, professional,
consultancy, audit services, investor relations, insurance, advertising, general and operational wages, and impairment of intangible assets.
The increase in expenses being driven predominantly by increased wages, as additional headcount has been added to support the operational
scale up process across both our UK and U.S. teams. Increases have also been seen in insurance, rent and depreciation and amortization,
which are considered to be directly related to the commercialization steps undertaken during the period. In addition to this, a non-cash
item charge of $291,534 was booked as a result of the mark-to-market impact from the revaluation of the foreign currency forward contracts
in place as of the fiscal period end, and one off impairment of intangible long held assets of $980,039.
As the Company continues
to scale up to service its existing order book, it is expected that general and administrative expenses will continue to exhibit a similar
higher cost profile moving forward, as the business continues to transition to an operationally focused base that is expected to result
in increased functional expenses relating to production, sales, marketing, customer service, as well as enhancements to other existing
functions.
Other Comprehensive Income
For the fiscal years ended March 31, 2023
and 2022 other comprehensive income saw a charge of $836,946 (2022 Charge of $257,885), arising from foreign currency translation adjustments.
Liquidity and Capital Resources
Going Concern and Liquidity
For the year ended March 31, 2023, the Company
recorded a net loss of $14,143,735 and used cash in operations of $8,451,781. These factors raise substantial doubt about the Company’s
ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements
do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. In addition, the Company’s
independent registered public accounting firm, in their report on the Company’s March 31, 2023 audited financial statements, raised
substantial doubt about the Company’s ability to continue as a going concern.
In evaluating the going concern position of
the company, management has considered potential funding providers and believes that financing to fund future operations could be provided
by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our
operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.
We have historically financed our operations
through a combination of debt and equity funding. During the fiscal year ended March 31, 2023, 4,796,536 shares of common stock were issued
for gross proceeds of $8,394,056, and net proceeds of $7,656,398 after deducting cost incurred in relation to the financing of $737,658.
At March 31, 2023, the Company had net working
capital deficiency of ($8,730,734) which included cash balances of $10,105,135 and current notes payable of $16,942,500.
Cash Flows
Net cash used by our operating activities
for the fiscal year ended March 31, 2023, was $8,451,781 which reflected the following key cashflow movements: a net loss of
$14,143,735 which included non-cash items booked as an expense relating to the accretion of the debt discount $1,871,593, change in
fair value of foreign exchange contract derivative liability of $291,534, change in fair value of warrant liability of $1,864,000
depreciation and amortization $444,177, inventory write down of $1,478,108, and impairment of intangible assets of $980,039.
Cashflows were also impacted by increases in
inventory of $1,745,189 and receivable/payable to related parties of $1,022,077 relating to the acquisition of raw materials to support
manufacture and delivery of product to our UK Licensee.
Working capital cashflow was also impacted
by an increase in accounts payable of $190,330, due to timing of purchases and a decrease in other liabilities and accrued expenses of
$427,748.
Net cash used by our operating activities
for the fiscal year ended March 31, 2022, was $6,504,041 which reflected the following key cashflow movements: a net loss of $13,886,805
which included non-cash items booked as an expense relating to the accretion of the debt discount ($6,666,630), mark-to-market valuation
of the foreign currency forward contracts that were held at fiscal year-end ($440,196), stock-based compensation paid to an employee combined
the fair value of options issued to directors ($220,917), and depreciation and amortization ($229,810).
Net cash used in investing activities was
$539,217 for the fiscal year ended March 31, 2023, which reflected expenditure on property and equipment to support the commencement of
manufacture of product for sale during the year of $376,170, combined with ongoing spend on software development ($27,879) and patent
costs ($135,168), to enhance the businesses digital offering and protect the intellectual property developed.
Net cash used in investing activities was
$956,482 for the fiscal year ended March 31, 2022, which reflected expenditure on property and equipment to support the commencement of
manufacture of product for sale during the year of $481,718, combined with ongoing spend on software development ($391,073) and patent
costs ($83,691), to enhance the businesses digital offering and protect the intellectual property developed.
Net cash provided by financing activities for
the fiscal year ended March 31, 2023, was $2,082,117. This includes repayments made in relation to debt funding of $10,274,281, which
was offset by the proceeds from the issuance of common stock in relation to equity funding of $8,393,361 with associated cash costs of
$737,658, and the receipt of funds from a new loan facility for $4,700,000.
Net cash utilized in financing activities
for the fiscal year ended March 31, 2022, was $6,368,315. This includes repayments made in relation to debt funding of $12,400,000, which
was partially offset by the proceeds from the issuance of common stock in relation to equity funding was $3,118,792, with associated cash
costs of $50,765, combined with the sale of warrants which provided a further $2,963,658 of cash funding.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Contractual Obligations
None.
Critical Accounting Policies and
Significant Judgments and Estimates
Our management’s discussion and analysis
of our financial condition and results of operations is based on our audited consolidated financial statements, which have been prepared
in accordance with United States generally accepted accounting principles (“U.S. GAAP”). The preparation of these consolidated
financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported results
of operations during the reporting periods. Our estimates are based on our historical experience and on various other factors that we
believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates under different
assumptions or conditions. Our significant accounting policies are described in more detail in the notes to our consolidated financial
statements included elsewhere in this Annual Report on Form 10-K.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
Not required for smaller reporting companies.
ITEM 8. FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of Nemaura
Medical Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance
sheet of Nemaura Medical Inc. (the “Company”) as of March 31, 2023, the related consolidated statements of operations and
comprehensive loss, changes in stockholders’ equity (deficit), and cash flows for the year then ended, and the related notes (collectively
referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of March 31, 2023, and the results of its operations and its cash flows for the year then ended,
in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, during the year ended
March 31, 2023, the Company incurred a net loss and utilized cash flows in operations, and has had recurring losses since inception. These
conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regards
to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are
matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the
audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions
on the critical audit matters or on the accounts or disclosures to which they relate.
Inventory Valuation
As described in Notes 3 and 5 to the financial statements,
the Company’s inventory is stated at the lower of cost or net realizable value, determined on first-in, first-out (“FIFO”)
basis. As of March 31, 2023, the Company held inventory of $1.8 million. The Company periodically evaluates the carrying value of inventory,
which requires management to make assumptions and estimate the amount necessary to adjust inventory for markdowns.
We identified the valuation of inventories as a critical
audit matter due to the significant judgments and estimates required by management. Determining whether a decline in value has occurred
requires significant judgments in estimating future demand and market conditions. This required a high degree of auditor judgment and
increased auditor effort in auditing such assumptions.
The primary procedures we performed to address this
critical audit matter included:
|
● |
We evaluated the reasonableness of management’s adjustment to inventory for markdowns by developing estimates of the adjustment to inventory for markdowns and comparing our estimates to management’s estimate. |
|
● |
We tested the accuracy and completeness of the inventory balance and the overall aging of inventory. |
|
● |
We tested the completeness of the inventory valuation adjustment by identifying slow-moving inventory and comparing to management’s analysis. |
|
● |
We tested the mathematical accuracy of the Company’s calculation of the adjustment to inventory for markdowns. |
Warrant liability
As described in Note 8 to the financial statements,
during the year ended March 31, 2023, the Company issued warrants that required management to assess whether the warrants required liability
classification. Management determined that the warrants were required to be accounted for as liabilities and recorded at fair value when
issued and subsequently remeasured to fair value upon settlement or at the end of each reporting period. The Company’s warrant liability
balance was $3.1 million at March 31, 2023. Management estimates the fair value of the warrant liabilities utilizing the Black-Scholes
pricing model.
We identified the accounting for and valuation of
the warrant liabilities as a critical audit matter due to the significant judgements used by management in determining whether the warrants
required liability classification, and the significant judgements used in determining the fair value of the warrant liabilities. This
required a high degree of auditor judgment and increased auditor effort in auditing the accounting for and valuation of the warrant liabilities.
The primary procedures we performed to address this
critical audit matter included:
|
● |
We obtained and read the warrant agreements to evaluate managements determination that the warrants met the criteria for classification as a liability. |
|
● |
We tested the reasonableness of the assumptions used by management in the Black-Scholes model, including exercise price, expected term, expected volatility, and risk-free interest rate. |
|
● |
We developed an independent expectation of the warrant liability using a Black-Scholes model and compared our independent expectation to managements estimate. |
Foreign exchange contract derivative liability
As described in Note 8 to the financial statements,
the Company has a foreign exchange contract that meets the definition of a derivative subject to the guidance of ASC 815, and is recognized
at fair value, with changes in fair value recognized in earnings at the end of each reporting period. The Company’s foreign exchange
contract derivative liability was $731,730 at March 31, 2023.
We identified auditing the valuation of the foreign
exchange contract derivative liability as a critical audit matter due to the significant judgements used by management in determining
the fair value of the foreign exchange contract derivative liability. This required a high degree of auditor judgment and increased auditor
effort in auditing the valuation of the foreign exchange contract derivative liability.
The primary procedures we performed to address this
critical audit matter included:
|
● |
We obtained and read the foreign exchange contract, and agreed the notional and leveraged amounts at March 31, 2023 to the terms of the contract. |
|
● |
We obtained management’s calculation of the fair value of the foreign exchange contract derivative liability. |
|
● |
We developed an independent expectation of the fair value of the foreign exchange contract derivative liability and compared our independent expectation to the Company’s estimate. |
We have served as the Company’s auditor since
2023.
/s/ Weinberg & Company, P.A.
Los
Angeles, California
July 13, 2023
REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
To the Board of Directors and Stockholders of Nemaura Medical
Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated
balance sheets of Nemaura Medical Inc. (the Company) as of March 31, 2022 and 2021, and the related consolidated statements of operations
and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-year period ended March 31, 2022,
and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of March 31, 2022 and 2021, and the results of its operations and its
cash flows for each of the years in the two-year period ended March 31, 2022, in conformity with accounting principles generally accepted
in the United States of America.
Substantial Doubt about Going Concern
The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has suffered recurring losses from operations, current debt due over current cash balances, and has accumulated deficits that raised substantial
doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising
from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee
and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there were no critical audit matters.
/s/ Mayer Hoffman McCann P.C.
We have served as the Company’s auditor since 2018.
Denver, Colorado
June 29, 2022
NEMAURA MEDICAL INC.
Consolidated Balance Sheets
| |
| | |
| |
| |
As of March 31, | | |
As of March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash | |
$ | 10,105,135 | | |
$ | 17,749,233 | |
Inventory, net | |
| 1,754,852 | | |
| 1,487,771 | |
Prepaid expenses and other current assets | |
| 357,934 | | |
| 495,055 | |
VAT receivable | |
| 409,648 | | |
| 255,112 | |
Deposit on foreign exchange contract | |
| 909,666 | | |
| — | |
Receivable from related parties | |
| — | | |
| 101,297 | |
Total current assets | |
| 13,537,235 | | |
| 20,088,468 | |
| |
| | | |
| | |
Property and equipment, net of accumulated depreciation | |
| 641,906 | | |
| 532,508 | |
Intangible assets, net of accumulated amortization | |
| 384,092 | | |
| 1,480,980 | |
| |
| | | |
| | |
Total assets | |
$ | 14,563,233 | | |
$ | 22,101,956 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 326,641 | | |
$ | 136,310 | |
Accrued expenses and other liabilities | |
| 130,678 | | |
| 558,426 | |
Notes payable, current portion | |
| 16,942,500 | | |
| 19,188,724 | |
Payable to related parties | |
| 920,780 | | |
| — | |
Deferred revenue, current portion | |
| 123,640 | | |
| 259,256 | |
Foreign exchange contract derivative liability | |
| 731,730 | | |
| 440,196 | |
Warrant liability | |
| 3,092,000 | | |
| — | |
Total current liabilities | |
| 22,267,969 | | |
| 20,582,912 | |
| |
| | | |
| | |
Notes payable, non-current portion | |
| 3,087,651 | | |
| — | |
Deferred revenue, non-current portion | |
| 1,021,811 | | |
| 1,052,960 | |
Total liabilities | |
| 26,377,431 | | |
| 21,635,872 | |
| |
| | | |
| | |
Commitments and contingencies | |
| — | | |
| — | |
| |
| | | |
| | |
Stockholders’ equity (deficit): | |
| | | |
| | |
Common stock, par value $0.001
– authorized: 42,000,000
shares; issued and outstanding: 28,899,402
and 24,102,866
as of March 31, 2023 and 2022, respectively | |
| 28,899 | | |
| 24,103 | |
Additional paid-in capital | |
| 40,991,377 | | |
| 38,295,775 | |
Accumulated deficit | |
| (51,875,211 | ) | |
| (37,731,476 | ) |
Accumulated other comprehensive (loss) income | |
| (959,263 | ) | |
| (122,318 | ) |
Total stockholders’ equity (deficit) | |
| (11,814,198 | ) | |
| 466,084 | |
Total liabilities and stockholders’ equity (deficit) | |
$ | 14,563,233 | | |
$ | 22,101,956 | |
See notes to consolidated financial
statements.
NEMAURA MEDICAL INC.
Consolidated Statements of Operations
and Comprehensive Loss
| |
| | |
| |
| |
Years Ended March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Sales | |
$ | 77,044 | | |
$ | 503,906 | |
Cost of sales | |
| (75,328 | ) | |
| (344,300 | ) |
Cost of sales-inventory write down | |
| (1,478,108 | ) | |
| — | |
Gross profit (loss) | |
| (1,476,392 | ) | |
| 159,606 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Research and development | |
| 1,538,615 | | |
| 1,556,988 | |
General and administrative | |
| 5,600,188 | | |
| 6,173,049 | |
Impairment of intangible assets | |
| 980,039 | | |
| — | |
Total operating expenses | |
| 8,118,842 | | |
| 7,730,037 | |
| |
| | | |
| | |
Loss from operations | |
| (9,595,234 | ) | |
| (7,570,431 | ) |
| |
| | | |
| | |
Interest expense | |
| (6,412,501 | ) | |
| (6,666,630 | ) |
Change in fair value of warrant liability | |
| 1,864,000 | | |
| | |
| |
| | | |
| | |
Provision for income tax benefit | |
| — | | |
| 350,256 | |
Net loss | |
| (14,143,735 | ) | |
| (13,886,805 | ) |
| |
| | | |
| | |
Other comprehensive income: | |
| | | |
| | |
Foreign currency translation adjustment | |
| (836,946 | ) | |
| (257,885 | ) |
Comprehensive loss | |
$ | (14,980,681 | ) | |
$ | (14,144,690 | ) |
| |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.57 | ) | |
$ | (0.59 | ) |
Weighted average number of shares outstanding | |
| 24,878,196 | | |
| 23,383,758 | |
See notes to consolidated financial
statements.
NEMAURA MEDICAL INC.
Consolidated Statements of Changes in
Stockholders’ Equity (Deficit)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
|
Amount |
|
|
|
Additional Paid-in Capital |
|
|
|
Accumulated Deficit |
|
|
|
Accumulated Other Comprehensive Loss |
|
|
|
Total Stockholders’ Equity (Deficit) |
|
Balance at March 31, 2021 |
|
|
22,941,157 |
|
|
$ |
22,941 |
|
|
$ |
32,044,335 |
|
|
$ |
(23,844,671 |
) |
|
$ |
135,567 |
|
|
$ |
8,358,172 |
|
Issuance of common shares, net of costs of $50,765 |
|
|
772,524 |
|
|
|
773 |
|
|
|
3,067,254 |
|
|
|
— |
|
|
|
— |
|
|
|
3,068,027 |
|
Exercise of warrants |
|
|
366,892 |
|
|
|
367 |
|
|
|
2,963,291 |
|
|
|
— |
|
|
|
— |
|
|
|
2,963,658 |
|
Restricted shares issued as stock-based compensation |
|
|
22,293 |
|
|
|
22 |
|
|
|
87,366 |
|
|
|
— |
|
|
|
— |
|
|
|
87,388 |
|
Options issued to directors |
|
|
— |
|
|
|
— |
|
|
|
133,529 |
|
|
|
— |
|
|
|
— |
|
|
|
133,529 |
|
Foreign currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(257,885 |
) |
|
|
(257,885 |
) |
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(13,886,805 |
) |
|
|
— |
|
|
|
(13,886,805 |
) |
Balance at March 31, 2022 |
|
|
24,102,866 |
|
|
|
24,103 |
|
|
|
38,295,775 |
|
|
|
(37,731,476 |
) |
|
|
(122,318 |
) |
|
|
466,084 |
|
Issuance of common shares, net of costs |
|
|
4,796,536 |
|
|
|
4,796 |
|
|
|
7,651,602 |
|
|
|
— |
|
|
|
— |
|
|
|
7,656,398 |
|
Fair value of warrant liability recognized in connection with issuance of common shares |
|
|
— |
|
|
|
— |
|
|
|
(4,956,000) |
|
|
|
— |
|
|
|
— |
|
|
|
(4,956,000 |
) |
Foreign currency translation adjustment |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(836,946 |
) |
|
|
(836,946 |
) |
Net loss |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
(14,143,735 |
) |
|
|
|
|
|
|
(14,143,735 |
) |
Balance at March 31, 2023 |
|
|
28,899,402 |
|
|
$ |
28,899 |
|
|
$ |
40,991,377 |
|
|
$ |
(51,875,211 |
) |
|
$ |
(959,263 |
) |
|
$ |
(11,814,198 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See notes to consolidated financial statements.
NEMAURA MEDICAL INC.
Consolidated Statements of Cash Flows
| |
| | |
| |
| |
Year Ended March 31, | |
| |
2023 | | |
2022 | |
Cash Flows from Operating Activities: | |
| | | |
| | |
Net loss | |
$ | (14,143,735 | ) | |
$ | (13,886,805 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 444,177 | | |
| 229,810 | |
Accretion of debt discount | |
| 1,871,593 | | |
| 6,666,630 | |
Monitoring fee interest expense added to notes payable | |
| 2,240,339 | | |
| — | |
Fees for note amendments expense added to note payable | |
| 2,304,539 | | |
| — | |
Inventory write-down | |
| 1,478,108 | | |
| — | |
Impairment of intangible assets | |
| 980,039 | | |
| — | |
Change in fair value of foreign exchange contract derivative liability | |
| 291,534 | | |
| 440,196 | |
Change in fair value of warrant liability | |
| (1,864,000 | ) | |
| — | |
Stock-based compensation | |
| — | | |
| 220,917 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Inventory | |
| (1,745,189 | ) | |
| (637,149 | ) |
Prepaid expenses and VAT receivable | |
| (17,415 | ) | |
| 519,346 | |
Deposit on foreign exchange contract | |
| (909,666 | ) | |
| — | |
Accounts payable | |
| 190,331 | | |
| (117,384 | ) |
Accrued expenses and other liabilities | |
| (427,748 | ) | |
| 310,490 | |
Receivable/payable to related parties | |
| 1,022,077 | | |
| (250,092 | ) |
Deferred revenue | |
| (166,765 | ) | |
| — | |
Net cash used in operating activities | |
| (8,451,781 | ) | |
| (6,504,041 | ) |
| |
| | | |
| | |
Cash Flows from Investing Activities: | |
| | | |
| | |
Purchase of property and equipment | |
| (376,170 | ) | |
| (481,718 | ) |
Capitalized patent costs | |
| (135,168 | ) | |
| (83,691 | ) |
Capitalized software development costs | |
| (27,879 | ) | |
| (391,073 | ) |
Net cash used in investing activities | |
| (539,217 | ) | |
| (956,482 | ) |
| |
| | | |
| | |
Cash Flows from Financing Activities: | |
| | | |
| | |
Proceeds from issuance of common shares | |
| 8,394,056 | | |
| 3,118,792 | |
Costs incurred in relation to equity financing | |
| (737,658 | ) | |
| (50,765 | ) |
Proceeds from warrant exercise | |
| — | | |
| 2,963,658 | |
Proceeds from issuance of long term debt, net of discount | |
| 4,700,000 | | |
| — | |
Repayments of notes payable | |
| (10,274,281 | ) | |
| (12,400,000 | ) |
Net cash (used in) provided by financing activities | |
| 2,082,117 | | |
| (6,368,315 | ) |
| |
| | | |
| | |
Net decrease in cash | |
| (6,908,881 | ) | |
| (13,828,838 | ) |
Effect of exchange rate changes on cash | |
| (735,217 | ) | |
| (287,300 | ) |
Cash at beginning of year | |
| 17,749,233 | | |
| 31,865,371 | |
Cash at end of year | |
$ | 10,105,135 | | |
$ | 17,749,233 | |
Supplemental cash flow information: | |
| | | |
| | |
Interest paid | |
| — | | |
| — | |
Taxes paid | |
| — | | |
| — | |
Supplemental disclosure of non-cash financing activities: | |
| | | |
| | |
Fair value of warrant liability recognized in connection with issuance
of common shares | |
$ | 4,956,000 | | |
$ | — | |
Monitoring fees added to notes payable | |
$ | 2,240,339 | | |
$ | 2,764,775 | |
See notes to consolidated financial
statements.
NEMAURA MEDICAL INC.
Notes to Consolidated Financial Statements
For the Years Ended March 31, 2023 and
2022
NOTE 1 – ORGANIZATION, PRINCIPAL ACTIVITIES AND
MANAGEMENT’S PLANS
Nemaura Medical Inc. (“Nemaura”
or the “Company”), through its operating subsidiaries, performs medical device research and manufacturing of a continuous
glucose monitoring system (“CGM”), named sugarBEAT®. The sugarBEAT® device is a non-invasive, wireless device for
use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. The sugarBEAT® device extracts
analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using unique sensors and interpreted
using a unique algorithm.
Nemaura is a Nevada holding company organized
in 2013. Nemaura owns one hundred percent (100%) of Dermal Diagnostic (Holdings) Limited, an England and Wales corporation (“DDHL”)
formed on December 11, 2013, which in turn owns one hundred percent (100%) of Dermal Diagnostics Limited, an England and Wales corporation
formed on January 20, 2009 (“DDL”), and one hundred percent (100%) of Trial Clinic Limited, an England and Wales corporation
formed on January 12, 2011 (“TCL”).
DDL is a diagnostic medical device company
headquartered in Loughborough, Leicestershire, England, and is engaged in the discovery, development and commercialization of diagnostic
medical devices. The Company’s initial focus has been on the development of the sugarBEAT® device, which consists of a disposable
patch containing a sensor, and a non-disposable miniature transmitter device with a re-chargeable power source, which is designed to enable
trending or tracking of blood glucose levels. All of the Company’s operations and assets are located in England.
The Company was incorporated in 2013 and
has reported recurring losses from operations to date. These operations
have resulted in the successful completion of clinical programs to support a CE mark (European Union approval of the product) approval,
as well as a De Novo 510(k) medical device application to the U.S. Food and Drug Administration (“FDA”) submission. The Company
expects to continue to incur losses from operations until revenues are generated through licensing fees or product sales. However, given
the completion of the requisite clinical programs, these losses are expected to decrease over time. Management has entered into licensing,
supply, or collaboration agreements with unrelated third parties relating to the United Kingdom (“UK”), Europe, Qatar, and
all countries in the Gulf Cooperation Council.
Going Concern
The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and
commitments in the normal course of business. As reflected in the accompanying financial statements, for the year ended March 31,
2023, the Company recorded a net loss of $14,143,735 and used cash in operations of $8,451,781.
These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date
that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.
In evaluating the going
concern position of the company, management has considered potential funding providers and believes that financing to fund future operations
could be provided by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions
on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.
NOTE 2 – BASIS OF PRESENTATION
The accompanying consolidated financial statements
include the accounts of the Company and the Company’s subsidiaries, DDL, TCL, and DDHL. The consolidated financial statements are
prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and all
intercompany balances and transactions have been eliminated in consolidation.
The functional currency for the majority
of the Company’s operations is the Great Britain Pound Sterling (“GBP”), and the reporting currency is the U.S. Dollar (“$”, “USD”).
NOTE
3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of estimates
The preparation of consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the
assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity
instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation
allowances. Actual results may differ from those estimates.
Revenue recognition
The Company recognizes revenue in accordance
with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from
Contracts with Customers (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of
goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise
judgment when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying
our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price
to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.
The Company only applies the five-step model to contracts when
it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to
the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods
or services promised within each contract and determines those that are performance obligations and assesses whether each promised good
or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.
The Company may enter into product development
and other agreements with collaborative partners. The terms of the agreements may include non-refundable signing and licensing fees, milestone
payments and royalties on any product sales derived from collaborations.
Royalty revenue will be recognized upon
the sale of the related products provided the Company has no remaining performance obligations under the agreement.
Deferred revenue
The Company has entered into license agreements
and recognizes up front license payments as revenue upon delivery of the license only if the license has stand-alone value to the customer.
However, where further performance criteria must be met, revenue is deferred and recognized on a basis that is considered to be appropriate
to the conditions associated with the license and over the period the Company is expected to complete these performance obligations.
Research and development expenses
The Company charges research and development expenses to operations
as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel and outside contractor
and consulting services. Other research and development expenses include the costs of materials and supplies used in research and development,
prototype manufacturing, clinical studies, related information technology and an allocation of facilities costs.
Cash and cash equivalents
Cash and cash equivalents consists primarily
of cash deposits maintained in the UK.
We maintain cash balances in U.S. Dollar (“USD”),
Great Britain Pound Sterling (“GBP”), and the Euro. The following table, reported in USD, disaggregates our cash balances
by currency denomination:
Schedule of disaggregates cash
balances by currency denomination | |
| | | |
| | |
| |
March
31, 2023 | | |
March 31,
2022 | |
Cash denominated in: | |
| | | |
| | |
USD | |
$ | 5,606,972 | | |
$ | 14,769,720 | |
GBP | |
| 4,446,720 | | |
| 2,911,117 | |
Euro | |
| 51,443 | | |
| 68,396 | |
Total | |
$ | 10,105,135 | | |
$ | 17,749,233 | |
Inventory
Inventory is stated at the lower of cost or net realizable
value, with cost determined on a first-in, first-out (“FIFO”) basis. The Company records adjustments to its inventory based
on an estimated forecast of the inventory demand, taking into consideration, among others, inventory turnover, inventory quantities on
hand, unfilled customer order quantities, and forecasted demand. If the estimated net realizable value is determined to be less than the
recorded cost of the inventory, the difference is recognized as a loss in the period in which it occurs. Once inventory has been written
down, it creates a new cost basis for inventory that may not be subsequently written up.
Property and equipment
Property and equipment is stated at cost and depreciated
using the straight-line method over the estimated useful lives of the assets, generally four to five years. Depreciation is charged
to operating expenses.
Intangible assets
Intangible assets consist of licenses and patents
associated primarily with the sugarBEAT® device and are amortized on a straight-line basis, generally over the shorter of their estimated
useful lives or legal lives. Costs capitalized relate to invoices received from third parties and not any internal costs. The Company
evaluates its intangible assets (all have finite lives) and other long-lived assets for impairment whenever events or circumstances indicate
that they may not be recoverable, or at least annually. Recoverability of finite life intangibles and other long-lived assets is measured
by comparing the carrying amount of an asset group to the future undiscounted net cash flows expected to be generated by that asset group.
The Company groups assets for purposes of such review at the lowest level for which identifiable cash flows of the asset group are largely
independent of the cash flows of the other groups of assets and liabilities. The amount of impairment to be recognized for finite life
intangibles and other long-lived assets is calculated as the difference between the carrying value and the fair value of the asset group,
generally measured by discounting estimated future cash flows.
Software development costs
The Company capitalizes costs incurred to
implement software for its internal use, including hosted applications costs to support the Company’s planned services. During the
year ended March 31, 2023, the Company determined that software development costs were impaired and recorded an impairment of $655,641.
Income taxes
Income taxes are accounted for under the
asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating
loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is
provided to reduce the carrying amount of deferred income tax assets if it is considered more likely than not that some portion, or all,
of the deferred income tax assets will not be realized.
The Company recognizes the effect of income
tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the
largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in
which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits as
part of income tax expense in the consolidated statements of comprehensive loss. The Company does not have any accrued interest or penalties
associated with any unrecognized tax benefits, nor was any interest expense related to unrecognized tax benefits recognized for the years
ended March 31, 2023 and 2022.
Earnings (loss) per share
Basic loss per share
is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the
period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number
of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common
shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options
and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings
of the entity.
Since the effects of outstanding options
and warrants are anti-dilutive for the years ended March 31, 2023 and 2022, shares of common stock underlying these instruments have been
excluded from the computation of loss per common share.
The following sets forth the number of shares
of common stock underlying outstanding options and warrants as of March 31, 2023 and 2022:
Schedule of common stock underlying outstanding options | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Warrants | |
| 6,369,304 | | |
| 1,573,098 | |
Stock options | |
| 40,000 | | |
| 40,000 | |
| |
| | | |
| | |
| |
| 6,409,304 | | |
| 1,613,098 | |
Foreign currency translation
The functional currency of the Company is the GBP,
while the reporting currency is the USD. Assets and liabilities are translated into USD using the exchange rate on the balance sheet
date, and the amounts of revenue and expense are translated at the average exchange rate prevailing during the period. Stockholders'
equity is translated at historical exchange rates. The gains and losses resulting from translation of financial statement amounts into
USD are recorded as a separate component of accumulated other comprehensive loss within stockholders’ deficit.
We used the exchange
rates in the following table to translate amounts denominated in non-USD currencies as of and for the periods noted:
Schedule of exchange rates translate amounts | |
| | | |
| | |
| |
As
of March 31, | |
| |
2023 | | |
2022 | |
Exchange rates at March 31: | |
| | |
| |
GBP:USD | |
| 1.236 | | |
| 1.316 | |
EURO:USD | |
| 1.138 | | |
| 1.184 | |
| |
For the Years Ended March 31, | |
| |
2023 | | |
2022 | |
Average exchange rate during the year ended March 31: | |
| | |
| |
GBP:USD | |
| 1.215 | | |
| 1.342 | |
Derivative Financial Instruments
The Company evaluates its financial instruments to
determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815,
"Derivatives and Hedging" (“ASC 815”). For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair
value reported in the statements of operations. The Company’s use of derivative financial instruments is generally limited to managing
foreign exchange rate risks. In addition, warrants issued by the Company that do not meet the criteria for equity treatment are recorded
as liabilities. We do not use financial instruments or derivatives for any trading purposes.
Fair value of financial instruments
In accordance with ASC 820, “Fair Value
Measurements and Disclosures,” the Company determines the fair value of financial instruments with the use of observable inputs
and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of
independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within
the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes
the inputs into three levels that may be used to measure fair value:
Level 1: Applies to assets or liabilities for
which there are quoted prices in active markets for identical assets or liabilities.
Level 2: Applies to assets or liabilities for
which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
Level 3: Applies to assets or liabilities
for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the
assets or liabilities.
The Company determines the
level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis
of the assets and liabilities at each reporting period end.
The following table sets
forth by level, within the fair value hierarchy, the Company’s assets and liabilities at fair value as of March 31, 2023 and 2022:
Schedule of assets and liabilities at fair value | |
| | | |
| | | |
| | | |
| | |
| |
March
31, 2023 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 731,730 | | |
$ | — | | |
$ | 731,730 | |
Warrant derivative liability | |
| — | | |
| — | | |
| 3,092,000 | | |
| 3,092,000 | |
Total liabilities | |
$ | — | | |
$ | 731,730 | | |
$ | 3,092,000 | | |
$ | 3,823,730 | |
| |
March
31, 2022 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
Total liabilities | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
As of March 31, 2022, there
was no warrant derivative liability. The following table provides a roll-forward of the warrant derivative liability measured at fair
value on a recurring basis using unobservable level 3 inputs for the year ended March 31, 2023 as follows:
Schedule of warrant derivative liability measured at fair value on a recurring basis | |
| | |
| |
March
31, 2023 | |
Warrant liability | |
| | |
Balance as of beginning of period – March 31, 2022 | |
$ | — | |
Fair value of warrant liability recognized upon issuance of warrants in January 2023 | |
| 4,956,000 | |
Change in fair value of warrant derivative liability | |
| (1,864,000 | ) |
Balance as of end of period – March 31, 2023 | |
$ | 3,092,000 | |
The Company believes the
carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates
fair value due to the short-term nature of such instruments.
Retirement benefit plan
The Company operates a retirement plan which
covers most of our regular employees in the UK and allows them to make contributions. The Company also provides a matching contribution
on a portion of the employee contributions. Total expenses incurred under this plan for the fiscal years ended March 31, 2023 and 2022,
were $37,645 and $24,300, respectively.
Stock-based
compensation
The Company
periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services
and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation
whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line
basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company
had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations
with classification depending on the nature of the services rendered.
The fair value
of the Company’s stock options is estimated using the Black-Scholes Option Pricing model, which uses certain assumptions
related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends.
Compensation expense is recorded based upon the value derived from the Black-Scholes Option Pricing model and based on actual experience.
The assumptions used in the Black-Scholes Option Pricing model could materially affect compensation expense recorded in future
periods.
Direct costs incurred for equity
offerings
The Company includes all direct costs incurred in connection
with successful equity offerings as a component of additional paid-in capital. Direct costs incurred for equity offerings that are
unsuccessful are expensed.
Reclassifications
Certain prior year balances have been reclassified to conform
with the current year presentation. In presenting the Company’s consolidated balance sheet at March 31, 2022, the Company presented
$255,112 VAT receivable as part of prepaid expenses and other receivables of $750,167. In presenting the Company’s consolidated
balance sheet at March 31, 2023, the Company has reclassified the balance of $255,112 as a separate line item VAT receivable, and the
balance of $495,055 is presented as prepaid expenses in the accompanying March 31, 2022 financial statements.
Recent accounting pronouncements
The Company continually assesses any new
accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's
financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements
and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect
the change.
NOTE 4 –
LICENSING AGREEMENT
In March 2014, the Company entered into an Exclusive
Marketing Rights Agreement with an unrelated third party that granted to the third party the exclusive right to market and promote
the sugarBEAT® device and related patches under its own brand in the United Kingdom and the Republic of Ireland, the Channel
Islands and the Isle of Man. Upon signing the agreement, the Company received a wholly non-refundable cash payment of GBP 1,000,000
(approximately $1.23
million and $1.32
million as of March 31, 2023 and 2022, respectively).
As the Company has continuing performance
obligations under the agreement, the up-front fees received from this agreement have been deferred and will be recorded as income over
the term of the commercial licensing agreement as the Company completes its performance obligations. At March 31, 2023, total deferred
revenue for the licensing agreement was $1,081,676.
NOTE 5 – INVENTORY
Inventory is valued at the lower of cost (first-in, first-out)
or net realizable value and is comprised of the following:
Schedule of inventory | |
| |
|
| |
March
31, 2023 | |
March
31, 2022 |
Raw materials | |
$ | 1,586,777 | | |
$ | 1,481,946 | |
Finished products | |
| 168,075 | | |
| 5,825 | |
Total | |
$ | 1,754,852 | | |
$ | 1,487,771 | |
At March 31, 2023, management
determined that the net realizable value of the Company’s inventory had fallen below its historical carrying cost.
Accordingly, for the year ended March 31, 2023, the Company recorded a write down of inventory of $1,478,108, which is included in cost of goods sold. At March 31, 2023, the
balance of inventory shown above reflects its new cost basis after the write down. For the year ended March 31, 2022, there was no write
down of inventory recorded.
NOTE
6 – PROPERTY AND EQUIPMENT
As of March 31, 2023 and 2022, property and equipment is summarized
as follows:
Schedule of property and equipment | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Property and Equipment | |
| | | |
| | |
Plant and machinery | |
$ | 998,635 | | |
$ | 727,250 | |
Furniture and fixtures | |
| 114,863 | | |
| 78,867 | |
Property and equipment gross | |
| 1,113,498 | | |
| 806,117 | |
Less Accumulated Depreciation | |
| (471,592 | ) | |
| (273,609 | ) |
Net Book Value | |
$ | 641,906 | | |
$ | 532,508 | |
Depreciation expense relating to property
and equipment for the years ended March 31, 2023 and 2022 was approximately $156,000
and $138,000, respectively.
NOTE 7 - INTANGIBLE ASSETS
The following table summarizes our intangible assets and capitalized software development
costs at March 31, 2023:
Schedule of Intangible Assets | |
| | | |
| | |
| |
March 31, |
| |
2023
| |
2022
|
| |
| |
|
Patents and licenses | |
$ | 1,175,580 | | |
$ | 1,084,081 | |
Less accumulated amortization | |
| (467,091 | ) | |
| (186,927 | ) |
Less impairment | |
| (324,397 | ) | |
| — | |
| |
| 384,092 | | |
| 897,154 | |
| |
| | | |
| | |
Software development costs | |
| 655,641 | | |
| 583,826 | |
Less impairment | |
| (655,641 | ) | |
| — | |
| |
| — | | |
| 583,826 | |
| |
$ | 384,092 | | |
$ | 1,480,980 | |
Amortization expensed within the consolidated statements of operations
and comprehensive loss relating to intangible assets for the years ended March 31, 2023 and 2022 was approximately $193,000 and $92,000,
respectively. At March 31, 2023, intangible assets and capitalized software costs
have been reduced for impairments of $324,397 and $655,641, respectively. At March 31, 2022, no impairments were recorded
NOTE
8 – DERIVATIVE LIABILITIES
Warrant liability
In
January 2023, the Company completed an equity offering (see Note 11), which included the issuance of 4,796,206
warrants. Upon the occurrence of certain transactions (“Fundamental Transactions,” as defined), the warrants provide for
a value determined using a Black Scholes model with inputs calculated as described in the warrant agreement which includes a 100%
floor on the volatility input to be utilized. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a
value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares.
Accordingly, pursuant to ASC 815, the Company has classified the fair value of the warrants as a liability to be re-measured at the
end of every reporting period with the change in value reported in the statement of operations.
The warrant liability was valued at the following
dates using a Black-Scholes model with the following assumptions:
Schedule of warrant liability | |
| | | |
| | |
| |
March
31, 2023 | | |
January
31, 2023 (date
issued) | |
Warrant liability: | |
| | | |
| | |
Stock
price | |
$ | 0.90 | | |
$ | 1.33 | |
Risk-free interest rate | |
| 3.60 | % | |
| 3.63 | % |
Expected volatility | |
| 108 | % | |
| 109 | % |
Expected life (in years) | |
| 5.34 | | |
| 5.50 | |
Expected dividend yield | |
| — | | |
| — | |
Fair value of Warrant liability | |
$ | 3,092,000 | | |
$ | 4,956,000 | |
The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant. Expected volatility was determined based on the historical volatility data of the Company, and the
expected term of the warrants granted are determined based on the duration of time the warrants are expected to be outstanding. The dividend
yield on the Company’s warrants is assumed to be zero as the Company has not historically paid dividends.
Foreign exchange contract liability
The Company is exposed to the impact of foreign
currency exchange fluctuations as a significant proportion of its expenses are denominated in GBP, and the Company’s cash is
in USD and GBP. In February 2021, the Company entered into a forward contract to sell USD and buy GBP. The contract meets the
definition of a derivative subject to the guidance of ASC 815, does not qualify for hedge accounting, and accordingly is recognized
at fair value, with changes in fair value recognized in earnings.
The term of the contract is 25 months, beginning
July, 2022, and ending August, 2024. The contract initially had a maximum notional amount of $6,250,000
(and a maximum leveraged amount equal to two times the notional amount, or$12,500,000).
$250,000
of the contractual notional amount is settled (expires) each month through August 2024. On
each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP
at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but
can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the settlement date, the Company is
obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can
pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty. During the
year ended March 31, 2023, $4,000,000
of the leveraged amount (and $2,000,000
of the notional amount) expired.
At March 31, 2023 and 2022, the fair value of the
foreign currency contract liability was valued as follows:
Schedule of fair value of the foreign currency contract liability | |
| | | |
| | |
| |
March
31, 2023 | | |
March
31,
2022 | |
| |
| | | |
| | |
Notional amount | |
$ | 4,250,000 | | |
$ | 6,250,000 | |
Leveraged amount (used to determine fair value of contract
liability at March 31, 2023 and 2022) | |
$ | 8,500,000 | | |
$ | 12,500,000 | |
Expected remaining term (in months) | |
| 17 | | |
| 25 | |
| |
| | | |
| | |
Fair Value: | |
| | | |
| | |
Foreign currency contract liability | |
$ | 731,730 | | |
$ | 440,196 | |
The Company’s foreign currency forward contracts are measured
at fair value on a recurring basis and are classified as Level 2 fair value measurement. As of March 31, 2023, the Company has deposited
$909,666 as collateral with the counterparty related to the foreign currency forward contract.
NOTE 9 – NOTES PAYABLE
Schedule of notes payable | |
| | | |
| | |
| |
March 31, |
| |
2023 | |
2022 |
| |
| |
|
Note Purchase Agreement 1 (paid off April 2022) | |
$ | — | | |
$ | 270,979 | |
Note Purchase Agreement 2 | |
| 14,772,293 | | |
| 20,241,421 | |
Note Purchase Agreement 3 | |
| 6,024,941 | | |
| — | |
Total notes payable | |
| 20,797,234 | | |
| 20,512,400 | |
Unamortized debt discount | |
| (767,083 | ) | |
| (1,323,676 | ) |
Notes payable, net of note discounts | |
| 20,030,151 | | |
| 19,188,724 | |
Current portion | |
| (16,942,500 | ) | |
| (19,188,724 | ) |
Non-current portion | |
$ | 3,087,651 | | |
$ | — | |
NOTE PURCHASE AGREEMENT 1 (paid off
April 2022)
On April 15, 2020, the Company issued a
note payable (“Note Purchase Agreement 1”) to a third-party investor. The note was for $6,015,000, matured on April 15, 2022,
and was secured by all the assets of the Company. The Company received cash proceeds of $4,675,000, resulting in a discount of $1,340,000
made up of an original issue discount (“OID”) of $1,000,000, commission of $325,000 that was paid from proceeds, and $15,000
to cover transaction expenses. In addition, the Company recorded a fee of 0.833% per month, which was in substance interest at an annual
rate of approximately 10%, that was added to the note principal each month (as payment in kind, or “PIK” interest). The debt
less discount and transaction expenses were accreted over the term of the note using the effective interest rate method. Note Purchase
Agreement 1 was repaid in April 2022 and replaced by Note Purchase Agreement 3 issued in May 2022 (see below).
NOTE PURCHASE AGREEMENT 2
On February 8, 2021, the Company
issued a note payable (“Note Purchase Agreement 2”, “Note 2”) to a third-party investor. The note was for
$24,015,000, originally matured on February 9, 2023, and is secured by all the assets of the Company. The Company received cash proceeds
of $18,800,000, resulting in a discount of $5,215,000 made up of an original issue discount (“OID”) of $4,000,000, commission
of $1,200,000 that was paid from proceeds, and $15,000 to cover transaction expenses. The Company agreed to make principal payments beginning
in August 2021 of $400,000 monthly, which increased in February 2022 to $2,000,000 monthly. In addition, the Company is required to accrue
a monthly PIK fee equal to 0.833% of the outstanding balance, which is in substance interest at an annual rate of approximately 10%, that
is added to the note principal each month. The debt less discount and transaction expenses will be accreted over the term of the note
using the effective interest rate method.
Note 2 was amended in May 2022 to
reduce principal payments from $2,000,000
a month to $500,000
a month. Note 2 was amended again in October 2022 to extend the maturity from February 9, 2023 to July
1, 2024, and to increase principal payments to $1,000,000
a month beginning in March 2023. In consideration, the Company agreed to pay aggregate fees of $2,304,539
to the investor which were added to the principal balance of Note 2. The Company accounted for the amendments under the debt
extinguishment model as the present value of cash flows of Note 2 under the terms of the amendments (the “new” note) was
more than 10% different from the present value of the remaining cash flows under the original terms of Note 2 (the “old”
note). The fair value of the new note was determined to be $17,090,513, less the carrying amount of the old note of $16,609,176,
plus the fees of $2,304,539, resulted in a loss on extinguishment of $2,785,876,
which is included in interest expense for the year ended March 31, 2023.
NOTE PURCHASE AGREEMENT 3
On May 20, 2022, the Company issued a note payable (“Note
Purchase Agreement 3”) with a third-party investor. The note was for $6,015,000,
matures on May
20, 2024, and is secured by all the assets of the Company. The Company received cash proceeds of $4,700,000,
resulting in a discount of $1,315,000
made up of an original issue discount (“OID”) of $1,000,000,
commission of $300,000
that was paid from proceeds, and $15,000
to cover transaction expenses. In addition, the Company is required to accrue a monthly PIK fee equal to 0.833% of the outstanding
balance, which is in substance interest at an annual rate of approximately 10%,
that is added to the note principal each month. The debt less discount and transaction expenses will be accreted over the term of the
note using the effective interest rate method. At March 31, 2023, the remaining debt discount to be amortized was $767,083.
NOTE 10 – RELATED PARTY TRANSACTIONS
Nemaura Pharma Limited (“Pharma”),
Black and White Health Care Limited (“B&W”) and NDM Technologies Limited (“NDM”) are entities controlled by
the Company’s chief executive officer and majority shareholder.
Pharma has a service agreement with DDL,
to undertake development, manufacture, and regulatory approvals under Pharma’s ISO13485 Accreditation. Pharma invoices DDL on a periodic basis for said services. Services are provided at cost plus a service surcharge amounting to less than
10% of the total costs incurred.
The following is a summary of activity between
the Company and Pharma, B&W and NDM for the years ended March 31, 2023 and 2022:
Schedule of related party transactions | |
| | | |
| | |
| |
March
31, |
| |
2023
| |
2022
|
| |
| |
|
Due to/(from) related parties at beginning of year | |
$ | (101,297 | ) | |
$ | 148,795 | |
Amounts invoiced by Pharma to DDL, NM and TCL primarily relating to
research and development expenses | |
| 4,767,586 | | |
| 3,245,985 | |
Amounts invoiced by DDL to Pharma | |
| — | | |
| (2,495 | ) |
Amounts repaid by DDL to Pharma | |
| (3,773,217 | ) | |
| (3,492,962 | ) |
Foreign exchange differences | |
| 27,708 | | |
| (620 | ) |
Due to/(from) related parties at end of year | |
$ | 920,780 | | |
$ | (101,297 | ) |
NOTE 11 – INCOME TAXES
The Company and its subsidiaries file separate
income tax returns.
United States of America
The Company is incorporated in the U.S.
and is subject to a U.S. federal corporate income tax rate of 21% for the year ended March 31, 2023 and 21% for the year ended March 2022.
British Virgin Islands
RGL was incorporated in the British Virgin Islands (“BVI”).
Under the current laws of the BVI, RGL was not subject to tax on income or capital gains. In addition, upon payments of dividends by
RGL, no BVI withholding tax was imposed. During the years ended March 31, 2022 and 2021, there were no income or expenses in the BVI;
RGL was formally dissolved as of April 23, 2021.
UK
DDL, TCL and DDHL are all incorporated in
the UK and the applicable UK statutory income tax rate for these companies is 19%.
For the fiscal years ended March 31, 2023
and 2022 loss before income tax benefit arose in the UK and U.S. as follows:
Schedule of loss before income tax | |
| | | |
| | |
| |
March
31, |
| |
2023
| |
2022
|
| |
| | | |
| | |
Loss before income taxes arising in UK | |
$ | (13,314,440 | ) | |
$ | (11,716,916 | ) |
Loss before income taxes arising in U.S. | |
| (829,295 | ) | |
| (2,520,145 | ) |
Total loss
before income tax benefit | |
$ | (14,143,735 | ) | |
$ | (14,237,061 | ) |
Reconciliation of our effective tax rate to the loss calculated at the statutory
U.S. federal tax rate is as follows:
Reconciliation of effective tax rate | |
| | | |
| | | |
| | | |
| | |
| |
March 31, |
| |
| 2023 | | |
| | | |
| 2022 | | |
| | |
Loss before income
taxes | |
$ | (14,143,735 | ) | |
| | | |
$ | (14,237,061 | ) | |
| | |
Expected tax benefit | |
| (3,145,943 | ) | |
| (22 | %) | |
| (2,989,783 | ) | |
| (21 | %) |
Foreign tax differential | |
| 235,938 | | |
| 2 | % | |
| 234,338 | | |
| 2 | % |
Enhanced research and development | |
| (369,946 | ) | |
| (3 | %) | |
| (463,591 | ) | |
| (3 | %) |
Prior year true-up of NOL’s | |
| (46,393 | ) | |
| 0 | % | |
| 2,401,930 | | |
| 17 | % |
Other | |
| 338,278 | | |
| 2 | % | |
| 74,579 | | |
| 1 | % |
Change in valuation allowance | |
| 2,988,066 | | |
| 21 | % | |
| 742,527 | | |
| 5 | % |
R&D credit received | |
| — | | |
| — | | |
| 350,256 | | |
| 2 | % |
Actual income tax benefit | |
$ | — | | |
| — | | |
$ | 350,256 | | |
| 2 | % |
The tax effects of the temporary differences that give rise
to significant portions of deferred income tax assets are presented below:
Schedule of deferred income tax assets | |
| | | |
| | |
| |
March
31, |
| |
2023 | |
2022 |
| |
| | | |
| | |
Net operating tax loss
carried forward | |
$ | 9,259,000 | | |
$ | 6,671,000 | |
Research and development enhancement | |
| 361,000 | | |
| 335,000 | |
Other items | |
| 38,000 | | |
| (335,000 | ) |
Valuation allowance | |
| (9,658,000 | ) | |
| (6,671,000 | ) |
Net deferred
tax assets | |
$ | — | | |
$ | — | |
In the fiscal year ended March 31, 2023, the Company received
no reimbursement from HMRC (Her Majesty’s Revenue and Customs) in tax credits relating to research and development expenses incurred
during the fiscal year ended March 31, 2022. In the fiscal year ended March 31, 2022, the Company received $350,256 from HMRC in tax credits relating to the reimbursement of research and development expenses incurred during the fiscal year
ended March 31, 2021.
For each of the fiscal years ended March 31, 2023 and 2022,
the Company did not have unrecognized tax benefits, and therefore no interest or penalties related to unrecognized tax benefits were
accrued. Management does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.
The Company mainly files income tax returns in the U.S. and
the UK. The Company is subject to U.S. federal income tax examination by tax authorities for tax years beginning in 2019. The UK
tax returns for the Company’s UK subsidiaries are open to examination by the UK tax authorities for the tax years beginning April
1, 2018.
As of March 31, 2023, the Company has net
operating losses (“NOLs”) of approximately $11,300,000 in the U.S. and $36,230,000 in the UK. NOLs may be carried forward
indefinitely. Additionally, the Company has a research and development enhancement deduction carry forward of approximately $1,899,000
for purposes of UK income tax filings.
NOTE 12 – STOCKHOLDERS’ EQUITY
The Company filed a shelf registration statement on Form
S-3 with the SEC, which was declared effective by the SEC on March 24, 2022 (the “2022 Shelf Registration Statement”). The
2022 Shelf Registration Statement provides the Company with the ability to issue common stock and other securities as described in the
registration statement from time to time up to an aggregate amount of $224.6 million,
dependent upon available shares.
In January 2023, Armistice Capital LLC and Alyeska Master
Fund LLC agreed to buy a total of 4,796,206
shares of common stock at $1.75
per share plus warrants to purchase 4,796,206
shares of common stock with an exercise price equal to $2.00
per share The gross proceeds totaled $8,393,361 before costs of $737,385
were deducted.
On July 23, 2021, the Company entered into an At The Market
Offering Agreement (the “2021 ATM”) with H.C. Wainwright & Co., LLC pursuant to which the Company may offer and
sell from time to time to, at its option, up to an aggregate of $100 million of shares (amended to $3
million as at April 1, 2022) in of its common stock.
During the year ended March 31, 2022, the Company issued
and sold 397,524 shares
of its common stock (including 375,000 shares to Tiger Trading Partners L.L.C., see below) at an average price of $4.07 per
share under the 2021 ATM for aggregate net proceeds of $1.6 million
after deducting commissions and offering expenses payable by the Company.
During the year ended March 31, 2022, the Company agreed to sell 750,000
shares to Tiger Trading Partners L.L.C. (an affiliate of Tiger Management L.L.C. (a vehicle for the family
office of Julian H. Robertson) at a price of $4
per share and gross proceeds of $3
million; 375,000 of the shares were sold within the 2021 ATM facility noted above,
and 375,000 of the shares were sold in a direct issuance completed on February 10, 2022.
Stock options
A summary of option activity for the years ended March 31, 2023
and 2022 is presented below:
Schedule of option award activity | |
| | | |
| | | |
| | |
| |
Number
of Options | | |
Weighted
Average Exercise Price | | |
Weight
Average remaining Contractual Term (years) | |
Balance at April 1, 2021 | |
| — | | |
| — | | |
| | |
Granted | |
| 40,000 | | |
$ | 3.98 | | |
| | |
Exercised | |
| — | | |
| — | | |
| | |
Forfeited | |
| — | | |
| — | | |
| | |
Expired | |
| — | | |
| — | | |
| | |
Balance at March 31, 2022 | |
| 40,000 | | |
| 3.98 | | |
| 4.83 | |
Granted | |
| — | | |
| — | | |
| | |
Exercised | |
| — | | |
| — | | |
| | |
Forfeited | |
| — | | |
| — | | |
| | |
Expired | |
| — | | |
| — | | |
| | |
Balance at March 31, 2023 | |
| 40,000 | | |
$ | 3.98 | | |
| 2.7 | |
Vested and exercisable at March 31, 2023 | |
| 40,000 | | |
$ | 3.98 | | |
| 2.7 | |
No stock options were granted during the fiscal year ended March
31, 2023.
On January 28, 2022, the Board of Directors
granted its directors options to purchase 40,000 shares of common stock at an exercise price of $3.98 per share, which was the closing
price of the Company’s common stock on the date of grant. The options were fully vested at grant and are exercisable for a period
of five years from the date of grant. The fair value of the stock options was determined to be $133,529 using a Black-Scholes Option
Pricing Model with the following assumptions:
Schedule of key assumptions |
|
Stock Price |
$3.98 |
Exercise Price |
$3.98 |
Term |
5 years |
Volatility |
122.52% |
Expected dividend yield (%) |
— |
Discount Rate (Bond Equivalent Yield) |
2.28% |
Stock Warrants
A summary of warrant activity for the years
ended March 31, 2023 and 2022 is presented below:
Schedule of warrant activity | |
| | | |
| | | |
| | |
| |
Number
of Warrants | | |
Weighted
Average Exercise Price | | |
Weight
Average remaining Contractual Term (years) | |
Balance at April 1, 2021 | |
| 1,939,990 | | |
$ | 6.30 | | |
| 4.62 | |
Granted | |
| — | | |
| | | |
| — | |
Exercised | |
| (366,892 | ) | |
| 8.08 | | |
| 4.08 | |
Forfeited | |
| — | | |
| | | |
| — | |
Expired | |
| — | | |
| | | |
| — | |
Balance at March 31, 2022 | |
| 1,573,098 | | |
| 6.64 | | |
| 4.07 | |
Granted | |
| 4,796,206 | | |
| 2.00 | | |
| 5.00 | |
Exercised | |
| — | | |
| | | |
| — | |
Forfeited | |
| — | | |
| | | |
| — | |
Expired | |
| — | | |
| 5.00 | | |
| — | |
Balance at March 31, 2023 | |
| 6,369,304 | | |
$ | 2.7 | | |
| 4.87 | |
Vested and exercisable at March 31, 2023 | |
| 6,369,304 | | |
$ | 2.7 | |
| | 4.87 |
NOTE 13 – CONTINGENCIES
COVID-19
The global outbreak of the novel coronavirus
(COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions
to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of COVID-19,
this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business operations
will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to
monitor the global outbreak of COVID-19 and are working with our employees, suppliers and other stakeholders to mitigate the risks posed
by its spread. COVID-19 is not expected to have any long-term detrimental effect on the Company’s success. Whilst restrictions associated
with COVID-19 have largely been removed in our operational locations, we will continue to assess the situation, including abiding by any
government-imposed restrictions, as and where relevant.
Inflation
Macroeconomic factors such as inflation, rising interest rates,
governmental responses there to and possible recession caused thereby also add significant uncertainty to our operations and possible
effects to the amount and type of financing available to the Company in the future.
NOTE 14 – SUBSEQUENT EVENTS
The Company performed an evaluation of subsequent events through the
date of filing of these consolidated financial statements with the SEC, and determined there were no material subsequent events which
affected, or could affect, the amounts or disclosures in the consolidated financial statements.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
The disclosure with respect to the change in our accountants
required under this section was previously reported as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as
amended, on a Current Report on Form 8-K filed with the Securities and Exchange Commission on May 31, 2022. As previously disclosed, there
were no disagreements or any reportable events to disclose.
ITEM 9A. CONTROLS AND
PROCEDURES.
Evaluation of Disclosure Controls
and Procedures
We have established
disclosure controls and procedures to ensure that the information required to be disclosed by the Company in the reports that it files
or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to the officers
who certify the Company's financial reports and to other members of senior management and the Board of Directors as appropriate to allow
timely decisions regarding required disclosure.
The Company’s
Chief Executive Officer / Chief Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2023. Based on their evaluation, the Chief Executive
Officer and Chief Financial Officer have concluded that as of March 31, 2023 our disclosure controls and procedures were not effective
due to material weaknesses in our internal control over financial reporting described below.
Management's
Annual Report on Internal Control over Financial Reporting
Our management
is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under
the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of the
Chief Executive Officer / Chief Financial Officer to provide reasonable assurance regarding the reliability of our financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.
Our
internal control over financial reporting includes those policies and procedures that:
1.
Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of our company;
2.
Provide reasonable assurance that the transaction is recorded as necessary to permit preparation of consolidated financial
statements in accordance with accounting
principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance
with authorizations of our management and directors; and
3. Provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the
consolidated financial statements.
Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide
only reasonable assurance of achieving their control objectives.
In evaluating the effectiveness of our internal control
over financial reporting, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control - Integrated Framework (2013).
Based on this evaluation, our Chief Executive Officer
/ Chief Financial Officer concluded that our internal controls over financial reporting were not effective as of March 31, 2023. Management
has identified the following material weaknesses in the Company’s internal control over financial reporting as of March 31, 2023:
Subsequent to filing our Form 10-Q for the second
quarter ended September 30, 2022 and as a result of additional analysis performed in preparation for the Form 10-Q for the third quarter
ended December 31, 2022 audit, management became aware that the Company did not maintain effective controls over the preparation and review
of (i) accounting for the foreign currency balance for a mark-to-market contract; and (ii) accounting for certain debt issuance costs
in the computation of the effective interest rate for a loan note, mainly due to the lack of adequate technical expertise, and the subsequent
impact on the quarterly periods ended June 30, 2022, and September 30, 2022. This resulted in an error in our interim consolidated quarterly
financial statements as originally reported in our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2022 and June
30, 2022, which in turn required a restatement of our interim consolidated financial data for those periods. Management determined that
this control deficiency constituted a material weakness in internal control over financial reporting as of June 30, 2022, and September
30, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected
on a timely basis.
Since we are a smaller
reporting company, this Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting
firm on internal control over financial reporting.
Changes in Internal Control
over Financial Reporting
There have been no changes in our internal control
over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934, as amended) during
the quarter ended March 31, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
Remediation of Material Weaknesses
Subsequent to September 30, 2022, the Company adopted
additional internal controls wherein if the accounting for (i) the foreign currency balance for a mark-to-market contract; and (ii) for
certain debt issuance costs in the computation of the effective interest rate for a loan note, or any other complex transaction is contemplated,
an accounting consultant will be engaged as to the financial statement impact that any such transaction may have, prior to consummation
of the transaction.
ITEM 9B. OTHER INFORMATION.
Not applicable.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS.
Not applicable.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS
AND CORPORATE GOVERNANCE.
The following persons are our executive officers and directors, and hold the positions
set forth opposite their respective names as of the date hereof.
Name | |
Age | |
Position | |
Date of Appointment |
Dewan Fazlul Hoque Chowdhury | |
| 50 | | |
Chief Executive Officer, President and Director | |
| December 24, 2013 | |
Arash Ghadar | |
| 46 | | |
Chief Operating Officer | |
| January 5, 2022 | |
Bashir Timol | |
| 47 | | |
Director, Chief Business Officer | |
| December 24, 2013 April 9, 2018 | |
Thomas Moore | |
| 59 | | |
Independent Director | |
| August 3, 2017 | |
Dr. Salim Natha | |
| 56 | | |
Independent Director | |
| July 26, 2017 | |
Timothy Johnson | |
| 39 | | |
Independent Director | |
| July 17, 2017 | |
Our directors hold office until the earlier
of their death, resignation, or removal or until their successors have been qualified.
Dewan Fazlul Hoque Chowdhury. Dr. D.F.H. Chowdhury has
been our President, Chief Executive Officer and a member of our board of directors since the incorporation of DDL on January 20, 2009.
He is in charge of research and development of our core technologies, product development, innovation and commercialization. He also
coordinates and oversees legal compliance; development of the company mission; policy and planning. Prior to establishing the Company,
Dr. D.F.H. Chowdhury was the founder and CEO of Microneedle Technologies and Nemaura Pharma Limited. Dr. D.F.H. Chowdhury has been responsible
for negotiating licensing deals for a transdermal patch to treat Alzheimer’s disease. Additionally, he is involved in commercial
negotiations and global strategy development.
Arash Ghadar. Dr Ghadar joined the
business as Chief Operating Officer on January 5, 2022, prior to joining Nemaura, Dr. Ghadar spent a decade as the Technical Director
of Datalink Electronics (Datalink) in Loughborough, England where he managed the design team as an autonomous entity within Datalink.
He was responsible for management of the day-to-day operations, business planning, legal affairs, finance, sales, and business development
of the design team. In this role, he also oversaw numerous technical projects for healthcare and industrial customers that included product
development lifecycle, feasibility studies, design, development, prototyping, validation, certification, quality management, and volume
manufacturing.
Dr. Ghadar is also currently a non-executive
director at Medilink Midlands, the Midlands (England) Life Sciences industry association with a vision to stimulate the growth of the
Midlands life science sector. He has a BSc Degree and Masters in Electronics and Control Systems Engineering, where he achieved a First
Class degree and Distinction respectively, and he also has a Ph.D. in Biosensors from the University of Warwick (U.K.).
Bashir Timol. Mr.
Timol has served as member of the board of Nemaura Medical since formation in December 2013. He has co-founded, managed, and funded several
biotech and life science companies, and led the investment consortium that provided capital for the initial two funding rounds for
Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.
Timothy Johnson. Mr. Johnson was
elected as a director in July 2017. He is currently serving in executive positions in several tax consultancy and accountancy businesses
in the UK. He is a practicing Chartered Tax Adviser and holds a first-class Master of Science in Mathematics and Physics from the University
of Manchester, UK. Mr Johnson’s work involves in depth review and analysis of financial statements on a daily basis, and he has
significant experience in matters relating to financial accounts, tax, financial management, financial regulatory requirements and anti-money
laundering requirements.
Thomas Moore. Mr. Moore was elected
as a director in August 2017. He is currently working as a director, tax consultant and co-owner of a tax consultancy and pensions administration
business (WestBridge), having built up three decades of experience in accounting and consulting fields at leading accounting firms including
Grant Thornton, KPMG and PricewaterhouseCoopers. Throughout the last five years, Mr Moore has held his current role with WestBridge since
May 2017 and before that was a Director with Grant Thornton UK PLC. He is a practicing Chartered Tax Adviser and earned his first-class
Bachelor of Arts in French and Russian from the University of Northumbria, UK. The qualifications Mr Moore brings to the role include
a wealth of experience in matters relating to accounts, financial management and financial regulatory requirements including his current
experience as an MLRO in two companies.
Dr. Salim Natha. Dr. Natha was elected as a director
in July 2017. He is currently practicing as an Eye Surgeon in the UK National Health Service (NHS), and is the clinical lead for a retinopathy
screening program for over 20,000 diabetics in the Ashton, Wigan and Leigh region. He has published several articles in the medical literature
and is a peer reviewer for the English National Diabetic Retinopathy Screening Program. Dr. Natha graduated with honours from the University
of Liverpool Medical School.
Family Relationships
There are no family relationships between any of our directors
or executive officers.
Involvement in Certain Legal Proceedings.
None.
Board of Directors
All directors hold office until the next
Annual Meeting of shareholders and until their successors have been duly elected and qualified. Directors are elected at the annual meetings
to serve for one-year terms. Officers are elected by, and serve at the discretion of, the Board of Directors. Our Board of Directors shall
hold meetings on at least a quarterly basis.
The Board of Directors complies with the NASDAQ Listing Rules
with respect to corporate governance matters. Under the NASDAQ rules we are required to maintain a board of directors comprised of at
least 50% independent directors, and an audit committee of at least two members, comprised solely of independent directors who also meet
the requirements of Rule 10A-3 under the Securities Exchange Act of 1934.
Director Independence
The board of directors has reviewed the independence of our
directors, applying the NASDAQ independence standards. Based on this review, the board of directors determined that each of Thomas Moore,
Dr. Salim Natha and Timothy Johnson are independent within the meaning of the NASDAQ rules. In making this determination, our board of
directors considered the relationships that each of these non-employee directors has with us and all other facts and circumstances our
board of directors deemed relevant in determining their independence. As required under applicable NASDAQ rules, we anticipate that our
independent directors will meet on a regular basis as often as necessary to fulfil their responsibilities, including at least annually
in executive session without the presence of non-independent directors and management.
Board Committees
Our board of directors has established standing committees
in connection with the discharge of its responsibilities. These committees include an Audit Committee, a Compensation Committee and a
Nominating and Corporate Governance Committee. Our board of directors has adopted written charters for each of these committees. Copies
of the charters are available on our website. Our board of directors may establish other committees as it deems necessary or appropriate
from time to time.
Audit Committee
Our Audit Committee is comprised of our
independent directors: Thomas Moore, Dr. Salim Natha and Timothy Johnson. Mr. Johnson qualifies as the Audit Committee financial expert
as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act.
According to its charter, the Audit Committee
consists of at least three members, each of whom shall be a non-employee director who has been determined by the Board to meet the independence
requirements of NASDAQ, and also Rule 10A-3(b)(1) of the SEC, subject to the exemptions provided in Rule 10A-3(c). The Audit Committee
Charter describes the primary functions of the Audit Committee, including the following:
| – | Oversee the Company’s accounting and financial reporting processes;
|
| – | Oversee audits of the Company’s consolidated financial statements;
|
| – | Discuss policies with respect to risk assessment and risk management, and
discuss the Company’s major financial risk exposures and the steps management has taken to monitor and control such exposures; |
| – | Review and discuss with management the Company’s audited consolidated
financial statements and review with management and the Company’s independent registered public accounting firm the Company’s
consolidated financial statements prior to the filing with the SEC of any report containing such consolidated financial statements. |
| – | Recommend to the board that the Company’s audited consolidated financial
statements be included in its annual report on Form 10-K for the last fiscal year; |
| – | Meet separately, periodically, with management, with the Company’s
internal auditors (or other personnel responsible for the internal audit function) and with the Company’s independent registered
public accounting firm; |
| – | Be directly responsible for the appointment, compensation, retention and
oversight of the work of any independent registered public accounting firm engaged to prepare or issue an audit report for the Company;
|
| – | Take, or recommend that the board take, appropriate action to oversee and
ensure the independence of the Company’s independent registered public accounting firm; and |
| – | Review major changes to the Company’s auditing and accounting principles
and practices as suggested by the Company’s independent registered public accounting firm, internal auditors or management. |
Compensation Committee
The Compensation Committee is responsible
for, among other matters:
| – | reviewing and approving, or recommending to the board of directors to approve
the compensation of our CEO and other executive officers and directors reviewing key employee compensation goals, policies, plans and
programs; |
| – | administering incentive and equity-based compensation; |
| – | reviewing and approving employment agreements and other similar arrangements
between us and our executive officers; and |
| – | appointing and overseeing any compensation consultants or advisors. |
Our Compensation Committee consists of Thomas
Moore, Dr. Salim Natha and Timothy Johnson. Dr. Salim Natha serves as chair of the Compensation Committee.
Corporate Governance and Nominating Committee
The Corporate Governance and Nominating
Committee is responsible for, among other matters:
| – | selecting or recommending for selection candidates for directorships; |
| – | evaluating the independence of directors and director nominees; |
| – | reviewing and making recommendations regarding the structure and composition
of our board and the board committees; |
| – | developing and recommending to the board corporate governance principles
and practices; |
| – | reviewing and monitoring the Company’s Code of Ethics; and |
| – | overseeing the evaluation of the Company’s management. |
Our Corporate Governance and Nominating
Committee consists of Thomas Moore, Dr. Salim Natha and Timothy Johnson. Mr. Johnson serves as chair of the Corporate Governance and Nominating
Committee.
Material Changes to Procedures by which Security Holders
May Recommend Board Nominees
We do not currently have a procedure by which security holders
may recommend nominees to the Board. Prior to the listing of our common stock on NASDAQ, as a private company with a limited shareholder
base, we did not believe that it was important to provide such a procedure. However, as a publicly traded NASDAQ company with the requirement
to hold annual shareholder meetings, we will consider implementing such a policy in the future.
The Board does not have a formal policy on Board candidate
qualifications. The Board may consider those factors it deems appropriate in evaluating director nominees made either by the Board or
stockholders, including judgment, skill, strength of character, experience with businesses and organizations comparable in size or scope
to the Company, experience and skill relative to other Board members, and specialized knowledge or experience. Depending upon the current
needs of the Board, certain factors may be weighed more or less heavily. In considering candidates for the Board, the directors evaluate
the entirety of each candidate’s credentials and do not have any specific minimum qualifications that must be met. The directors
will consider candidates from any reasonable source, including current Board members, stockholders, professional search firms or other
persons. The directors will not evaluate candidates differently based on who has made the recommendation.
Board Leadership Structure and Role in Risk Oversight
Dr. Chowdhury holds the positions of chief
financial officer, chief executive officer, and chairman of the board of the Company. Mr. Justin Mclarney held the position of chief financial
officer from September 2020 until July 2022. The board believes that Dr. Chowdhury’s services as chief financial officer, chief
executive officer and chairman of the board is in the best interest of the Company and its shareholders. The process is ongoing in recruiting
for the position of chief financial officer. Dr. Chowdhury possesses detailed and in-depth knowledge of the issues, opportunities and
challenges facing the Company in its business and is thus best positioned to develop agendas that ensure that the Board’s time and
attention are focused on the most critical matters relating to the business of the Company. His combined role enables decisive leadership,
ensures clear accountability, and enhances the Company’s ability to communicate its message and strategy clearly and consistently
to the Company’s shareholders, employees and customers.
The board has not designated a lead director. Given the limited
number of directors comprising the Board, the independent directors call and plan their executive sessions collaboratively and, between
meetings of the Board, communicate with management and one another directly. Under these circumstances, the directors believe designating
a lead director to take on responsibility for functions in which they all currently participate might detract from rather than enhance
performance of their responsibilities as directors.
Management is responsible for assessing
and managing risk, subject to oversight by the board of directors. The board oversees our risk management policies and risk appetite,
including operational risks and risks relating to our business strategy and transactions. Various committees of the board assist the board
in this oversight responsibility in their respective areas of expertise.
| – | The Audit Committee assists the board with the oversight of our financial
reporting, independent auditors, and internal controls. It is charged with identifying any flaws in business management and recommending
remedies, detecting fraud risks and implementing anti-fraud measures. The audit committee further discusses Nemaura’s policies with
respect to risk assessment and management with respect to financial reporting. |
| – | The Compensation Committee oversees compensation, retention, succession
and other human resources-related issues and risks. |
| – | The Corporate Governance and Nominating Committee overviews risks relating
to our governance policies and initiatives. |
Code of Ethics
We have adopted a Code of Ethics that applies
to our principal executive officer, principal financial officer and other persons performing similar functions. A copy of our Code of
Ethics is available on our website. We intend to post amendments to, or waivers from a provision of, our Code of Ethics that apply to
our principal executive officer, principal financial officer or persons performing similar functions on our website.
ITEM 11. EXECUTIVE COMPENSATION.
2023 Summary Compensation Table
This table provides disclosure, for fiscal
years 2023 and 2022, of the compensation paid to our named executive officers.
Named Executive Officer and Principal
Position | |
Year | | |
Salary | | |
Bonus | | |
Stock
Awards | | |
Option
Awards | | |
All Other
Compensation | | |
Total | |
| |
| | | |
| $ | | |
| $ | | |
| $ | | |
| $ | | |
| $ | | |
| $ | |
Dr. D.F.H. Chowdhury, | |
| 2023 | | |
| 98,913 | | |
| — | | |
| — | | |
| — | | |
| 239,665 | (4) | |
| 337,577 | |
Chief Executive Officer and President | |
| 2022 | | |
| 109,416 | | |
| — | | |
| — | | |
| 26,706 | (1) | |
| 3,849 | | |
| 139,971 | |
Justin McLarney
| |
| 2023 | | |
| 28,245 | | |
| — | | |
| — | | |
| | | |
| 50,728 | | |
| 78,973 | |
Chief Financial Officer (2) | |
| 2022 | | |
| 256,444 | (3) | |
| — | | |
| — | | |
| — | | |
| 2,498 | | |
| 258,942 | |
(1) |
On January 28, 2022, in compensation for Dr. Chowdhury’s service as a director, the Company’s Board of Directors granted to Dr. Chowdhury an option to purchase 8,000 shares of common stock at an exercise price of $3.98 per share, the closing price of the Company’s common stock on the date of grant. The option was fully vested at grant and is exercisable for a period of five years from the date of grant. The fair value attributed to the options has been calculated using a Black-Scholes Option Pricing Model. |
(2) |
Mr. Mclarney left his position as Chief Financial Officer of the Company in July 2022. Thereafter, Dr. Chowdhury acted as Interim Chief Financial Officer. |
(3) |
Of this amount, $169,055 was paid in cash, and $87,389 was paid in stock. At Mr. Mclarney’s election, a portion of his base salary was paid in stock. Accordingly, on January 31, 2022, Mr. Mclarney received 22,293 shares at the market price of $3.92. |
(4) |
In April 2022 the remuneration Committee agreed to change the remuneration for Dr. Chowdhury, which had not changed since 2013. It was determined that his remuneration should be $400,000 per annum plus a discretionary bonus (performance requirements to be determined at a later date). The Board approved this in July 2022. This also includes payments into the pension scheme. |
Dr. D.F.H. Chowdhury
We entered into an employment agreement
with Dr. D.F.H. Chowdhury on November 2, 2013. Dr. D.F.H. Chowdhury’s contract is for an unspecified period. He may leave the Company
with notice, or the Company may terminate his contract with notice. Termination may be with or without cause. Dr. D.F.H. Chowdhury receives
an annual salary of £80,000 pounds sterling (approximately $109,000). Our contract with Dr. D.F.H. Chowdhury does not include any
provision for stock options or equity incentives.
Under the executive employment agreement
Dr. D.F.H. Chowdhury’s annual salary was adjusted on a pro rata basis to reflect only work that was performed for Nemaura Medical
Inc. The disclosure set forth in the table reflects his pro rata compensation for the periods ending March 31, 2022 and March 31, 2021,
respectively.
Mr. J. McLarney
We entered into an employment agreement
with our Chief Financial Officer, Mr. Justin Mclarney on September 15, 2020. Mr Mclarney’s contract is for an unspecified period.
He may leave the Company with notice, or the Company may terminate his contract with notice. Termination may be with or without cause.
Mr Mclarney receives an annual base salary of £90,000 pounds sterling (approximately $123,000). Our contractual arrangements with
Mr Mclarney allow for stock options, and equity or cash incentives to be provided upon certain conditions having been met. Employment
was terminated by mutual consent in July 2022.
Outstanding Equity Awards for fiscal
year ended March 31, 2023.
The table below sets forth the outstanding option awards for
the named executive officers, as of March 31, 2023; there were no new outstanding stock awards as of this date:
| |
Number
of Securities Underlying Unexercised Options (#) Exercisable | | |
Number
of Securities Underlying Unexercised Options (#) Unexercisable | | |
Option
Exercise Price ($) | | |
Option Expiration Date |
Dr. D.F.H. Chowdhury
| |
| 8,000 | | |
| — | | |
| 3.98 | | |
January 28, 2027 |
Potential payments upon termination or change-in-control.
None.
Director Compensation
Each of our independent directors received annual fees of £5,000
pounds sterling (approximately $6,182) for the year ended March 31, 2023, for their service on our board of directors and committees.
Name | |
Fees
Earned or Paid in Cash ($) | |
Timothy Johnson | |
| 6,182 | |
Dr. Salim Natha | |
| 6,182 | |
Thomas Moore | |
| 6,182 | |
ITEM 12. SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
The following tables set forth certain information
as of March 31, 2022, regarding the beneficial ownership of our common stock, by (i) each person or entity who, to our knowledge, owns
more than 5% of our common stock; (ii) our named executive officers; (iii) each director; and (iv) all of our executive officers and directors
as a group.
Unless otherwise indicated in the footnotes
to the following table, each person named in the table has sole voting and investment power and that person’s address is c/o NEMAURA
MEDICAL INC., Advanced Technology Innovation Centre, 5 Oakwood Drive, Loughborough, Leicestershire, United Kingdom LE11 3QF.
Name of Beneficial Owner |
Amount and Nature of Beneficial Ownership |
Percentage (1) |
Dr. D.F.H. Chowdhury |
8,761,700 (2) |
30.3% |
Bashir Timol |
2,798,310 (3) |
9.7% |
Timothy Johnson |
8,000 (4) |
* |
Dr. Salim Natha |
408,640 (2) |
1.4% |
Thomas Moore |
8,000 (4) |
* |
All Executive Officers and Directors as a Group (6 persons) |
12,025,693 (5) |
41.5% |
Holders of 5% or more of our common stock |
|
|
Ismail, Sufyan (6) |
2,134,295 |
7.4% |
* Less than 1%.
(1) Based upon 24,102,866 shares of our common stock outstanding
at March 31, 2022.
(2) Includes 8,000 shares the reporting person has the right
to acquire within 60 days of March 31, 2022 upon exercise of a vested option to purchase 8,000 shares of common stock.
(3) Represents (i) 2,708,210 shares held directly by the reporting
person, (ii) 82,100 shares held by the reporting person’s spouse, and (iii) 8,000 shares the reporting person has the right to acquire
within 60 days of March 31, 2022 upon exercise of a vested option to purchase 8,000 shares of common stock.
(4) Represents 8,000 shares the reporting person has the right
to acquire within 60 days of March 31, 2022 upon exercise of a vested option to purchase 8,000 shares of common stock.
(5) Includes 40,000 shares the Company’s executive officers
and directors have the right to acquire within 60 days of March 31, 2022 upon exercise of vested options to purchase 40,000 shares of
common stock.
(6) Mr. Ismail’s address is Hollybank High Bank Lane, Lostock,
Bolton, Lancashire BL6 HDT United Kingdom.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
Pharma and NDM are entities controlled by
our Chief Executive Officer, President, Chairman of the Board and majority shareholder, Dr. D.F.H. Chowdhury.
Pharma has invoiced our subsidiaries, DDL
and TCL for research and development services. In addition, certain operating expenses of DDL and TCL were incurred and paid by Pharma
and NDM which have been invoiced to us. Certain costs incurred by Pharma and NDM are directly attributable to DDL and TCL and such costs
were billed to us.
Total costs charged to us by Pharma and NDM were $4,767,586
for the year ended March 31, 2023.
The following is a summary of activity between
the Company and Pharma and NDM for the years ended March 31, 2023 and 2022.
| |
March
31, | |
| |
2023 | | |
2022 | |
| |
($) | | |
($) | |
Liability due to related parties at beginning of year | |
| (101,297 | ) | |
| 148,795 | |
Amounts invoiced by Pharma to DDL, NM and TCL | |
| 4,767,586 | | |
| 3,245,985 | |
Amounts invoiced by DDL to Pharma | |
| (3,245 | ) | |
| (2,495 | ) |
Amounts paid by DDL to Pharma | |
| (3,773,217 | ) | |
| (3,492,962 | ) |
Foreign exchange differences | |
| 30,953 | | |
| (620 | ) |
(Receivable) / Liability due (from) / to related parties at end of year | |
| 920,780 | | |
| (101,297 | ) |
REVIEW, APPROVAL OR RATIFICATION OF TRANSACTIONS
WITH RELATED PERSONS
It is Company policy to not enter any transaction (other than
compensation arrangements in the ordinary course) with any director, executive officer, employee, or principal stockholder or party related
to them, unless authorized by a majority of the directors having no interest in the transaction, upon a favorable recommendation by the
Audit Committee (or a majority of its disinterested members).
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The following table sets forth the aggregate
fees billed in the fiscal years ended March 31, 2023 and 2022 by Mayer Hoffman McCann P.C. and Weinberg & Company P.A.
| |
2023 | | |
2022 | |
| |
($) | | |
($) | |
Audit Fees | |
| 217,000 | | |
| 87,500 | |
Audit Related Fees | |
| 40,000 | | |
| 80,000 | |
Tax Fees | |
| — | | |
| 10,000 | |
Other Fees | |
| 31,000 | | |
| 10,000 | |
Totals | |
| 288,000 | | |
| 187,500 | |
Audit fees represent amounts billed for professional services
rendered or expected to be rendered for the audit of our annual consolidated financial statements.
Audit-related fees represent professional services rendered
or expected to be rendered for assurance and related services by the accounting firm that are reasonably related to the performance of
the audit or review of our consolidated financial statements that are not reported under audit fees.
Tax fees represent professional services
rendered by the accounting firm for tax compliance and this includes preparing our annual tax filings.
Other fees represent charges made for the provision of a comfort
letter..
The Audit Committee approves all auditing services and the
terms thereof and non-audit services (other than non-audit services published under Section 10A(g) of the Exchange Act or the applicable
rules of the SEC or the Pubic Company Accounting Oversight Board) to be provided to us by the independent auditor; provided, however,
the pre-approval requirement is waived with respect to the provisions of non-audit services for us if the “de minimus” provisions
of Section 10A(i)(1)(B) of the Exchange Act are satisfied.
Audit Committee Pre-Approval Policy
Under provisions of the Sarbanes-Oxley Act
of 2002, our principal accountant may not be engaged to provide non-audit services that are prohibited by law or regulation to be provided
by it, and the Audit Committee must pre-approve the engagement of our independent accountant to provide audit and permissible non-audit
services. The Audit Committee has not established any policies or procedures other than those required by applicable laws and regulations.
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Exhibit No. |
Description |
3.1 |
Articles of Incorporation December 24, 2013 (Incorporated by reference from the registrant’s registration statement on Form S-1 (File No. 333-194857)) |
3.1(a) |
Certificate of Amendment to the Articles of Incorporation
(Incorporated by reference from the registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2018, filed June
12, 2018) |
3.2 |
Certificate of Designation for Series A Convertible Preferred Stock (Incorporated by reference from the registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2018, filed with the SEC on June 12, 2018 ) |
3.3 |
Bylaws (incorporated by reference from the Registrant’s Registration Statement on Form S-1 (File No. 333-194857), filed March 28, 2014) |
3.4 |
Amended and Restated Company By-laws (Incorporated by reference from the registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2018, filed June 12, 2018) |
4.1 |
Form of Subscription Agreement (incorporated by reference from the Registrant’s Current Report on Form 8-K filed on December 2, 2015) |
4.2 |
Common Stock Purchase Warrant by and between Nemaura Medical Inc. and Dr. Dallas John Burston, dated November 26, 2015 (Incorporated by reference from the registrant’s Current Report on Form 8-K filed with the SEC on December 2, 2015) |
4.3 |
Description of Registrant’s Securities (Incorporated by reference from
the registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed June 29, 2021) |
10.1† |
Employment Agreement dated November 1, 2013, between the Company and Dewan F.H. Chowdhury (incorporated by reference from the Registrant’s Registration Statement on Form S-1 (File No. 333-194857), filed March 28, 2014) |
10.2 |
Exclusive Rights License Agreement between Dallas Burston Pharma (DBP) Jersey Limited and Dermal Diagnostics Limited, dated March 31, 2014 (incorporated by reference from the Registrant’s Registration Statement on Form S-1/A (File No. 333-194857), filed July 11, 2014) |
10.3 |
Assignment Agreement between NDM Technologies Limited and Dermal Diagnostics Limited, dated May 8, 2014 (incorporated by reference from the Registrant’s Registration Statement on Form S-1 (File No. 333-194857), filed July 30, 2014) |
10.4 |
Assignment Agreement between Nemaura Pharma Limited and Dermal Diagnostics Limited, dated May 8, 2014 (incorporated by reference from the Registrant’s Registration Statement on Form S-1 (File No. 333-194857), filed July 30, 2014) |
10.5+ |
License, Supply and Distribution Agreement (incorporated by reference from
the Registrant’s Current Report on Form 8-K filed on December 2, 2015) |
10.6 |
Form of Common Stock Exchange Agreement (incorporated by reference from the Registrant’s Current Report on Form 8-K filed on November 7, 2017) |
10.7+ |
Joint Collaboration Agreement, between Dallas Burston Ethitronix (Europe) Limited and Nemaura Medical Inc., dated May 21, 2018 (incorporated by reference from the Registrant’s Current Report on Form 8-K filed on May 25, 2018) |
10.8† |
Employment Agreement dated September 15, 2020 between Dermal Diagnostics Limited and Justin Mclarney (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 21, 2020). |
10.9 |
Healthimation
License Agreement dated as of September 16, 2020 by and between Healthimation, LLC and the registrant (incorporated by reference
to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on November 2, 2020). |
10.10 |
Amendment,
dated as of October 23, 2020, to Healthimation License Agreement by and between Healthimation, LLC and the registrant
(incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on November 2,
2020). |
10.11 |
Note Purchase Agreement between the Registrant and Uptown Capital, LLC dated February 8, 2021 (Please note that portions of this exhibit have been omitted) (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 11, 2021). |
10.12 |
Secured Promissory Note of the Registrant issued to Uptown Capital, LLC dated February 8, 2021 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on February 11, 2021). |
10.13 |
Security Agreement between the Registrant and Uptown Capital, LLC dated February 8, 2021 (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on February 11, 2021). |
10.14 |
License, Supply and Distribution Agreement, entered into on September 24, 2021 and dated as of September 17, 2021, by and between Nemaura Medical Inc. and MySugarWatch Duopack Limited (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on September 31, 2021). |
10.15† |
Statement of Main Terms of Employment dated January 5, 2022 (incorporated by reference to the Registrant’s Current Report on Form 8-K filed on January 10, 2022). |
14.1 |
Code of Ethics adopted by the Board of Directors (incorporated by reference from the Registrant’s Registration Statement on Form S-1 (File No. 333-194857), filed March 28, 2014) |
21.1* |
Subsidiaries |
23.1* |
Consent of Mayer Hoffman McCann P.C. |
23.2* |
Consent of Weinberg & Company, P.A. |
31.1* |
Rule 13a-14(a)/15d-14(a)
– Certification of Principal Executive Officer |
31.2* |
Rule 13a-14(a)/15d-14(a)
- Certification of Chief Financial Officer |
32.1** |
Certification pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.INS* |
Inline XBRL Instance Document |
101.SCH* |
Inline XBRL Taxonomy Extension Schema Document |
101.CAL* |
Inline XBRL Taxonomy Extension Calculation Linkbase |
101.DEF* |
Inline XBRL Taxonomy Extension Definition Linkbase |
101.LAB* |
Inline XBRL Taxonomy Extension Labels Linkbase |
101.PRE* |
Inline XBRL Taxonomy Extension Presentation Linkbase |
104* |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
*Filed herewith.
** Furnished herewith.
+Portions of this Exhibit have been omitted
pursuant to a request for confidential treatment.
† Management contract or compensatory
plan or arrangement.
ITEM 16. FORM 10-K SUMMARY.
None
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf on July 13, 2023,
by the undersigned thereunto duly authorized.
NEMAURA MEDICAL INC.
/s/ Dr. D.F.H. Chowdhury
Dr. D.F.H. Chowdhury
President and Chief Executive Officer (Principal
Executive Officer)
Pursuant to the requirements of the Securities and Exchange Act
of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Dr. D.F.H. Chowdhury |
|
President, Chief Executive Officer and Director |
|
July 13, 2023 |
Dr. D.F.H.Chowdhury |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Bashir Timol |
|
Director |
|
July 13, 2023 |
Bashir Timol |
|
|
|
|
|
|
|
|
|
/s/ Timothy Johnson |
|
Director |
|
July 13, 2023 |
Timothy Johnson |
|
|
|
|
|
|
|
|
|
/s/ Salim Natha |
|
Director |
|
July 13, 2023 |
Salim Natha |
|
|
|
|
|
|
|
|
|
/s/ Thomas Moore |
|
Director |
|
July 13, 2023 |
Thomas Moore |
|
|
|
|
EXHIBIT 21.1
SUBSIDIARIES
Entity Name |
|
Jurisdiction of Incorporation or Organization |
|
|
|
|
|
|
Dermal Diagnostics (Holdings) Limited |
|
England and Wales
|
Dermal Diagnostics Limited |
|
England and Wales
|
Trial Clinic Limited |
|
England and Wales |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM
We consent to the inclusion in Form
10-K of our report dated June 29, 2022, with respect to the consolidated financial statements of Nemaura Medical, Inc. as of March 31,
2022 and for the year then ended, which report includes an explanatory paragraph regarding the existence of substantial doubt about the
Company’s ability to continue as a going concern, included in this annual report on Form 10-K of Nemaura Medical, Inc. as of and
for the year ended March 31, 2023.
/s/ Mayer Hoffman McCann P.C.
Denver, Colorado
July 13, 2023
Exhibit
23.2
CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation
by reference in the Registration Statement on Form S-3 (No. 333-230535) of our report dated July 14, 2023, relating to the financial statements
of Nemaura Medical Inc. as of and for the year ended March 31, 2023 (which report includes an explanatory paragraph relating to substantial
doubt about the Company’s ability to continue as a going concern) which appear in Nemaura Medical Inc.’s Annual Report on
Form 10-K for the year ended March 31, 2023.
/s/Weinberg and Company,
P.A.
Los Angeles, California
July 13, 2023
EXHIBIT 31.1
CERTIFICATION
I, Dr. D.F.H. Chowdhury, certify that:
1. I have reviewed this Annual Report on
Form 10-K of Nemaura Medical Inc.;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external
purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this
report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
and
5. The registrant's other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting.
Date: July 13, 2023
|
|
By: /s/ Dr. D. F. H. Chowdhury
|
|
|
|
|
|
Name: Dr. D. F. H. Chowdhury |
|
|
Title: Chief Executive Officer (Principal Executive Officer) |
EXHIBIT 31.2
CERTIFICATION
I, Dr. D.F.H. Chowdhury, certify that:
1. I have reviewed this Annual Report on
Form 10-K of Nemaura Medical Inc.;
2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
(a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
(b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external
purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this
report any change in the registrant's internal control over financial reporting that occurred during the registrant's fourth fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
and
5. The registrant's other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and
the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant
deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether
or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial
reporting.
Date: July 13, 2023
|
|
By: /s/ Dr. D. F. H. Chowdhury
|
|
|
|
|
|
Name: Dr. D. F. H. Chowdhury |
|
|
Title: Interim Chief Financial Officer (Principal Financial Officer) |
EXHIBIT 32.1
CERTIFICATION
Pursuant to 18 U.S.C. 1350 as adopted by Section 906
of the Sarbanes-Oxley Act of 2002
Each of the
undersigned, Dr.D.F.H. Chowdhury, Chief Executive Officer (Principal
Executive Officer) and Interim Chief Financial Officer (Principal Financial Officer) of the Company, has executed this certification in connection with the filing with the
Securities and Exchange Commission of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023 (the
“Report”).
Each of the undersigned hereby certifies that:
1. | | The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | | The
information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company |
|
July 13, 2023 |
|
/s/ Dr. D. F. H. Chowdhury |
Dr. D. F. H. Chowdhury |
Chief Executive Officer
(Principal Executive Officer) Interim Chief Financial Officer (Principal Financial Officer) |
v3.23.2
Cover - USD ($) $ in Thousands |
12 Months Ended |
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Jul. 13, 2023 |
Cover [Abstract] |
|
|
|
Document Type |
10-K/A
|
|
|
Amendment Flag |
true
|
|
|
Amendment Description |
Amendment No 1
|
|
|
Document Annual Report |
true
|
|
|
Document Transition Report |
false
|
|
|
Document Period End Date |
Mar. 31, 2023
|
|
|
Document Fiscal Period Focus |
FY
|
|
|
Document Fiscal Year Focus |
2023
|
|
|
Current Fiscal Year End Date |
--03-31
|
|
|
Entity File Number |
001-38355
|
|
|
Entity Registrant Name |
NEMAURA MEDICAL INC.
|
|
|
Entity Central Index Key |
0001602078
|
|
|
Entity Tax Identification Number |
46-5027260
|
|
|
Entity Incorporation, State or Country Code |
NV
|
|
|
Entity Address, Address Line One |
57 West 57th Street
|
|
|
Entity Address, City or Town |
New York
|
|
|
Entity Address, State or Province |
NY
|
|
|
Entity Address, Postal Zip Code |
10019
|
|
|
City Area Code |
646
|
|
|
Local Phone Number |
416-8000
|
|
|
Title of 12(b) Security |
Common Stock
|
|
|
Trading Symbol |
NMRD
|
|
|
Security Exchange Name |
NASDAQ
|
|
|
Entity Well-known Seasoned Issuer |
No
|
|
|
Entity Voluntary Filers |
No
|
|
|
Entity Current Reporting Status |
Yes
|
|
|
Entity Interactive Data Current |
Yes
|
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
|
Entity Small Business |
true
|
|
|
Entity Emerging Growth Company |
false
|
|
|
Entity Shell Company |
false
|
|
|
Entity Public Float |
$ 25,200
|
|
|
Entity Common Stock, Shares Outstanding |
|
|
28,899,402
|
ICFR Auditor Attestation Flag |
false
|
|
|
Document Financial Statement Error Correction [Flag] |
false
|
|
|
Auditor Firm ID |
572
|
199
|
|
Auditor Name |
Weinberg & Company, P.A.
|
Mayer Hoffman McCann P.C
|
|
Auditor Location |
Los
Angeles, California
|
Colorado
|
|
X |
- DefinitionDescription of changes contained within amended document.
+ References
+ Details
Name: |
dei_AmendmentDescription |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPCAOB issued Audit Firm Identifier
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_AuditorFirmId |
Namespace Prefix: |
dei_ |
Data Type: |
dei:nonemptySequenceNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_AuditorLocation |
Namespace Prefix: |
dei_ |
Data Type: |
dei:internationalNameItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_AuditorName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:internationalNameItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an annual report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_DocumentAnnualReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection w
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_DocumentFinStmtErrorCorrectionFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
+ Details
Name: |
dei_EntityPublicFloat |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
+ Details
Name: |
dei_EntityVoluntaryFilers |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 405
+ Details
Name: |
dei_EntityWellKnownSeasonedIssuer |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_IcfrAuditorAttestationFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Consolidated Balance Sheets - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Current assets: |
|
|
Cash |
$ 10,105,135
|
$ 17,749,233
|
Inventory, net |
1,754,852
|
1,487,771
|
Prepaid expenses and other current assets |
357,934
|
495,055
|
VAT receivable |
409,648
|
255,112
|
Deposit on foreign exchange contract |
909,666
|
0
|
Receivable from related parties |
0
|
101,297
|
Total current assets |
13,537,235
|
20,088,468
|
Property and equipment, net of accumulated depreciation |
641,906
|
532,508
|
Intangible assets, net of accumulated amortization |
384,092
|
1,480,980
|
Total assets |
14,563,233
|
22,101,956
|
Current liabilities: |
|
|
Accounts payable |
326,641
|
136,310
|
Accrued expenses and other liabilities |
130,678
|
558,426
|
Notes payable, current portion |
16,942,500
|
19,188,724
|
Payable to related parties |
920,780
|
0
|
Deferred revenue, current portion |
123,640
|
259,256
|
Foreign exchange contract derivative liability |
731,730
|
440,196
|
Warrant liability |
3,092,000
|
0
|
Total current liabilities |
22,267,969
|
20,582,912
|
Notes payable, non-current portion |
3,087,651
|
0
|
Deferred revenue, non-current portion |
1,021,811
|
1,052,960
|
Total liabilities |
26,377,431
|
21,635,872
|
Commitments and contingencies |
|
|
Stockholders’ equity (deficit): |
|
|
Common stock, par value $0.001 – authorized: 42,000,000 shares; issued and outstanding: 28,899,402 and 24,102,866 as of March 31, 2023 and 2022, respectively |
28,899
|
24,103
|
Additional paid-in capital |
40,991,377
|
38,295,775
|
Accumulated deficit |
(51,875,211)
|
(37,731,476)
|
Accumulated other comprehensive (loss) income |
(959,263)
|
(122,318)
|
Total stockholders’ equity (deficit) |
(11,814,198)
|
466,084
|
Total liabilities and stockholders’ equity (deficit) |
$ 14,563,233
|
$ 22,101,956
|
X |
- References
+ Details
Name: |
nmrd_DepositOnForeignExchangeContract |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_ForeignExchangeContractDerivativeLiability |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_WarrantLiability |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.
+ References
+ Details
Name: |
us-gaap_AccruedLiabilitiesAndOtherLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapitalCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenueAndCreditsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenueCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ValueAddedTaxReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Statement of Financial Position [Abstract] |
|
|
Common stock, par value per share |
$ 0.001
|
$ 0.001
|
Common stock, shares authorized |
42,000,000
|
42,000,000
|
Common stock, shares issued |
28,899,402
|
24,102,866
|
Common stock, shares outstanding |
28,899,402
|
24,102,866
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Income Statement [Abstract] |
|
|
Sales |
$ 77,044
|
$ 503,906
|
Cost of sales |
(75,328)
|
(344,300)
|
Cost of sales-inventory write down |
(1,478,108)
|
0
|
Gross profit (loss) |
(1,476,392)
|
159,606
|
Operating expenses: |
|
|
Research and development |
1,538,615
|
1,556,988
|
General and administrative |
5,600,188
|
6,173,049
|
Impairment of intangible assets |
980,039
|
0
|
Total operating expenses |
8,118,842
|
7,730,037
|
Loss from operations |
(9,595,234)
|
(7,570,431)
|
Interest expense |
(6,412,501)
|
(6,666,630)
|
Change in fair value of warrant liability |
1,864,000
|
|
Loss before income tax benefit |
(14,143,735)
|
(14,237,061)
|
Provision for income tax benefit |
0
|
350,256
|
Net loss |
(14,143,735)
|
(13,886,805)
|
Other comprehensive income: |
|
|
Foreign currency translation adjustment |
(836,946)
|
(257,885)
|
Comprehensive loss |
$ (14,980,681)
|
$ (14,144,690)
|
X |
- References
+ Details
Name: |
nmrd_ChangeInFairValueOfWarrantLiability |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_CostOfSalesinventoryWriteDown |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4
+ Details
Name: |
us-gaap_AssetImpairmentCharges |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of operating interest income (expense).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_InterestIncomeExpenseNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
+ Details
Name: |
us-gaap_Revenues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cumulative translation gain (loss), before tax, from translating foreign currency financial statements into the reporting currency.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.2
Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - $ / shares
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Income Statement [Abstract] |
|
|
Earnings per share, basic |
$ (0.57)
|
$ (0.59)
|
Earnings per share, diluted |
$ (0.57)
|
$ (0.59)
|
Weighted average number of shares outstanding, basic |
24,878,196
|
23,383,758
|
Weighted average number of shares outstanding, diluted |
24,878,196
|
23,383,758
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
AOCI Attributable to Parent [Member] |
Total |
Beginning balance, value at Mar. 31, 2021 |
$ 22,941
|
$ 32,044,335
|
$ (23,844,671)
|
$ 135,567
|
$ 8,358,172
|
Beginning Balance, Shares at Mar. 31, 2021 |
22,941,157
|
|
|
|
|
Issuance of common shares, net of costs of $50,765 |
$ 773
|
3,067,254
|
|
|
3,068,027
|
Issuance of common shares, net of costs, shares |
772,524
|
|
|
|
|
Exercise of warrants |
$ 367
|
2,963,291
|
|
|
2,963,658
|
Exercise of warrants, Shares |
366,892
|
|
|
|
|
Restricted shares issued as stock-based compensation |
$ 22
|
87,366
|
|
|
87,388
|
Restricted shares issued as stock-based compensation, Shares |
22,293
|
|
|
|
|
Options issued to directors |
|
133,529
|
|
|
133,529
|
Foreign currency translation adjustment |
|
|
|
(257,885)
|
(257,885)
|
Net loss |
|
|
(13,886,805)
|
|
(13,886,805)
|
Ending balance, value at Mar. 31, 2022 |
$ 24,103
|
38,295,775
|
(37,731,476)
|
(122,318)
|
466,084
|
Ending Balance, Shares at Mar. 31, 2022 |
24,102,866
|
|
|
|
|
Issuance of common shares, net of costs |
$ 4,796
|
7,651,602
|
|
|
7,656,398
|
Issuance of common shares, net of costs, shares |
4,796,536
|
|
|
|
|
Fair value of warrant liability recognized in connection with issuance of common shares |
|
(4,956,000)
|
|
|
(4,956,000)
|
Foreign currency translation adjustment |
|
|
|
(836,946)
|
(836,946)
|
Net loss |
|
|
(14,143,735)
|
|
(14,143,735)
|
Ending balance, value at Mar. 31, 2023 |
$ 28,899
|
$ 40,991,377
|
$ (51,875,211)
|
$ (959,263)
|
$ (11,814,198)
|
Ending Balance, Shares at Mar. 31, 2023 |
28,899,402
|
|
|
|
|
X |
- References
+ Details
Name: |
nmrd_ExerciseOfWarrantsAmount |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_ExerciseOfWarrantsShares |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfWarrantLiabilityRecognizedInConnectionWithIssuanceOfCommonSharesAmount |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_RestrictedSharesIssuedAsStockbasedCompensationAmount |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_RestrictedSharesIssuedAsStockbasedCompensationShares |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued as a result of the exercise of stock options.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
X |
- References
+ Details
Name: |
nmrd_IssuanceOfCommonSharesNetOfCosts |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfStockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Consolidated Statements of Cash Flows - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Cash Flows from Operating Activities: |
|
|
Net loss |
$ (14,143,735)
|
$ (13,886,805)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
Depreciation and amortization |
444,177
|
229,810
|
Accretion of debt discount |
1,871,593
|
6,666,630
|
Monitoring fee interest expense added to notes payable |
2,240,339
|
0
|
Fees for note amendments expense added to note payable |
2,304,539
|
0
|
Inventory write-down |
1,478,108
|
0
|
Impairment of intangible assets |
980,039
|
0
|
Change in fair value of foreign exchange contract derivative liability |
291,534
|
440,196
|
Change in fair value of warrant liability |
(1,864,000)
|
0
|
Stock-based compensation |
0
|
220,917
|
Changes in operating assets and liabilities: |
|
|
Inventory |
(1,745,189)
|
(637,149)
|
Prepaid expenses and VAT receivable |
(17,415)
|
519,346
|
Deposit on foreign exchange contract |
(909,666)
|
0
|
Accounts payable |
190,331
|
(117,384)
|
Accrued expenses and other liabilities |
(427,748)
|
310,490
|
Receivable/payable to related parties |
1,022,077
|
(250,092)
|
Deferred revenue |
(166,765)
|
0
|
Net cash used in operating activities |
(8,451,781)
|
(6,504,041)
|
Cash Flows from Investing Activities: |
|
|
Purchase of property and equipment |
(376,170)
|
(481,718)
|
Capitalized patent costs |
(135,168)
|
(83,691)
|
Capitalized software development costs |
(27,879)
|
(391,073)
|
Net cash used in investing activities |
(539,217)
|
(956,482)
|
Cash Flows from Financing Activities: |
|
|
Proceeds from issuance of common shares |
8,394,056
|
3,118,792
|
Costs incurred in relation to equity financing |
(737,658)
|
(50,765)
|
Proceeds from warrant exercise |
0
|
2,963,658
|
Proceeds from issuance of long term debt, net of discount |
4,700,000
|
0
|
Repayments of notes payable |
(10,274,281)
|
(12,400,000)
|
Net cash (used in) provided by financing activities |
2,082,117
|
(6,368,315)
|
Net decrease in cash |
(6,908,881)
|
(13,828,838)
|
Effect of exchange rate changes on cash |
(735,217)
|
(287,300)
|
Cash at beginning of year |
17,749,233
|
31,865,371
|
Cash at end of year |
10,105,135
|
17,749,233
|
Supplemental cash flow information: |
|
|
Interest paid |
0
|
0
|
Taxes paid |
0
|
0
|
Supplemental disclosure of non-cash financing activities: |
|
|
Fair value of warrant liability recognized in connection with issuance of common shares |
4,956,000
|
0
|
Monitoring fees added to notes payable |
$ 2,240,339
|
$ 2,764,775
|
X |
- References
+ Details
Name: |
nmrd_ChangeInFairValueOfForeignExchangeContract |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_ChangesInFairValueOfWarrantLiability |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_CostsIncurredInRelationToEquityFinancing |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_DepositOnForeignExchangeContracts |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfWarrantLiabilityRecognizedInConnectionWithIssuanceOfCommonShares |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_FeesForNoteAmendmentsExpenseAddedToNotePayable |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_MonitoringFeeInterestExpenseAddedToNotesPayable |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_MonitoringFeesAddedToNotesPayable |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaid |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2
+ Details
Name: |
us-gaap_InventoryWriteDown |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToDevelopSoftware |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
ORGANIZATION, PRINCIPAL ACTIVITIES AND MANAGEMENT’S PLANS
|
12 Months Ended |
Mar. 31, 2023 |
Accounting Policies [Abstract] |
|
ORGANIZATION, PRINCIPAL ACTIVITIES AND MANAGEMENT’S PLANS |
NOTE 1 – ORGANIZATION, PRINCIPAL ACTIVITIES AND
MANAGEMENT’S PLANS
Nemaura Medical Inc. (“Nemaura”
or the “Company”), through its operating subsidiaries, performs medical device research and manufacturing of a continuous
glucose monitoring system (“CGM”), named sugarBEAT®. The sugarBEAT® device is a non-invasive, wireless device for
use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. The sugarBEAT® device extracts
analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using unique sensors and interpreted
using a unique algorithm.
Nemaura is a Nevada holding company organized
in 2013. Nemaura owns one hundred percent (100%) of Dermal Diagnostic (Holdings) Limited, an England and Wales corporation (“DDHL”)
formed on December 11, 2013, which in turn owns one hundred percent (100%) of Dermal Diagnostics Limited, an England and Wales corporation
formed on January 20, 2009 (“DDL”), and one hundred percent (100%) of Trial Clinic Limited, an England and Wales corporation
formed on January 12, 2011 (“TCL”).
DDL is a diagnostic medical device company
headquartered in Loughborough, Leicestershire, England, and is engaged in the discovery, development and commercialization of diagnostic
medical devices. The Company’s initial focus has been on the development of the sugarBEAT® device, which consists of a disposable
patch containing a sensor, and a non-disposable miniature transmitter device with a re-chargeable power source, which is designed to enable
trending or tracking of blood glucose levels. All of the Company’s operations and assets are located in England.
The Company was incorporated in 2013 and
has reported recurring losses from operations to date. These operations
have resulted in the successful completion of clinical programs to support a CE mark (European Union approval of the product) approval,
as well as a De Novo 510(k) medical device application to the U.S. Food and Drug Administration (“FDA”) submission. The Company
expects to continue to incur losses from operations until revenues are generated through licensing fees or product sales. However, given
the completion of the requisite clinical programs, these losses are expected to decrease over time. Management has entered into licensing,
supply, or collaboration agreements with unrelated third parties relating to the United Kingdom (“UK”), Europe, Qatar, and
all countries in the Gulf Cooperation Council.
Going Concern
The accompanying financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and
commitments in the normal course of business. As reflected in the accompanying financial statements, for the year ended March 31,
2023, the Company recorded a net loss of $14,143,735 and used cash in operations of $8,451,781.
These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date
that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the
Company is unable to continue as a going concern.
In evaluating the going
concern position of the company, management has considered potential funding providers and believes that financing to fund future operations
could be provided by equity and/or debt financing. Even if the Company is able to obtain additional financing, it may contain undue restrictions
on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//250/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
BASIS OF PRESENTATION
|
12 Months Ended |
Mar. 31, 2023 |
Accounting Policies [Abstract] |
|
BASIS OF PRESENTATION |
NOTE 2 – BASIS OF PRESENTATION
The accompanying consolidated financial statements
include the accounts of the Company and the Company’s subsidiaries, DDL, TCL, and DDHL. The consolidated financial statements are
prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and all
intercompany balances and transactions have been eliminated in consolidation.
The functional currency for the majority
of the Company’s operations is the Great Britain Pound Sterling (“GBP”), and the reporting currency is the U.S. Dollar (“$”, “USD”).
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
12 Months Ended |
Mar. 31, 2023 |
Accounting Policies [Abstract] |
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
NOTE
3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of estimates
The preparation of consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the
assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity
instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation
allowances. Actual results may differ from those estimates.
Revenue recognition
The Company recognizes revenue in accordance
with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from
Contracts with Customers (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of
goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise
judgment when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying
our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price
to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.
The Company only applies the five-step model to contracts when
it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to
the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods
or services promised within each contract and determines those that are performance obligations and assesses whether each promised good
or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.
The Company may enter into product development
and other agreements with collaborative partners. The terms of the agreements may include non-refundable signing and licensing fees, milestone
payments and royalties on any product sales derived from collaborations.
Royalty revenue will be recognized upon
the sale of the related products provided the Company has no remaining performance obligations under the agreement.
Deferred revenue
The Company has entered into license agreements
and recognizes up front license payments as revenue upon delivery of the license only if the license has stand-alone value to the customer.
However, where further performance criteria must be met, revenue is deferred and recognized on a basis that is considered to be appropriate
to the conditions associated with the license and over the period the Company is expected to complete these performance obligations.
Research and development expenses
The Company charges research and development expenses to operations
as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel and outside contractor
and consulting services. Other research and development expenses include the costs of materials and supplies used in research and development,
prototype manufacturing, clinical studies, related information technology and an allocation of facilities costs.
Cash and cash equivalents
Cash and cash equivalents consists primarily
of cash deposits maintained in the UK.
We maintain cash balances in U.S. Dollar (“USD”),
Great Britain Pound Sterling (“GBP”), and the Euro. The following table, reported in USD, disaggregates our cash balances
by currency denomination:
Schedule of disaggregates cash
balances by currency denomination | |
| | | |
| | |
| |
March
31, 2023 | | |
March 31,
2022 | |
Cash denominated in: | |
| | | |
| | |
USD | |
$ | 5,606,972 | | |
$ | 14,769,720 | |
GBP | |
| 4,446,720 | | |
| 2,911,117 | |
Euro | |
| 51,443 | | |
| 68,396 | |
Total | |
$ | 10,105,135 | | |
$ | 17,749,233 | |
Inventory
Inventory is stated at the lower of cost or net realizable
value, with cost determined on a first-in, first-out (“FIFO”) basis. The Company records adjustments to its inventory based
on an estimated forecast of the inventory demand, taking into consideration, among others, inventory turnover, inventory quantities on
hand, unfilled customer order quantities, and forecasted demand. If the estimated net realizable value is determined to be less than the
recorded cost of the inventory, the difference is recognized as a loss in the period in which it occurs. Once inventory has been written
down, it creates a new cost basis for inventory that may not be subsequently written up.
Property and equipment
Property and equipment is stated at cost and depreciated
using the straight-line method over the estimated useful lives of the assets, generally four to five years. Depreciation is charged
to operating expenses.
Intangible assets
Intangible assets consist of licenses and patents
associated primarily with the sugarBEAT® device and are amortized on a straight-line basis, generally over the shorter of their estimated
useful lives or legal lives. Costs capitalized relate to invoices received from third parties and not any internal costs. The Company
evaluates its intangible assets (all have finite lives) and other long-lived assets for impairment whenever events or circumstances indicate
that they may not be recoverable, or at least annually. Recoverability of finite life intangibles and other long-lived assets is measured
by comparing the carrying amount of an asset group to the future undiscounted net cash flows expected to be generated by that asset group.
The Company groups assets for purposes of such review at the lowest level for which identifiable cash flows of the asset group are largely
independent of the cash flows of the other groups of assets and liabilities. The amount of impairment to be recognized for finite life
intangibles and other long-lived assets is calculated as the difference between the carrying value and the fair value of the asset group,
generally measured by discounting estimated future cash flows.
Software development costs
The Company capitalizes costs incurred to
implement software for its internal use, including hosted applications costs to support the Company’s planned services. During the
year ended March 31, 2023, the Company determined that software development costs were impaired and recorded an impairment of $655,641.
Income taxes
Income taxes are accounted for under the
asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating
loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is
provided to reduce the carrying amount of deferred income tax assets if it is considered more likely than not that some portion, or all,
of the deferred income tax assets will not be realized.
The Company recognizes the effect of income
tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the
largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in
which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits as
part of income tax expense in the consolidated statements of comprehensive loss. The Company does not have any accrued interest or penalties
associated with any unrecognized tax benefits, nor was any interest expense related to unrecognized tax benefits recognized for the years
ended March 31, 2023 and 2022.
Earnings (loss) per share
Basic loss per share
is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the
period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number
of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common
shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options
and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings
of the entity.
Since the effects of outstanding options
and warrants are anti-dilutive for the years ended March 31, 2023 and 2022, shares of common stock underlying these instruments have been
excluded from the computation of loss per common share.
The following sets forth the number of shares
of common stock underlying outstanding options and warrants as of March 31, 2023 and 2022:
Schedule of common stock underlying outstanding options | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Warrants | |
| 6,369,304 | | |
| 1,573,098 | |
Stock options | |
| 40,000 | | |
| 40,000 | |
| |
| | | |
| | |
| |
| 6,409,304 | | |
| 1,613,098 | |
Foreign currency translation
The functional currency of the Company is the GBP,
while the reporting currency is the USD. Assets and liabilities are translated into USD using the exchange rate on the balance sheet
date, and the amounts of revenue and expense are translated at the average exchange rate prevailing during the period. Stockholders'
equity is translated at historical exchange rates. The gains and losses resulting from translation of financial statement amounts into
USD are recorded as a separate component of accumulated other comprehensive loss within stockholders’ deficit.
We used the exchange
rates in the following table to translate amounts denominated in non-USD currencies as of and for the periods noted:
Schedule of exchange rates translate amounts | |
| | | |
| | |
| |
As
of March 31, | |
| |
2023 | | |
2022 | |
Exchange rates at March 31: | |
| | |
| |
GBP:USD | |
| 1.236 | | |
| 1.316 | |
EURO:USD | |
| 1.138 | | |
| 1.184 | |
| |
For the Years Ended March 31, | |
| |
2023 | | |
2022 | |
Average exchange rate during the year ended March 31: | |
| | |
| |
GBP:USD | |
| 1.215 | | |
| 1.342 | |
Derivative Financial Instruments
The Company evaluates its financial instruments to
determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815,
"Derivatives and Hedging" (“ASC 815”). For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair
value reported in the statements of operations. The Company’s use of derivative financial instruments is generally limited to managing
foreign exchange rate risks. In addition, warrants issued by the Company that do not meet the criteria for equity treatment are recorded
as liabilities. We do not use financial instruments or derivatives for any trading purposes.
Fair value of financial instruments
In accordance with ASC 820, “Fair Value
Measurements and Disclosures,” the Company determines the fair value of financial instruments with the use of observable inputs
and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of
independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within
the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes
the inputs into three levels that may be used to measure fair value:
Level 1: Applies to assets or liabilities for
which there are quoted prices in active markets for identical assets or liabilities.
Level 2: Applies to assets or liabilities for
which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
Level 3: Applies to assets or liabilities
for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the
assets or liabilities.
The Company determines the
level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis
of the assets and liabilities at each reporting period end.
The following table sets
forth by level, within the fair value hierarchy, the Company’s assets and liabilities at fair value as of March 31, 2023 and 2022:
Schedule of assets and liabilities at fair value | |
| | | |
| | | |
| | | |
| | |
| |
March
31, 2023 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 731,730 | | |
$ | — | | |
$ | 731,730 | |
Warrant derivative liability | |
| — | | |
| — | | |
| 3,092,000 | | |
| 3,092,000 | |
Total liabilities | |
$ | — | | |
$ | 731,730 | | |
$ | 3,092,000 | | |
$ | 3,823,730 | |
| |
March
31, 2022 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
Total liabilities | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
As of March 31, 2022, there
was no warrant derivative liability. The following table provides a roll-forward of the warrant derivative liability measured at fair
value on a recurring basis using unobservable level 3 inputs for the year ended March 31, 2023 as follows:
Schedule of warrant derivative liability measured at fair value on a recurring basis | |
| | |
| |
March
31, 2023 | |
Warrant liability | |
| | |
Balance as of beginning of period – March 31, 2022 | |
$ | — | |
Fair value of warrant liability recognized upon issuance of warrants in January 2023 | |
| 4,956,000 | |
Change in fair value of warrant derivative liability | |
| (1,864,000 | ) |
Balance as of end of period – March 31, 2023 | |
$ | 3,092,000 | |
The Company believes the
carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates
fair value due to the short-term nature of such instruments.
Retirement benefit plan
The Company operates a retirement plan which
covers most of our regular employees in the UK and allows them to make contributions. The Company also provides a matching contribution
on a portion of the employee contributions. Total expenses incurred under this plan for the fiscal years ended March 31, 2023 and 2022,
were $37,645 and $24,300, respectively.
Stock-based
compensation
The Company
periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services
and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation
whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line
basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company
had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations
with classification depending on the nature of the services rendered.
The fair value
of the Company’s stock options is estimated using the Black-Scholes Option Pricing model, which uses certain assumptions
related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends.
Compensation expense is recorded based upon the value derived from the Black-Scholes Option Pricing model and based on actual experience.
The assumptions used in the Black-Scholes Option Pricing model could materially affect compensation expense recorded in future
periods.
Direct costs incurred for equity
offerings
The Company includes all direct costs incurred in connection
with successful equity offerings as a component of additional paid-in capital. Direct costs incurred for equity offerings that are
unsuccessful are expensed.
Reclassifications
Certain prior year balances have been reclassified to conform
with the current year presentation. In presenting the Company’s consolidated balance sheet at March 31, 2022, the Company presented
$255,112 VAT receivable as part of prepaid expenses and other receivables of $750,167. In presenting the Company’s consolidated
balance sheet at March 31, 2023, the Company has reclassified the balance of $255,112 as a separate line item VAT receivable, and the
balance of $495,055 is presented as prepaid expenses in the accompanying March 31, 2022 financial statements.
Recent accounting pronouncements
The Company continually assesses any new
accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's
financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements
and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect
the change.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
LICENSING AGREEMENT
|
12 Months Ended |
Mar. 31, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
LICENSING AGREEMENT |
NOTE 4 –
LICENSING AGREEMENT
In March 2014, the Company entered into an Exclusive
Marketing Rights Agreement with an unrelated third party that granted to the third party the exclusive right to market and promote
the sugarBEAT® device and related patches under its own brand in the United Kingdom and the Republic of Ireland, the Channel
Islands and the Isle of Man. Upon signing the agreement, the Company received a wholly non-refundable cash payment of GBP 1,000,000
(approximately $1.23
million and $1.32
million as of March 31, 2023 and 2022, respectively).
As the Company has continuing performance
obligations under the agreement, the up-front fees received from this agreement have been deferred and will be recorded as income over
the term of the commercial licensing agreement as the Company completes its performance obligations. At March 31, 2023, total deferred
revenue for the licensing agreement was $1,081,676.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INVENTORY
|
12 Months Ended |
Mar. 31, 2023 |
Inventory Disclosure [Abstract] |
|
INVENTORY |
NOTE 5 – INVENTORY
Inventory is valued at the lower of cost (first-in, first-out)
or net realizable value and is comprised of the following:
Schedule of inventory | |
| |
|
| |
March
31, 2023 | |
March
31, 2022 |
Raw materials | |
$ | 1,586,777 | | |
$ | 1,481,946 | |
Finished products | |
| 168,075 | | |
| 5,825 | |
Total | |
$ | 1,754,852 | | |
$ | 1,487,771 | |
At March 31, 2023, management
determined that the net realizable value of the Company’s inventory had fallen below its historical carrying cost.
Accordingly, for the year ended March 31, 2023, the Company recorded a write down of inventory of $1,478,108, which is included in cost of goods sold. At March 31, 2023, the
balance of inventory shown above reflects its new cost basis after the write down. For the year ended March 31, 2022, there was no write
down of inventory recorded.
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
PROPERTY AND EQUIPMENT
|
12 Months Ended |
Mar. 31, 2023 |
Property, Plant and Equipment [Abstract] |
|
PROPERTY AND EQUIPMENT |
NOTE
6 – PROPERTY AND EQUIPMENT
As of March 31, 2023 and 2022, property and equipment is summarized
as follows:
Schedule of property and equipment | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Property and Equipment | |
| | | |
| | |
Plant and machinery | |
$ | 998,635 | | |
$ | 727,250 | |
Furniture and fixtures | |
| 114,863 | | |
| 78,867 | |
Property and equipment gross | |
| 1,113,498 | | |
| 806,117 | |
Less Accumulated Depreciation | |
| (471,592 | ) | |
| (273,609 | ) |
Net Book Value | |
$ | 641,906 | | |
$ | 532,508 | |
Depreciation expense relating to property
and equipment for the years ended March 31, 2023 and 2022 was approximately $156,000
and $138,000, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INTANGIBLE ASSETS
|
12 Months Ended |
Mar. 31, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
INTANGIBLE ASSETS |
NOTE 7 - INTANGIBLE ASSETS
The following table summarizes our intangible assets and capitalized software development
costs at March 31, 2023:
Schedule of Intangible Assets | |
| | | |
| | |
| |
March 31, |
| |
2023
| |
2022
|
| |
| |
|
Patents and licenses | |
$ | 1,175,580 | | |
$ | 1,084,081 | |
Less accumulated amortization | |
| (467,091 | ) | |
| (186,927 | ) |
Less impairment | |
| (324,397 | ) | |
| — | |
| |
| 384,092 | | |
| 897,154 | |
| |
| | | |
| | |
Software development costs | |
| 655,641 | | |
| 583,826 | |
Less impairment | |
| (655,641 | ) | |
| — | |
| |
| — | | |
| 583,826 | |
| |
$ | 384,092 | | |
$ | 1,480,980 | |
Amortization expensed within the consolidated statements of operations
and comprehensive loss relating to intangible assets for the years ended March 31, 2023 and 2022 was approximately $193,000 and $92,000,
respectively. At March 31, 2023, intangible assets and capitalized software costs
have been reduced for impairments of $324,397 and $655,641, respectively. At March 31, 2022, no impairments were recorded
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
DERIVATIVE LIABILITIES
|
12 Months Ended |
Mar. 31, 2023 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
|
DERIVATIVE LIABILITIES |
NOTE
8 – DERIVATIVE LIABILITIES
Warrant liability
In
January 2023, the Company completed an equity offering (see Note 11), which included the issuance of 4,796,206
warrants. Upon the occurrence of certain transactions (“Fundamental Transactions,” as defined), the warrants provide for
a value determined using a Black Scholes model with inputs calculated as described in the warrant agreement which includes a 100%
floor on the volatility input to be utilized. The Company has determined that this provision introduces leverage to the holders of the warrants that could result in a
value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares.
Accordingly, pursuant to ASC 815, the Company has classified the fair value of the warrants as a liability to be re-measured at the
end of every reporting period with the change in value reported in the statement of operations.
The warrant liability was valued at the following
dates using a Black-Scholes model with the following assumptions:
Schedule of warrant liability | |
| | | |
| | |
| |
March
31, 2023 | | |
January
31, 2023 (date
issued) | |
Warrant liability: | |
| | | |
| | |
Stock
price | |
$ | 0.90 | | |
$ | 1.33 | |
Risk-free interest rate | |
| 3.60 | % | |
| 3.63 | % |
Expected volatility | |
| 108 | % | |
| 109 | % |
Expected life (in years) | |
| 5.34 | | |
| 5.50 | |
Expected dividend yield | |
| — | | |
| — | |
Fair value of Warrant liability | |
$ | 3,092,000 | | |
$ | 4,956,000 | |
The risk-free rate is based on the U.S. Treasury yield
curve in effect at the time of grant. Expected volatility was determined based on the historical volatility data of the Company, and the
expected term of the warrants granted are determined based on the duration of time the warrants are expected to be outstanding. The dividend
yield on the Company’s warrants is assumed to be zero as the Company has not historically paid dividends.
Foreign exchange contract liability
The Company is exposed to the impact of foreign
currency exchange fluctuations as a significant proportion of its expenses are denominated in GBP, and the Company’s cash is
in USD and GBP. In February 2021, the Company entered into a forward contract to sell USD and buy GBP. The contract meets the
definition of a derivative subject to the guidance of ASC 815, does not qualify for hedge accounting, and accordingly is recognized
at fair value, with changes in fair value recognized in earnings.
The term of the contract is 25 months, beginning
July, 2022, and ending August, 2024. The contract initially had a maximum notional amount of $6,250,000
(and a maximum leveraged amount equal to two times the notional amount, or$12,500,000).
$250,000
of the contractual notional amount is settled (expires) each month through August 2024. On
each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP
at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but
can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the settlement date, the Company is
obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can
pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty. During the
year ended March 31, 2023, $4,000,000
of the leveraged amount (and $2,000,000
of the notional amount) expired.
At March 31, 2023 and 2022, the fair value of the
foreign currency contract liability was valued as follows:
Schedule of fair value of the foreign currency contract liability | |
| | | |
| | |
| |
March
31, 2023 | | |
March
31,
2022 | |
| |
| | | |
| | |
Notional amount | |
$ | 4,250,000 | | |
$ | 6,250,000 | |
Leveraged amount (used to determine fair value of contract
liability at March 31, 2023 and 2022) | |
$ | 8,500,000 | | |
$ | 12,500,000 | |
Expected remaining term (in months) | |
| 17 | | |
| 25 | |
| |
| | | |
| | |
Fair Value: | |
| | | |
| | |
Foreign currency contract liability | |
$ | 731,730 | | |
$ | 440,196 | |
The Company’s foreign currency forward contracts are measured
at fair value on a recurring basis and are classified as Level 2 fair value measurement. As of March 31, 2023, the Company has deposited
$909,666 as collateral with the counterparty related to the foreign currency forward contract.
|
X |
- References
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//815/tableOfContent
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
NOTES PAYABLE
|
12 Months Ended |
Mar. 31, 2023 |
Debt Disclosure [Abstract] |
|
NOTES PAYABLE |
NOTE 9 – NOTES PAYABLE
Schedule of notes payable | |
| | | |
| | |
| |
March 31, |
| |
2023 | |
2022 |
| |
| |
|
Note Purchase Agreement 1 (paid off April 2022) | |
$ | — | | |
$ | 270,979 | |
Note Purchase Agreement 2 | |
| 14,772,293 | | |
| 20,241,421 | |
Note Purchase Agreement 3 | |
| 6,024,941 | | |
| — | |
Total notes payable | |
| 20,797,234 | | |
| 20,512,400 | |
Unamortized debt discount | |
| (767,083 | ) | |
| (1,323,676 | ) |
Notes payable, net of note discounts | |
| 20,030,151 | | |
| 19,188,724 | |
Current portion | |
| (16,942,500 | ) | |
| (19,188,724 | ) |
Non-current portion | |
$ | 3,087,651 | | |
$ | — | |
NOTE PURCHASE AGREEMENT 1 (paid off
April 2022)
On April 15, 2020, the Company issued a
note payable (“Note Purchase Agreement 1”) to a third-party investor. The note was for $6,015,000, matured on April 15, 2022,
and was secured by all the assets of the Company. The Company received cash proceeds of $4,675,000, resulting in a discount of $1,340,000
made up of an original issue discount (“OID”) of $1,000,000, commission of $325,000 that was paid from proceeds, and $15,000
to cover transaction expenses. In addition, the Company recorded a fee of 0.833% per month, which was in substance interest at an annual
rate of approximately 10%, that was added to the note principal each month (as payment in kind, or “PIK” interest). The debt
less discount and transaction expenses were accreted over the term of the note using the effective interest rate method. Note Purchase
Agreement 1 was repaid in April 2022 and replaced by Note Purchase Agreement 3 issued in May 2022 (see below).
NOTE PURCHASE AGREEMENT 2
On February 8, 2021, the Company
issued a note payable (“Note Purchase Agreement 2”, “Note 2”) to a third-party investor. The note was for
$24,015,000, originally matured on February 9, 2023, and is secured by all the assets of the Company. The Company received cash proceeds
of $18,800,000, resulting in a discount of $5,215,000 made up of an original issue discount (“OID”) of $4,000,000, commission
of $1,200,000 that was paid from proceeds, and $15,000 to cover transaction expenses. The Company agreed to make principal payments beginning
in August 2021 of $400,000 monthly, which increased in February 2022 to $2,000,000 monthly. In addition, the Company is required to accrue
a monthly PIK fee equal to 0.833% of the outstanding balance, which is in substance interest at an annual rate of approximately 10%, that
is added to the note principal each month. The debt less discount and transaction expenses will be accreted over the term of the note
using the effective interest rate method.
Note 2 was amended in May 2022 to
reduce principal payments from $2,000,000
a month to $500,000
a month. Note 2 was amended again in October 2022 to extend the maturity from February 9, 2023 to July
1, 2024, and to increase principal payments to $1,000,000
a month beginning in March 2023. In consideration, the Company agreed to pay aggregate fees of $2,304,539
to the investor which were added to the principal balance of Note 2. The Company accounted for the amendments under the debt
extinguishment model as the present value of cash flows of Note 2 under the terms of the amendments (the “new” note) was
more than 10% different from the present value of the remaining cash flows under the original terms of Note 2 (the “old”
note). The fair value of the new note was determined to be $17,090,513, less the carrying amount of the old note of $16,609,176,
plus the fees of $2,304,539, resulted in a loss on extinguishment of $2,785,876,
which is included in interest expense for the year ended March 31, 2023.
NOTE PURCHASE AGREEMENT 3
On May 20, 2022, the Company issued a note payable (“Note
Purchase Agreement 3”) with a third-party investor. The note was for $6,015,000,
matures on May
20, 2024, and is secured by all the assets of the Company. The Company received cash proceeds of $4,700,000,
resulting in a discount of $1,315,000
made up of an original issue discount (“OID”) of $1,000,000,
commission of $300,000
that was paid from proceeds, and $15,000
to cover transaction expenses. In addition, the Company is required to accrue a monthly PIK fee equal to 0.833% of the outstanding
balance, which is in substance interest at an annual rate of approximately 10%,
that is added to the note principal each month. The debt less discount and transaction expenses will be accreted over the term of the
note using the effective interest rate method. At March 31, 2023, the remaining debt discount to be amortized was $767,083.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
RELATED PARTY TRANSACTIONS
|
12 Months Ended |
Mar. 31, 2023 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
NOTE 10 – RELATED PARTY TRANSACTIONS
Nemaura Pharma Limited (“Pharma”),
Black and White Health Care Limited (“B&W”) and NDM Technologies Limited (“NDM”) are entities controlled by
the Company’s chief executive officer and majority shareholder.
Pharma has a service agreement with DDL,
to undertake development, manufacture, and regulatory approvals under Pharma’s ISO13485 Accreditation. Pharma invoices DDL on a periodic basis for said services. Services are provided at cost plus a service surcharge amounting to less than
10% of the total costs incurred.
The following is a summary of activity between
the Company and Pharma, B&W and NDM for the years ended March 31, 2023 and 2022:
Schedule of related party transactions | |
| | | |
| | |
| |
March
31, |
| |
2023
| |
2022
|
| |
| |
|
Due to/(from) related parties at beginning of year | |
$ | (101,297 | ) | |
$ | 148,795 | |
Amounts invoiced by Pharma to DDL, NM and TCL primarily relating to
research and development expenses | |
| 4,767,586 | | |
| 3,245,985 | |
Amounts invoiced by DDL to Pharma | |
| — | | |
| (2,495 | ) |
Amounts repaid by DDL to Pharma | |
| (3,773,217 | ) | |
| (3,492,962 | ) |
Foreign exchange differences | |
| 27,708 | | |
| (620 | ) |
Due to/(from) related parties at end of year | |
$ | 920,780 | | |
$ | (101,297 | ) |
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INCOME TAXES
|
12 Months Ended |
Mar. 31, 2023 |
Income Tax Disclosure [Abstract] |
|
INCOME TAXES |
NOTE 11 – INCOME TAXES
The Company and its subsidiaries file separate
income tax returns.
United States of America
The Company is incorporated in the U.S.
and is subject to a U.S. federal corporate income tax rate of 21% for the year ended March 31, 2023 and 21% for the year ended March 2022.
British Virgin Islands
RGL was incorporated in the British Virgin Islands (“BVI”).
Under the current laws of the BVI, RGL was not subject to tax on income or capital gains. In addition, upon payments of dividends by
RGL, no BVI withholding tax was imposed. During the years ended March 31, 2022 and 2021, there were no income or expenses in the BVI;
RGL was formally dissolved as of April 23, 2021.
UK
DDL, TCL and DDHL are all incorporated in
the UK and the applicable UK statutory income tax rate for these companies is 19%.
For the fiscal years ended March 31, 2023
and 2022 loss before income tax benefit arose in the UK and U.S. as follows:
Schedule of loss before income tax | |
| | | |
| | |
| |
March
31, |
| |
2023
| |
2022
|
| |
| | | |
| | |
Loss before income taxes arising in UK | |
$ | (13,314,440 | ) | |
$ | (11,716,916 | ) |
Loss before income taxes arising in U.S. | |
| (829,295 | ) | |
| (2,520,145 | ) |
Total loss
before income tax benefit | |
$ | (14,143,735 | ) | |
$ | (14,237,061 | ) |
Reconciliation of our effective tax rate to the loss calculated at the statutory
U.S. federal tax rate is as follows:
Reconciliation of effective tax rate | |
| | | |
| | | |
| | | |
| | |
| |
March 31, |
| |
| 2023 | | |
| | | |
| 2022 | | |
| | |
Loss before income
taxes | |
$ | (14,143,735 | ) | |
| | | |
$ | (14,237,061 | ) | |
| | |
Expected tax benefit | |
| (3,145,943 | ) | |
| (22 | %) | |
| (2,989,783 | ) | |
| (21 | %) |
Foreign tax differential | |
| 235,938 | | |
| 2 | % | |
| 234,338 | | |
| 2 | % |
Enhanced research and development | |
| (369,946 | ) | |
| (3 | %) | |
| (463,591 | ) | |
| (3 | %) |
Prior year true-up of NOL’s | |
| (46,393 | ) | |
| 0 | % | |
| 2,401,930 | | |
| 17 | % |
Other | |
| 338,278 | | |
| 2 | % | |
| 74,579 | | |
| 1 | % |
Change in valuation allowance | |
| 2,988,066 | | |
| 21 | % | |
| 742,527 | | |
| 5 | % |
R&D credit received | |
| — | | |
| — | | |
| 350,256 | | |
| 2 | % |
Actual income tax benefit | |
$ | — | | |
| — | | |
$ | 350,256 | | |
| 2 | % |
The tax effects of the temporary differences that give rise
to significant portions of deferred income tax assets are presented below:
Schedule of deferred income tax assets | |
| | | |
| | |
| |
March
31, |
| |
2023 | |
2022 |
| |
| | | |
| | |
Net operating tax loss
carried forward | |
$ | 9,259,000 | | |
$ | 6,671,000 | |
Research and development enhancement | |
| 361,000 | | |
| 335,000 | |
Other items | |
| 38,000 | | |
| (335,000 | ) |
Valuation allowance | |
| (9,658,000 | ) | |
| (6,671,000 | ) |
Net deferred
tax assets | |
$ | — | | |
$ | — | |
In the fiscal year ended March 31, 2023, the Company received
no reimbursement from HMRC (Her Majesty’s Revenue and Customs) in tax credits relating to research and development expenses incurred
during the fiscal year ended March 31, 2022. In the fiscal year ended March 31, 2022, the Company received $350,256 from HMRC in tax credits relating to the reimbursement of research and development expenses incurred during the fiscal year
ended March 31, 2021.
For each of the fiscal years ended March 31, 2023 and 2022,
the Company did not have unrecognized tax benefits, and therefore no interest or penalties related to unrecognized tax benefits were
accrued. Management does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.
The Company mainly files income tax returns in the U.S. and
the UK. The Company is subject to U.S. federal income tax examination by tax authorities for tax years beginning in 2019. The UK
tax returns for the Company’s UK subsidiaries are open to examination by the UK tax authorities for the tax years beginning April
1, 2018.
As of March 31, 2023, the Company has net
operating losses (“NOLs”) of approximately $11,300,000 in the U.S. and $36,230,000 in the UK. NOLs may be carried forward
indefinitely. Additionally, the Company has a research and development enhancement deduction carry forward of approximately $1,899,000
for purposes of UK income tax filings.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
STOCKHOLDERS’ EQUITY
|
12 Months Ended |
Mar. 31, 2023 |
Equity [Abstract] |
|
STOCKHOLDERS’ EQUITY |
NOTE 12 – STOCKHOLDERS’ EQUITY
The Company filed a shelf registration statement on Form
S-3 with the SEC, which was declared effective by the SEC on March 24, 2022 (the “2022 Shelf Registration Statement”). The
2022 Shelf Registration Statement provides the Company with the ability to issue common stock and other securities as described in the
registration statement from time to time up to an aggregate amount of $224.6 million,
dependent upon available shares.
In January 2023, Armistice Capital LLC and Alyeska Master
Fund LLC agreed to buy a total of 4,796,206
shares of common stock at $1.75
per share plus warrants to purchase 4,796,206
shares of common stock with an exercise price equal to $2.00
per share The gross proceeds totaled $8,393,361 before costs of $737,385
were deducted.
On July 23, 2021, the Company entered into an At The Market
Offering Agreement (the “2021 ATM”) with H.C. Wainwright & Co., LLC pursuant to which the Company may offer and
sell from time to time to, at its option, up to an aggregate of $100 million of shares (amended to $3
million as at April 1, 2022) in of its common stock.
During the year ended March 31, 2022, the Company issued
and sold 397,524 shares
of its common stock (including 375,000 shares to Tiger Trading Partners L.L.C., see below) at an average price of $4.07 per
share under the 2021 ATM for aggregate net proceeds of $1.6 million
after deducting commissions and offering expenses payable by the Company.
During the year ended March 31, 2022, the Company agreed to sell 750,000
shares to Tiger Trading Partners L.L.C. (an affiliate of Tiger Management L.L.C. (a vehicle for the family
office of Julian H. Robertson) at a price of $4
per share and gross proceeds of $3
million; 375,000 of the shares were sold within the 2021 ATM facility noted above,
and 375,000 of the shares were sold in a direct issuance completed on February 10, 2022.
Stock options
A summary of option activity for the years ended March 31, 2023
and 2022 is presented below:
Schedule of option award activity | |
| | | |
| | | |
| | |
| |
Number
of Options | | |
Weighted
Average Exercise Price | | |
Weight
Average remaining Contractual Term (years) | |
Balance at April 1, 2021 | |
| — | | |
| — | | |
| | |
Granted | |
| 40,000 | | |
$ | 3.98 | | |
| | |
Exercised | |
| — | | |
| — | | |
| | |
Forfeited | |
| — | | |
| — | | |
| | |
Expired | |
| — | | |
| — | | |
| | |
Balance at March 31, 2022 | |
| 40,000 | | |
| 3.98 | | |
| 4.83 | |
Granted | |
| — | | |
| — | | |
| | |
Exercised | |
| — | | |
| — | | |
| | |
Forfeited | |
| — | | |
| — | | |
| | |
Expired | |
| — | | |
| — | | |
| | |
Balance at March 31, 2023 | |
| 40,000 | | |
$ | 3.98 | | |
| 2.7 | |
Vested and exercisable at March 31, 2023 | |
| 40,000 | | |
$ | 3.98 | | |
| 2.7 | |
No stock options were granted during the fiscal year ended March
31, 2023.
On January 28, 2022, the Board of Directors
granted its directors options to purchase 40,000 shares of common stock at an exercise price of $3.98 per share, which was the closing
price of the Company’s common stock on the date of grant. The options were fully vested at grant and are exercisable for a period
of five years from the date of grant. The fair value of the stock options was determined to be $133,529 using a Black-Scholes Option
Pricing Model with the following assumptions:
Schedule of key assumptions |
|
Stock Price |
$3.98 |
Exercise Price |
$3.98 |
Term |
5 years |
Volatility |
122.52% |
Expected dividend yield (%) |
— |
Discount Rate (Bond Equivalent Yield) |
2.28% |
Stock Warrants
A summary of warrant activity for the years
ended March 31, 2023 and 2022 is presented below:
Schedule of warrant activity | |
| | | |
| | | |
| | |
| |
Number
of Warrants | | |
Weighted
Average Exercise Price | | |
Weight
Average remaining Contractual Term (years) | |
Balance at April 1, 2021 | |
| 1,939,990 | | |
$ | 6.30 | | |
| 4.62 | |
Granted | |
| — | | |
| | | |
| — | |
Exercised | |
| (366,892 | ) | |
| 8.08 | | |
| 4.08 | |
Forfeited | |
| — | | |
| | | |
| — | |
Expired | |
| — | | |
| | | |
| — | |
Balance at March 31, 2022 | |
| 1,573,098 | | |
| 6.64 | | |
| 4.07 | |
Granted | |
| 4,796,206 | | |
| 2.00 | | |
| 5.00 | |
Exercised | |
| — | | |
| | | |
| — | |
Forfeited | |
| — | | |
| | | |
| — | |
Expired | |
| — | | |
| 5.00 | | |
| — | |
Balance at March 31, 2023 | |
| 6,369,304 | | |
$ | 2.7 | | |
| 4.87 | |
Vested and exercisable at March 31, 2023 | |
| 6,369,304 | | |
$ | 2.7 | |
| | 4.87 |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
CONTINGENCIES
|
12 Months Ended |
Mar. 31, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
CONTINGENCIES |
NOTE 13 – CONTINGENCIES
COVID-19
The global outbreak of the novel coronavirus
(COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions
to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of COVID-19,
this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business operations
will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to
monitor the global outbreak of COVID-19 and are working with our employees, suppliers and other stakeholders to mitigate the risks posed
by its spread. COVID-19 is not expected to have any long-term detrimental effect on the Company’s success. Whilst restrictions associated
with COVID-19 have largely been removed in our operational locations, we will continue to assess the situation, including abiding by any
government-imposed restrictions, as and where relevant.
Inflation
Macroeconomic factors such as inflation, rising interest rates,
governmental responses there to and possible recession caused thereby also add significant uncertainty to our operations and possible
effects to the amount and type of financing available to the Company in the future.
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
+ Details
Name: |
us-gaap_OtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SUBSEQUENT EVENTS
|
12 Months Ended |
Mar. 31, 2023 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
NOTE 14 – SUBSEQUENT EVENTS
The Company performed an evaluation of subsequent events through the
date of filing of these consolidated financial statements with the SEC, and determined there were no material subsequent events which
affected, or could affect, the amounts or disclosures in the consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
|
12 Months Ended |
Mar. 31, 2023 |
Accounting Policies [Abstract] |
|
Use of estimates |
Use of estimates
The preparation of consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the
assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity
instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation
allowances. Actual results may differ from those estimates.
|
Revenue recognition |
Revenue recognition
The Company recognizes revenue in accordance
with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from
Contracts with Customers (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of
goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise
judgment when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying
our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price
to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.
The Company only applies the five-step model to contracts when
it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to
the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods
or services promised within each contract and determines those that are performance obligations and assesses whether each promised good
or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective
performance obligation when (or as) the performance obligation is satisfied.
The Company may enter into product development
and other agreements with collaborative partners. The terms of the agreements may include non-refundable signing and licensing fees, milestone
payments and royalties on any product sales derived from collaborations.
Royalty revenue will be recognized upon
the sale of the related products provided the Company has no remaining performance obligations under the agreement.
|
Deferred revenue |
Deferred revenue
The Company has entered into license agreements
and recognizes up front license payments as revenue upon delivery of the license only if the license has stand-alone value to the customer.
However, where further performance criteria must be met, revenue is deferred and recognized on a basis that is considered to be appropriate
to the conditions associated with the license and over the period the Company is expected to complete these performance obligations.
|
Research and development expenses |
Research and development expenses
The Company charges research and development expenses to operations
as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel and outside contractor
and consulting services. Other research and development expenses include the costs of materials and supplies used in research and development,
prototype manufacturing, clinical studies, related information technology and an allocation of facilities costs.
|
Cash and cash equivalents |
Cash and cash equivalents
Cash and cash equivalents consists primarily
of cash deposits maintained in the UK.
We maintain cash balances in U.S. Dollar (“USD”),
Great Britain Pound Sterling (“GBP”), and the Euro. The following table, reported in USD, disaggregates our cash balances
by currency denomination:
Schedule of disaggregates cash
balances by currency denomination | |
| | | |
| | |
| |
March
31, 2023 | | |
March 31,
2022 | |
Cash denominated in: | |
| | | |
| | |
USD | |
$ | 5,606,972 | | |
$ | 14,769,720 | |
GBP | |
| 4,446,720 | | |
| 2,911,117 | |
Euro | |
| 51,443 | | |
| 68,396 | |
Total | |
$ | 10,105,135 | | |
$ | 17,749,233 | |
|
Inventory |
Inventory
Inventory is stated at the lower of cost or net realizable
value, with cost determined on a first-in, first-out (“FIFO”) basis. The Company records adjustments to its inventory based
on an estimated forecast of the inventory demand, taking into consideration, among others, inventory turnover, inventory quantities on
hand, unfilled customer order quantities, and forecasted demand. If the estimated net realizable value is determined to be less than the
recorded cost of the inventory, the difference is recognized as a loss in the period in which it occurs. Once inventory has been written
down, it creates a new cost basis for inventory that may not be subsequently written up.
|
Property and equipment |
Property and equipment
Property and equipment is stated at cost and depreciated
using the straight-line method over the estimated useful lives of the assets, generally four to five years. Depreciation is charged
to operating expenses.
|
Intangible assets |
Intangible assets
Intangible assets consist of licenses and patents
associated primarily with the sugarBEAT® device and are amortized on a straight-line basis, generally over the shorter of their estimated
useful lives or legal lives. Costs capitalized relate to invoices received from third parties and not any internal costs. The Company
evaluates its intangible assets (all have finite lives) and other long-lived assets for impairment whenever events or circumstances indicate
that they may not be recoverable, or at least annually. Recoverability of finite life intangibles and other long-lived assets is measured
by comparing the carrying amount of an asset group to the future undiscounted net cash flows expected to be generated by that asset group.
The Company groups assets for purposes of such review at the lowest level for which identifiable cash flows of the asset group are largely
independent of the cash flows of the other groups of assets and liabilities. The amount of impairment to be recognized for finite life
intangibles and other long-lived assets is calculated as the difference between the carrying value and the fair value of the asset group,
generally measured by discounting estimated future cash flows.
|
Software development costs |
Software development costs
The Company capitalizes costs incurred to
implement software for its internal use, including hosted applications costs to support the Company’s planned services. During the
year ended March 31, 2023, the Company determined that software development costs were impaired and recorded an impairment of $655,641.
|
Income taxes |
Income taxes
Income taxes are accounted for under the
asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating
loss carry forwards. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is
provided to reduce the carrying amount of deferred income tax assets if it is considered more likely than not that some portion, or all,
of the deferred income tax assets will not be realized.
The Company recognizes the effect of income
tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the
largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in
which the change in judgment occurs. The Company has elected to classify interest and penalties related to unrecognized tax benefits as
part of income tax expense in the consolidated statements of comprehensive loss. The Company does not have any accrued interest or penalties
associated with any unrecognized tax benefits, nor was any interest expense related to unrecognized tax benefits recognized for the years
ended March 31, 2023 and 2022.
|
Earnings (loss) per share |
Earnings (loss) per share
Basic loss per share
is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the
period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number
of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common
shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible debentures, options
and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings
of the entity.
Since the effects of outstanding options
and warrants are anti-dilutive for the years ended March 31, 2023 and 2022, shares of common stock underlying these instruments have been
excluded from the computation of loss per common share.
The following sets forth the number of shares
of common stock underlying outstanding options and warrants as of March 31, 2023 and 2022:
Schedule of common stock underlying outstanding options | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Warrants | |
| 6,369,304 | | |
| 1,573,098 | |
Stock options | |
| 40,000 | | |
| 40,000 | |
| |
| | | |
| | |
| |
| 6,409,304 | | |
| 1,613,098 | |
|
Foreign currency translation |
Foreign currency translation
The functional currency of the Company is the GBP,
while the reporting currency is the USD. Assets and liabilities are translated into USD using the exchange rate on the balance sheet
date, and the amounts of revenue and expense are translated at the average exchange rate prevailing during the period. Stockholders'
equity is translated at historical exchange rates. The gains and losses resulting from translation of financial statement amounts into
USD are recorded as a separate component of accumulated other comprehensive loss within stockholders’ deficit.
We used the exchange
rates in the following table to translate amounts denominated in non-USD currencies as of and for the periods noted:
Schedule of exchange rates translate amounts | |
| | | |
| | |
| |
As
of March 31, | |
| |
2023 | | |
2022 | |
Exchange rates at March 31: | |
| | |
| |
GBP:USD | |
| 1.236 | | |
| 1.316 | |
EURO:USD | |
| 1.138 | | |
| 1.184 | |
| |
For the Years Ended March 31, | |
| |
2023 | | |
2022 | |
Average exchange rate during the year ended March 31: | |
| | |
| |
GBP:USD | |
| 1.215 | | |
| 1.342 | |
|
Derivative Financial Instruments |
Derivative Financial Instruments
The Company evaluates its financial instruments to
determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815,
"Derivatives and Hedging" (“ASC 815”). For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair
value reported in the statements of operations. The Company’s use of derivative financial instruments is generally limited to managing
foreign exchange rate risks. In addition, warrants issued by the Company that do not meet the criteria for equity treatment are recorded
as liabilities. We do not use financial instruments or derivatives for any trading purposes.
|
Fair value of financial instruments |
Fair value of financial instruments
In accordance with ASC 820, “Fair Value
Measurements and Disclosures,” the Company determines the fair value of financial instruments with the use of observable inputs
and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of
independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within
the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes
the inputs into three levels that may be used to measure fair value:
Level 1: Applies to assets or liabilities for
which there are quoted prices in active markets for identical assets or liabilities.
Level 2: Applies to assets or liabilities for
which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
Level 3: Applies to assets or liabilities
for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the
assets or liabilities.
The Company determines the
level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that
is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis
of the assets and liabilities at each reporting period end.
The following table sets
forth by level, within the fair value hierarchy, the Company’s assets and liabilities at fair value as of March 31, 2023 and 2022:
Schedule of assets and liabilities at fair value | |
| | | |
| | | |
| | | |
| | |
| |
March
31, 2023 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 731,730 | | |
$ | — | | |
$ | 731,730 | |
Warrant derivative liability | |
| — | | |
| — | | |
| 3,092,000 | | |
| 3,092,000 | |
Total liabilities | |
$ | — | | |
$ | 731,730 | | |
$ | 3,092,000 | | |
$ | 3,823,730 | |
| |
March
31, 2022 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
Total liabilities | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
As of March 31, 2022, there
was no warrant derivative liability. The following table provides a roll-forward of the warrant derivative liability measured at fair
value on a recurring basis using unobservable level 3 inputs for the year ended March 31, 2023 as follows:
Schedule of warrant derivative liability measured at fair value on a recurring basis | |
| | |
| |
March
31, 2023 | |
Warrant liability | |
| | |
Balance as of beginning of period – March 31, 2022 | |
$ | — | |
Fair value of warrant liability recognized upon issuance of warrants in January 2023 | |
| 4,956,000 | |
Change in fair value of warrant derivative liability | |
| (1,864,000 | ) |
Balance as of end of period – March 31, 2023 | |
$ | 3,092,000 | |
The Company believes the
carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates
fair value due to the short-term nature of such instruments.
|
Retirement benefit plan |
Retirement benefit plan
The Company operates a retirement plan which
covers most of our regular employees in the UK and allows them to make contributions. The Company also provides a matching contribution
on a portion of the employee contributions. Total expenses incurred under this plan for the fiscal years ended March 31, 2023 and 2022,
were $37,645 and $24,300, respectively.
|
Stock-based compensation |
Stock-based
compensation
The Company
periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services
and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation
whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line
basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company
had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations
with classification depending on the nature of the services rendered.
The fair value
of the Company’s stock options is estimated using the Black-Scholes Option Pricing model, which uses certain assumptions
related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends.
Compensation expense is recorded based upon the value derived from the Black-Scholes Option Pricing model and based on actual experience.
The assumptions used in the Black-Scholes Option Pricing model could materially affect compensation expense recorded in future
periods.
|
Direct costs incurred for equity offerings |
Direct costs incurred for equity
offerings
The Company includes all direct costs incurred in connection
with successful equity offerings as a component of additional paid-in capital. Direct costs incurred for equity offerings that are
unsuccessful are expensed.
|
Reclassifications |
Reclassifications
Certain prior year balances have been reclassified to conform
with the current year presentation. In presenting the Company’s consolidated balance sheet at March 31, 2022, the Company presented
$255,112 VAT receivable as part of prepaid expenses and other receivables of $750,167. In presenting the Company’s consolidated
balance sheet at March 31, 2023, the Company has reclassified the balance of $255,112 as a separate line item VAT receivable, and the
balance of $495,055 is presented as prepaid expenses in the accompanying March 31, 2022 financial statements.
|
Recent accounting pronouncements |
Recent accounting pronouncements
The Company continually assesses any new
accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company's
financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements
and assures that there are proper controls in place to ascertain that the Company's consolidated financial statements properly reflect
the change.
|
X |
- References
+ Details
Name: |
nmrd_DeferredRevenuePolicyTextBlock |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_DirectCostsIncurredForEquityOfferingsPolicyTextBlock |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_StockbasedCompensationPolicyTextBlock |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7
+ Details
Name: |
us-gaap_DerivativesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//830/tableOfContent
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_IntangibleAssetsFiniteLivedPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details
Name: |
us-gaap_InventoryPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//712/tableOfContent
+ Details
Name: |
us-gaap_PostemploymentBenefitPlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1
+ Details
Name: |
us-gaap_PriorPeriodReclassificationAdjustmentDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 4 -SubTopic 50 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482610/350-50-25-4
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 1 -SubTopic 40 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482633/350-40-30-1
+ Details
Name: |
us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
+ Details
Name: |
us-gaap_RevenueRecognitionPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Accounting Policies [Abstract] |
|
Schedule of disaggregates cash balances by currency denomination |
Schedule of disaggregates cash
balances by currency denomination | |
| | | |
| | |
| |
March
31, 2023 | | |
March 31,
2022 | |
Cash denominated in: | |
| | | |
| | |
USD | |
$ | 5,606,972 | | |
$ | 14,769,720 | |
GBP | |
| 4,446,720 | | |
| 2,911,117 | |
Euro | |
| 51,443 | | |
| 68,396 | |
Total | |
$ | 10,105,135 | | |
$ | 17,749,233 | |
|
Schedule of common stock underlying outstanding options |
Schedule of common stock underlying outstanding options | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Warrants | |
| 6,369,304 | | |
| 1,573,098 | |
Stock options | |
| 40,000 | | |
| 40,000 | |
| |
| | | |
| | |
| |
| 6,409,304 | | |
| 1,613,098 | |
|
Schedule of exchange rates translate amounts |
Schedule of exchange rates translate amounts | |
| | | |
| | |
| |
As
of March 31, | |
| |
2023 | | |
2022 | |
Exchange rates at March 31: | |
| | |
| |
GBP:USD | |
| 1.236 | | |
| 1.316 | |
EURO:USD | |
| 1.138 | | |
| 1.184 | |
| |
For the Years Ended March 31, | |
| |
2023 | | |
2022 | |
Average exchange rate during the year ended March 31: | |
| | |
| |
GBP:USD | |
| 1.215 | | |
| 1.342 | |
|
Schedule of assets and liabilities at fair value |
Schedule of assets and liabilities at fair value | |
| | | |
| | | |
| | | |
| | |
| |
March
31, 2023 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 731,730 | | |
$ | — | | |
$ | 731,730 | |
Warrant derivative liability | |
| — | | |
| — | | |
| 3,092,000 | | |
| 3,092,000 | |
Total liabilities | |
$ | — | | |
$ | 731,730 | | |
$ | 3,092,000 | | |
$ | 3,823,730 | |
| |
March
31, 2022 | |
| |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Total | |
Assets | |
$ |
— | | |
$ |
— | | |
$ |
— | | |
$ |
— | |
Total assets | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Foreign exchange contract derivative
liability | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
Total liabilities | |
$ | — | | |
$ | 440,196 | | |
$ | — | | |
$ | 440,196 | |
|
Schedule of warrant derivative liability measured at fair value on a recurring basis |
Schedule of warrant derivative liability measured at fair value on a recurring basis | |
| | |
| |
March
31, 2023 | |
Warrant liability | |
| | |
Balance as of beginning of period – March 31, 2022 | |
$ | — | |
Fair value of warrant liability recognized upon issuance of warrants in January 2023 | |
| 4,956,000 | |
Change in fair value of warrant derivative liability | |
| (1,864,000 | ) |
Balance as of end of period – March 31, 2023 | |
$ | 3,092,000 | |
|
X |
- References
+ Details
Name: |
nmrd_ScheduleOfTableToTranslateAmountsDenominatedInNonUsdCurrenciesTableTextBlock |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the change in common stock outstanding.
+ References
+ Details
Name: |
us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of long-term intercompany foreign balances, including related intercompany entity, underlying foreign currencies and amounts of intercompany foreign currency transactions that are of a long-term investment nature (that is settlement is not planned or anticipated in the foreseeable future), as of the balance sheet date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INVENTORY (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Inventory Disclosure [Abstract] |
|
Schedule of inventory |
Schedule of inventory | |
| |
|
| |
March
31, 2023 | |
March
31, 2022 |
Raw materials | |
$ | 1,586,777 | | |
$ | 1,481,946 | |
Finished products | |
| 168,075 | | |
| 5,825 | |
Total | |
$ | 1,754,852 | | |
$ | 1,487,771 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
PROPERTY AND EQUIPMENT (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Property, Plant and Equipment [Abstract] |
|
Schedule of property and equipment |
Schedule of property and equipment | |
| | | |
| | |
| |
March 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Property and Equipment | |
| | | |
| | |
Plant and machinery | |
$ | 998,635 | | |
$ | 727,250 | |
Furniture and fixtures | |
| 114,863 | | |
| 78,867 | |
Property and equipment gross | |
| 1,113,498 | | |
| 806,117 | |
Less Accumulated Depreciation | |
| (471,592 | ) | |
| (273,609 | ) |
Net Book Value | |
$ | 641,906 | | |
$ | 532,508 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INTANGIBLE ASSETS (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
Schedule of Intangible Assets |
Schedule of Intangible Assets | |
| | | |
| | |
| |
March 31, |
| |
2023
| |
2022
|
| |
| |
|
Patents and licenses | |
$ | 1,175,580 | | |
$ | 1,084,081 | |
Less accumulated amortization | |
| (467,091 | ) | |
| (186,927 | ) |
Less impairment | |
| (324,397 | ) | |
| — | |
| |
| 384,092 | | |
| 897,154 | |
| |
| | | |
| | |
Software development costs | |
| 655,641 | | |
| 583,826 | |
Less impairment | |
| (655,641 | ) | |
| — | |
| |
| — | | |
| 583,826 | |
| |
$ | 384,092 | | |
$ | 1,480,980 | |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
DERIVATIVE LIABILITIES (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
Schedule of fair value of the foreign currency contract liability |
Schedule of fair value of the foreign currency contract liability | |
| | | |
| | |
| |
March
31, 2023 | | |
March
31,
2022 | |
| |
| | | |
| | |
Notional amount | |
$ | 4,250,000 | | |
$ | 6,250,000 | |
Leveraged amount (used to determine fair value of contract
liability at March 31, 2023 and 2022) | |
$ | 8,500,000 | | |
$ | 12,500,000 | |
Expected remaining term (in months) | |
| 17 | | |
| 25 | |
| |
| | | |
| | |
Fair Value: | |
| | | |
| | |
Foreign currency contract liability | |
$ | 731,730 | | |
$ | 440,196 | |
|
Warrant [Member] |
|
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] |
|
Schedule of warrant liability |
Schedule of warrant liability | |
| | | |
| | |
| |
March
31, 2023 | | |
January
31, 2023 (date
issued) | |
Warrant liability: | |
| | | |
| | |
Stock
price | |
$ | 0.90 | | |
$ | 1.33 | |
Risk-free interest rate | |
| 3.60 | % | |
| 3.63 | % |
Expected volatility | |
| 108 | % | |
| 109 | % |
Expected life (in years) | |
| 5.34 | | |
| 5.50 | |
Expected dividend yield | |
| — | | |
| — | |
Fair value of Warrant liability | |
$ | 3,092,000 | | |
$ | 4,956,000 | |
|
X |
- References
+ Details
Name: |
nmrd_ScheduleOfFairValueOfTheForeignCurrencyContractLiabilityTableTextBlock |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_ScheduleOfWarrantLiabilityValuationAssumptionsTableTextBlock |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
+ Details
Name: |
us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
NOTES PAYABLE (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Debt Disclosure [Abstract] |
|
Schedule of notes payable |
Schedule of notes payable | |
| | | |
| | |
| |
March 31, |
| |
2023 | |
2022 |
| |
| |
|
Note Purchase Agreement 1 (paid off April 2022) | |
$ | — | | |
$ | 270,979 | |
Note Purchase Agreement 2 | |
| 14,772,293 | | |
| 20,241,421 | |
Note Purchase Agreement 3 | |
| 6,024,941 | | |
| — | |
Total notes payable | |
| 20,797,234 | | |
| 20,512,400 | |
Unamortized debt discount | |
| (767,083 | ) | |
| (1,323,676 | ) |
Notes payable, net of note discounts | |
| 20,030,151 | | |
| 19,188,724 | |
Current portion | |
| (16,942,500 | ) | |
| (19,188,724 | ) |
Non-current portion | |
$ | 3,087,651 | | |
$ | — | |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
+ Details
Name: |
us-gaap_ScheduleOfDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
RELATED PARTY TRANSACTIONS (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Related Party Transactions [Abstract] |
|
Schedule of related party transactions |
Schedule of related party transactions | |
| | | |
| | |
| |
March
31, |
| |
2023
| |
2022
|
| |
| |
|
Due to/(from) related parties at beginning of year | |
$ | (101,297 | ) | |
$ | 148,795 | |
Amounts invoiced by Pharma to DDL, NM and TCL primarily relating to
research and development expenses | |
| 4,767,586 | | |
| 3,245,985 | |
Amounts invoiced by DDL to Pharma | |
| — | | |
| (2,495 | ) |
Amounts repaid by DDL to Pharma | |
| (3,773,217 | ) | |
| (3,492,962 | ) |
Foreign exchange differences | |
| 27,708 | | |
| (620 | ) |
Due to/(from) related parties at end of year | |
$ | 920,780 | | |
$ | (101,297 | ) |
|
X |
- DefinitionTabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
+ Details
Name: |
us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INCOME TAXES (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Income Tax Disclosure [Abstract] |
|
Schedule of loss before income tax |
Schedule of loss before income tax | |
| | | |
| | |
| |
March
31, |
| |
2023
| |
2022
|
| |
| | | |
| | |
Loss before income taxes arising in UK | |
$ | (13,314,440 | ) | |
$ | (11,716,916 | ) |
Loss before income taxes arising in U.S. | |
| (829,295 | ) | |
| (2,520,145 | ) |
Total loss
before income tax benefit | |
$ | (14,143,735 | ) | |
$ | (14,237,061 | ) |
|
Reconciliation of effective tax rate |
Reconciliation of effective tax rate | |
| | | |
| | | |
| | | |
| | |
| |
March 31, |
| |
| 2023 | | |
| | | |
| 2022 | | |
| | |
Loss before income
taxes | |
$ | (14,143,735 | ) | |
| | | |
$ | (14,237,061 | ) | |
| | |
Expected tax benefit | |
| (3,145,943 | ) | |
| (22 | %) | |
| (2,989,783 | ) | |
| (21 | %) |
Foreign tax differential | |
| 235,938 | | |
| 2 | % | |
| 234,338 | | |
| 2 | % |
Enhanced research and development | |
| (369,946 | ) | |
| (3 | %) | |
| (463,591 | ) | |
| (3 | %) |
Prior year true-up of NOL’s | |
| (46,393 | ) | |
| 0 | % | |
| 2,401,930 | | |
| 17 | % |
Other | |
| 338,278 | | |
| 2 | % | |
| 74,579 | | |
| 1 | % |
Change in valuation allowance | |
| 2,988,066 | | |
| 21 | % | |
| 742,527 | | |
| 5 | % |
R&D credit received | |
| — | | |
| — | | |
| 350,256 | | |
| 2 | % |
Actual income tax benefit | |
$ | — | | |
| — | | |
$ | 350,256 | | |
| 2 | % |
|
Schedule of deferred income tax assets |
Schedule of deferred income tax assets | |
| | | |
| | |
| |
March
31, |
| |
2023 | |
2022 |
| |
| | | |
| | |
Net operating tax loss
carried forward | |
$ | 9,259,000 | | |
$ | 6,671,000 | |
Research and development enhancement | |
| 361,000 | | |
| 335,000 | |
Other items | |
| 38,000 | | |
| (335,000 | ) |
Valuation allowance | |
| (9,658,000 | ) | |
| (6,671,000 | ) |
Net deferred
tax assets | |
$ | — | | |
$ | — | |
|
X |
- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 12 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of income before income tax between domestic and foreign jurisdictions.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
STOCKHOLDERS’ EQUITY (Tables)
|
12 Months Ended |
Mar. 31, 2023 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Schedule of option award activity |
Schedule of option award activity | |
| | | |
| | | |
| | |
| |
Number
of Options | | |
Weighted
Average Exercise Price | | |
Weight
Average remaining Contractual Term (years) | |
Balance at April 1, 2021 | |
| — | | |
| — | | |
| | |
Granted | |
| 40,000 | | |
$ | 3.98 | | |
| | |
Exercised | |
| — | | |
| — | | |
| | |
Forfeited | |
| — | | |
| — | | |
| | |
Expired | |
| — | | |
| — | | |
| | |
Balance at March 31, 2022 | |
| 40,000 | | |
| 3.98 | | |
| 4.83 | |
Granted | |
| — | | |
| — | | |
| | |
Exercised | |
| — | | |
| — | | |
| | |
Forfeited | |
| — | | |
| — | | |
| | |
Expired | |
| — | | |
| — | | |
| | |
Balance at March 31, 2023 | |
| 40,000 | | |
$ | 3.98 | | |
| 2.7 | |
Vested and exercisable at March 31, 2023 | |
| 40,000 | | |
$ | 3.98 | | |
| 2.7 | |
|
Schedule of key assumptions |
Schedule of key assumptions |
|
Stock Price |
$3.98 |
Exercise Price |
$3.98 |
Term |
5 years |
Volatility |
122.52% |
Expected dividend yield (%) |
— |
Discount Rate (Bond Equivalent Yield) |
2.28% |
|
Warrant [Member] |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
Schedule of option award activity |
Schedule of warrant activity | |
| | | |
| | | |
| | |
| |
Number
of Warrants | | |
Weighted
Average Exercise Price | | |
Weight
Average remaining Contractual Term (years) | |
Balance at April 1, 2021 | |
| 1,939,990 | | |
$ | 6.30 | | |
| 4.62 | |
Granted | |
| — | | |
| | | |
| — | |
Exercised | |
| (366,892 | ) | |
| 8.08 | | |
| 4.08 | |
Forfeited | |
| — | | |
| | | |
| — | |
Expired | |
| — | | |
| | | |
| — | |
Balance at March 31, 2022 | |
| 1,573,098 | | |
| 6.64 | | |
| 4.07 | |
Granted | |
| 4,796,206 | | |
| 2.00 | | |
| 5.00 | |
Exercised | |
| — | | |
| | | |
| — | |
Forfeited | |
| — | | |
| | | |
| — | |
Expired | |
| — | | |
| 5.00 | | |
| — | |
Balance at March 31, 2023 | |
| 6,369,304 | | |
$ | 2.7 | | |
| 4.87 | |
Vested and exercisable at March 31, 2023 | |
| 6,369,304 | | |
$ | 2.7 | |
| | 4.87 |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Total cash and cash equivalents |
$ 10,105,135
|
$ 17,749,233
|
United States of America, Dollars |
|
|
Total cash and cash equivalents |
5,606,972
|
14,769,720
|
United Kingdom, Pounds |
|
|
Total cash and cash equivalents |
4,446,720
|
2,911,117
|
Euro Member Countries, Euro |
|
|
Total cash and cash equivalents |
$ 51,443
|
$ 68,396
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_CurrencyAxis=currency_USD |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_CurrencyAxis=currency_GBP |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_CurrencyAxis=currency_EUR |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
ORGANIZATION, PRINCIPAL ACTIVITIES AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Net loss |
$ 14,143,735
|
$ 13,886,805
|
Cash in operations |
$ 8,451,781
|
$ 6,504,041
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details 1) - shares
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Warrant outstanding |
6,409,304
|
1,613,098
|
Warrants [Member] |
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Warrant outstanding |
6,369,304
|
1,573,098
|
Stock Options [Member] |
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
Warrant outstanding |
40,000
|
40,000
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=nmrd_WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=nmrd_StockOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- References
+ Details
Name: |
nmrd_ForeignCurrencyAverageExchangeRates1 |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:pureItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionForeign exchange rate used to translate amounts denominated in functional currency to reporting currency.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479424/830-30-S99-1
+ Details
Name: |
us-gaap_ForeignCurrencyExchangeRateTranslation1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:pureItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_CurrencyAxis=currency_GBP |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_CurrencyAxis=currency_EUR |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details 3) - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Platform Operator, Crypto-Asset [Line Items] |
|
|
Foreign exchange contract liability |
$ 731,730
|
$ 440,196
|
Fair Value, Inputs, Level 1 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
0
|
0
|
Foreign exchange contract liability |
0
|
0
|
Warrant derivative liability |
0
|
|
Total liabilities |
0
|
0
|
Fair Value, Inputs, Level 2 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
0
|
0
|
Foreign exchange contract liability |
731,730
|
440,196
|
Warrant derivative liability |
0
|
|
Total liabilities |
731,730
|
440,196
|
Fair Value, Inputs, Level 3 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
0
|
0
|
Foreign exchange contract liability |
0
|
0
|
Warrant derivative liability |
3,092,000
|
|
Total liabilities |
3,092,000
|
0
|
Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Total assets |
0
|
0
|
Foreign exchange contract liability |
731,730
|
440,196
|
Warrant derivative liability |
3,092,000
|
|
Total liabilities |
$ 3,823,730
|
$ 440,196
|
X |
- References
+ Details
Name: |
nmrd_WarrantDerivativeLiabilityFairValue |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_AssetsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.
+ References
+ Details
Name: |
us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value of financial and nonfinancial obligations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS (Details 4) - Fair Value, Inputs, Level 3 [Member]
|
12 Months Ended |
Mar. 31, 2023
USD ($)
|
Platform Operator, Crypto-Asset [Line Items] |
|
Warrant derivative liability, beginning balance |
$ 0
|
Fair value of warrant derivative liability recognized upon issuance of warrants |
4,956,000
|
Gain on change in fair value of warrant derivative liability |
(1,864,000)
|
Warrant derivative liability, ending balance |
$ 3,092,000
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfWarrantDerivativeLiabilityRecognizedUponIssuanceOfWarrants |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_GainOnChangeInFairValueOfWarrantDerivativeLiability |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_WarrantDerivativeLiability |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Software develpoment costs |
$ 655,641
|
|
Unrecognized tax benefits |
0
|
$ 0
|
Retirement benefit plan expenses |
37,645
|
24,300
|
VAT receivable |
255,112
|
255,112
|
Prepaid expenses and other receivables |
|
750,167
|
Prepaid expenses balance |
$ 357,934
|
$ 495,055
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_CapitalizedComputerSoftwareGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of tax benefit for recognition of expense of award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.
+ References
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ValueAddedTaxReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
LICENSING AGREEMENT (Details Narrative)
|
Mar. 31, 2023
USD ($)
|
Mar. 31, 2023
GBP (£)
|
Mar. 31, 2022
USD ($)
|
Commitments and Contingencies Disclosure [Abstract] |
|
|
|
Non refundable, upfront cash payment | £ |
|
£ 1,000,000
|
|
Non-refundable, upfront cash payment |
$ 1,230,000
|
|
$ 1,320,000
|
Deferred Revenue |
$ 1,081,676
|
|
|
X |
- DefinitionThe amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483172/928-340-45-1
+ Details
Name: |
us-gaap_AdvanceRoyalties |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable. This amount is expected to be consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483172/928-340-45-1
+ Details
Name: |
us-gaap_AdvanceRoyaltiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
INVENTORY (Details) - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Inventory Disclosure [Abstract] |
|
|
Raw materials |
$ 1,586,777
|
$ 1,481,946
|
Finished products |
168,075
|
5,825
|
Total |
$ 1,754,852
|
$ 1,487,771
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryFinishedGoods |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryRawMaterials |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2
+ Details
Name: |
us-gaap_InventoryWriteDown |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
PROPERTY AND EQUIPMENT (Details) - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Property, Plant and Equipment [Abstract] |
|
|
Plant and machinery |
$ 998,635
|
$ 727,250
|
Furniture and fixtures |
114,863
|
78,867
|
Property and equipment gross |
1,113,498
|
806,117
|
Less Accumulated Depreciation |
(471,592)
|
(273,609)
|
Net Book Value |
$ 641,906
|
$ 532,508
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_FurnitureAndFixturesGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_MachineryAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INTANGIBLE ASSETS (Details) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] |
|
|
Less impairment |
$ (324,397)
|
$ 0
|
Software develpoment costs |
655,641
|
|
Intangible assets net |
384,092
|
1,480,980
|
Patents [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Patents and licenses |
1,175,580
|
1,084,081
|
Less accumulated amortization |
(467,091)
|
(186,927)
|
Less impairment |
(324,397)
|
0
|
Intangible assets, gross |
384,092
|
897,154
|
Computer Software, Intangible Asset [Member] |
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
Less impairment |
(655,641)
|
0
|
Intangible assets, gross |
0
|
583,826
|
Software develpoment costs |
$ 655,641
|
$ 583,826
|
X |
- DefinitionAmount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_CapitalizedComputerSoftwareGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedPatentsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3
+ Details
Name: |
us-gaap_ImpairmentOfIntangibleAssetsFinitelived |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_CapitalizedComputerSoftwareGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3
+ Details
Name: |
us-gaap_ImpairmentOfIntangibleAssetsFinitelived |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
+ Details
Name: |
us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
DERIVATIVE LIABILITIES (Details 1) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
|
|
Notional amount |
$ 4,250,000
|
$ 6,250,000
|
Leveraged amount (used to determine fair value of contract liability) |
$ 8,500,000
|
$ 12,500,000
|
Expected remaining term (in months) |
17 months
|
25 months
|
Foreign currency contract liability |
$ 731,730
|
$ 440,196
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfContractLiabilitiesExpectedRemainingTerm |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfContractLiabilityLeveragedAmounts |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNominal or face amount used to calculate payments on the derivative liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column E)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
+ Details
Name: |
us-gaap_DerivativeLiabilityNotionalAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.
+ References
+ Details
Name: |
us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
DERIVATIVE LIABILITIES (Details Narrative) - USD ($)
|
1 Months Ended |
12 Months Ended |
Jan. 31, 2023 |
Mar. 31, 2023 |
Mar. 31, 2022 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] |
|
|
|
Warrants issued |
4,796,206
|
|
|
Volatility interest rate |
100.00%
|
|
|
Notional amount |
|
$ 4,250,000
|
$ 6,250,000
|
Leveraged amount |
|
8,500,000
|
12,500,000
|
Contractual notional amount |
|
$ 2,000,000
|
250,000
|
Description of conversion terms for debt instrument |
|
On
each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP
at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but
can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the settlement date, the Company is
obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can
pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty.
|
|
Leverage leveraged amount |
|
$ 4,000,000
|
|
Deposit on foreign exchange contract |
|
$ 909,666
|
$ 0
|
X |
- References
+ Details
Name: |
nmrd_DepositOnForeignExchangeContract |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfContractLiabilityLeveragedAmounts |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfContractLiabilityLeveragedAmountsExpired |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_VolatilityInterestRate |
Namespace Prefix: |
nmrd_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_WarrantsIssued |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of conversion terms for debt instrument.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments including both interest and principal payments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNominal or face amount used to calculate payments on the derivative liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column E)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
+ Details
Name: |
us-gaap_DerivativeLiabilityNotionalAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.23.2
NOTES PAYABLE (Details) - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
Balance of notes payable, net of note discounts |
$ 20,030,151
|
$ 19,188,724
|
Total notes payable |
20,797,234
|
20,512,400
|
Unamortized debt discount |
(767,083)
|
(1,323,676)
|
Long term debt, Current portion |
(16,942,500)
|
(19,188,724)
|
Long term debt, Non-current portion |
3,087,651
|
0
|
Note Purchase Agreement 1 [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Balance of notes payable, net of note discounts |
0
|
270,979
|
Note Purchase Agreement 2 [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Balance of notes payable, net of note discounts |
14,772,293
|
20,241,421
|
Note Purchase Agreement 3 [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Balance of notes payable, net of note discounts |
$ 6,024,941
|
$ 0
|
X |
- DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_LongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermDebtNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=nmrd_NotePurchaseAgreement1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=nmrd_NotePurchaseAgreement2Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=nmrd_NotePurchaseAgreement3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
NOTES PAYABLE (Details Narrative) - USD ($)
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
May 20, 2022 |
Feb. 08, 2021 |
Apr. 15, 2020 |
Oct. 31, 2022 |
Feb. 28, 2022 |
Mar. 31, 2023 |
Mar. 31, 2022 |
May 31, 2022 |
Apr. 30, 2022 |
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
Debt discount |
|
|
|
|
|
$ 20,797,234
|
$ 20,512,400
|
|
|
Debt discount amortized |
|
|
|
|
|
767,083
|
1,323,676
|
|
|
Debt instrument periodic payment |
|
|
|
|
|
2,000,000
|
$ 250,000
|
|
|
Secured Note [Member] | Investor [Member] | Note Purchase Agreement 1 [Member] |
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 6,015,000
|
|
|
|
|
|
|
Maturity date |
|
|
Apr. 15, 2022
|
|
|
|
|
|
|
Cash proceeds |
|
|
$ 4,675,000
|
|
|
|
|
|
|
Debt discount |
|
|
1,340,000
|
|
|
|
|
|
|
Debt discount amortized |
|
|
1,000,000
|
|
|
|
|
|
|
Commissions paid |
|
|
325,000
|
|
|
|
|
|
|
Transaction expenses |
|
|
$ 15,000
|
|
|
|
|
|
|
Interest rate |
|
|
10.00%
|
|
|
|
|
|
|
Secured Note [Member] | Investor [Member] | Note Purchase Agreement 2 [Member] |
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
Principal amount |
|
$ 24,015,000
|
|
$ 1,000,000
|
|
|
|
$ 500,000
|
$ 2,000,000
|
Maturity date |
|
Feb. 09, 2023
|
|
Jul. 01, 2024
|
|
|
|
|
|
Cash proceeds |
|
$ 18,800,000
|
|
|
|
|
|
|
|
Debt discount |
|
5,215,000
|
|
|
|
|
|
|
|
Debt discount amortized |
|
4,000,000
|
|
|
|
|
|
|
|
Commissions paid |
|
1,200,000
|
|
|
|
|
|
|
|
Transaction expenses |
|
$ 15,000
|
|
|
|
|
|
|
|
Interest rate |
|
10.00%
|
|
|
|
|
|
|
|
Debt instrument periodic payment |
|
$ 400,000
|
|
|
|
|
|
|
|
Debt instrument increased periodic payment |
|
|
|
|
$ 2,000,000
|
|
|
|
|
Aggregate fees |
|
2,304,539
|
|
|
|
|
|
|
|
fair value of debt |
|
|
|
|
|
17,090,513
|
|
|
|
Carrying amount of old debt |
|
|
|
|
|
16,609,176
|
|
|
|
Debt instruments fees |
|
|
|
|
|
2,304,539
|
|
|
|
Extinguishment debt |
|
2,785,876
|
|
|
|
|
|
|
|
Secured Note [Member] | Investor [Member] | Note Purchase Agreement 3 [Member] |
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
Principal amount |
$ 6,015,000
|
|
|
|
|
|
|
|
|
Maturity date |
May 20, 2024
|
|
|
|
|
|
|
|
|
Cash proceeds |
$ 4,700,000
|
|
|
|
|
|
|
|
|
Debt discount |
1,315,000
|
|
|
|
|
|
|
|
|
Debt discount amortized |
|
$ 1,000,000
|
|
|
|
$ 767,083
|
|
|
|
Commissions paid |
300,000
|
|
|
|
|
|
|
|
|
Transaction expenses |
$ 15,000
|
|
|
|
|
|
|
|
|
Interest rate |
10.00%
|
|
|
|
|
|
|
|
|
X |
- References
+ Details
Name: |
nmrd_AggregateFees |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_DebtInstrumentIncreasedPeriodicPayment |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_TransactionExpenses |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of fees associated with providing collateral for the debt instrument.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_DebtInstrumentCollateralFee |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10
+ Details
Name: |
us-gaap_DebtInstrumentFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments including both interest and principal payments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionGross amount of debt extinguished.
+ References
+ Details
Name: |
us-gaap_ExtinguishmentOfDebtAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying amount of items included in each line item in the statement of financial position that are not eligible for the fair value option.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
+ Details
Name: |
us-gaap_FairValueOptionIneligibleItemsAggregateCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of cash paid for commissions during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForCommissions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=nmrd_SecuredNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=nmrd_NotePurchaseAgreement1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=nmrd_NotePurchaseAgreement2Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=nmrd_NotePurchaseAgreement3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
RELATED PARTY TRANSACTIONS (Details) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Related Party Transactions [Abstract] |
|
|
Due (to)/from related parties at beginning of year |
$ (101,297)
|
$ 148,795
|
Amounts invoiced by Pharma to DDL, NM and TCL primarily relating to research and development expenses |
4,767,586
|
3,245,985
|
Amounts invoiced by DDL to Pharma |
0
|
2,495
|
Amounts invoiced by DDL to Pharma |
0
|
(2,495)
|
Amounts repaid by DDL to Pharma |
(3,773,217)
|
(3,492,962)
|
Foreign exchange differences |
27,708
|
620
|
Foreign exchange differences |
(27,708)
|
(620)
|
Due (to)/from related parties at end of year |
$ 920,780
|
$ (101,297)
|
X |
- References
+ Details
Name: |
nmrd_AmountsInvoicedByDdlToPharma |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_AmountsRepaidByDdlToPharma |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.2
INCOME TAXES (Details) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
|
Loss before income taxes arising in UK |
$ (13,314,440)
|
$ (11,716,916)
|
Loss before income taxes arising in U.S. |
(829,295)
|
(2,520,145)
|
Total loss before income tax benefit |
$ (14,143,735)
|
$ (14,237,061)
|
X |
- DefinitionAmount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_IncomeLossAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.2
INCOME TAXES (Details 1) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
|
Loss before income taxes |
$ (14,143,735)
|
$ (14,237,061)
|
Expected tax benefit |
$ (3,145,943)
|
$ (2,989,783)
|
Expected tax benefit, Percentage |
(22.00%)
|
(21.00%)
|
Foreign tax differential |
$ 235,938
|
$ 234,338
|
Foreign tax differential, Percentage |
2.00%
|
2.00%
|
Enhanced research and development |
$ (369,946)
|
$ (463,591)
|
Enhanced research and development, Percentage |
(3.00%)
|
(3.00%)
|
Prior year true up of nol |
$ (46,393)
|
$ 2,401,930
|
Prior year true up of nol, Percentage |
0.00%
|
17.00%
|
Other |
$ 338,278
|
$ 74,579
|
Other, Percentage |
2.00%
|
1.00%
|
Change in valuation allowance |
$ 2,988,066
|
$ 742,527
|
Change in valuation allowance, Percentage |
21.00%
|
5.00%
|
R&D credit received |
$ 0
|
$ 350,256
|
R&D credit received, Percentage |
0.00%
|
2.00%
|
Actual income tax benefit |
$ 0
|
$ 350,256
|
Income tax benefit, Percentage |
0.00%
|
2.00%
|
X |
- References
+ Details
Name: |
nmrd_PriorYearTrueupOfNols |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_RdCreditReceived |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.2
INCOME TAXES (Details 2) - USD ($)
|
Mar. 31, 2023 |
Mar. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
|
Net operating tax loss carried forward |
$ 9,259,000
|
$ 6,671,000
|
Research and development enhancement |
361,000
|
335,000
|
Other items |
38,000
|
(335,000)
|
Valuation allowance |
(9,658,000)
|
(6,671,000)
|
Net deferred tax assets |
$ 0
|
$ 0
|
X |
- References
+ Details
Name: |
nmrd_OtherItems |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_ResearchAndDevelopmentEnhancement |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
INCOME TAXES (Details Narrative) - USD ($)
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Income tax rate |
22.00%
|
21.00%
|
HMRC tax credit |
$ 0
|
$ 350,256
|
Research and development |
$ 369,946
|
$ 463,591
|
UNITED STATES |
|
|
Income tax rate |
21.00%
|
21.00%
|
Net operating losses |
$ 11,300,000
|
|
UNITED KINGDOM |
|
|
Income tax rate |
19.00%
|
|
Net operating losses |
$ 36,230,000
|
|
Research and development |
$ 1,899,000
|
|
X |
- DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3
+ Details
Name: |
us-gaap_OperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=country_US |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementGeographicalAxis=country_GB |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
STOCKHOLDERS' EQUITY (Details) - Equity Option [Member] - $ / shares
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Offsetting Assets [Line Items] |
|
|
Number of Options, Outstanding beginning |
40,000
|
0
|
Weighted Average Exercise Price, Outstanding beginning |
$ 3.98
|
$ 0
|
Number of Options, Granted |
0
|
40,000
|
Weighted Average Exercise Price, Granted |
$ 0
|
$ 3.98
|
Number of Options, Exercised |
0
|
0
|
Weighted Average Exercise Price, Exercised |
$ 0
|
$ 0
|
Number of Options, Forfeited |
0
|
0
|
Weighted Average Exercise Price, Forfeited |
$ 0
|
$ 0
|
Number of Options, Expired |
0
|
0
|
Weighted Average Exercise Price, Exercised |
$ 0
|
|
Weight Average remaining Contractual Term (years) |
2 years 8 months 12 days
|
4 years 9 months 29 days
|
Number of Options, Outstanding ending |
40,000
|
40,000
|
Weighted Average Exercise Price, Outstanding ending |
$ 3.98
|
$ 3.98
|
Number of Options, Vested and exercisable |
40,000
|
|
Weighted Average Exercise Price, Vested and exercisable |
$ 3.98
|
|
Weight Average remaining Contractual Term (years), Vested and exercisable |
2 years 8 months 12 days
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_OffsettingAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_OffsettingAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDiscount rate from fair value on purchase date that participants pay for shares.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
STOCKHOLDERS' EQUITY (Details 2) - Warrant [Member] - $ / shares
|
12 Months Ended |
Mar. 31, 2023 |
Mar. 31, 2022 |
Mar. 31, 2021 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
Number of Options, Outstanding beginning |
1,573,098
|
1,939,990
|
|
Weighted Average Exercise Price, Outstanding beginning |
$ 6.64
|
$ 6.30
|
|
Weight Average remaining Contractual Term (years) |
4 years 10 months 13 days
|
4 years 25 days
|
4 years 7 months 13 days
|
Number of Options, Granted |
4,796,206
|
0
|
|
Number of Options, Exercised |
0
|
(366,892)
|
|
Weighted Average Exercise Price, Granted |
$ 2.00
|
$ 8.08
|
|
Weight Average remaining Contractual Term (years) exercised |
|
4 years 29 days
|
|
Number of Options, Forfeited |
0
|
0
|
|
Number of Options, Expired |
0
|
0
|
|
Weight Average remaining Contractual Term (years) granted |
|
5 years
|
|
Weighted Average Exercise Price, Expired |
$ 5.00
|
|
|
Number of Options, Outstanding ending |
6,369,304
|
1,573,098
|
1,939,990
|
Weighted Average Exercise Price, Outstanding ending |
$ 2.7
|
$ 6.64
|
$ 6.30
|
Number of Options, Vested and exercisable |
6,369,304
|
|
|
Weighted Average Exercise Price Vested and exercisable |
$ 2.7
|
|
|
Weight Average remaining Contractual Term (years), Vested and exercisable |
4 years 10 months 13 days
|
|
|
X |
- References
+ Details
Name: |
nmrd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of share options (or share units) exercised during the current period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
|
|
|
1 Months Ended |
12 Months Ended |
|
|
Feb. 10, 2022 |
Jan. 28, 2022 |
Jan. 31, 2023 |
Mar. 31, 2022 |
Mar. 24, 2022 |
Apr. 02, 2021 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Aggregate amount |
|
|
|
|
$ 224,600,000
|
|
Gross proceeds |
|
|
|
$ 1,600,000
|
|
|
At The Marketoffering Agreement [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Number of common stock sold |
|
|
|
397,524
|
|
|
Sale of Stock, Price Per Share |
|
|
|
$ 4.07
|
|
|
A T M Facility 2021 [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Sale of stock |
375,000
|
|
|
375,000
|
|
|
Armistice Capital L L C And Alyeska Master Fund L L C [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Gross proceeds total |
|
|
$ 8,393,361
|
|
|
|
Costs deducted in relation to equity financing |
|
|
$ 737,385
|
|
|
|
H C Wainwright And Co L L C [Member] | Market Offering Agreement [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Aggregate shares price value |
|
|
|
|
|
$ 3,000,000
|
Tiger Trading Partners L L C [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Number of common stock sold |
|
|
|
375,000
|
|
|
Tiger Management L L C [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Exercise price |
|
|
|
$ 4
|
|
|
Number of common stock sold |
|
|
|
750,000
|
|
|
Gross proceeds |
|
|
|
$ 3,000,000
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Number of common stock sold |
|
|
|
772,524
|
|
|
Common Stock [Member] | Board Of Directors [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Exercise price |
|
$ 3.98
|
|
|
|
|
Options granted |
|
40,000
|
|
|
|
|
Fair value of stock options |
|
$ 133,529
|
|
|
|
|
Common Stock [Member] | Armistice Capital L L C And Alyeska Master Fund L L C [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Number of shares purchased |
|
|
4,796,206
|
|
|
|
Exercise price |
|
|
$ 1.75
|
|
|
|
Warrant [Member] | Armistice Capital L L C And Alyeska Master Fund L L C [Member] |
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
Number of shares purchased |
|
|
4,796,206
|
|
|
|
Exercise price |
|
|
$ 2.00
|
|
|
|
X |
- References
+ Details
Name: |
nmrd_AggregateAmount |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_AggregateSharesPriceValue |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
nmrd_CostsDeductedInRelationToEquityFinancing |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
nmrd_FairValueOfStockOptions |
Namespace Prefix: |
nmrd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOrSaleOfEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCash received on stock transaction after deduction of issuance costs.
+ References
+ Details
Name: |
us-gaap_SaleOfStockConsiderationReceivedOnTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockRepurchasedDuringPeriodShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=nmrd_AtTheMarketofferingAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=nmrd_ATMFacility2021Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=nmrd_ArmisticeCapitalLLCAndAlyeskaMasterFundLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=nmrd_HCWainwrightAndCoLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=nmrd_MarketOfferingAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=nmrd_TigerTradingPartnersLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=nmrd_TigerManagementLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=nmrd_BoardOfDirectorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2024 to May 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From May 2023 to May 2024